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ABSTRACT 
Tareg Hadi Ahmed Hadeiba 
The role of iron in oxidative stress accelerated endothelial dysfunction 
in chronic kidney disease 
Key words: Endothelial cell, intravenous iron preparations, oxidative stress, 
chronic kidney disease (CKD), and cardiovascular disease.  
          Chronic kidney disease (CKD) is growing global public health problem 
affecting 1 in 10 adults in developed countries and recognised as an 
important risk factor for cardiovascular disease (CVD) development. CVD is 
the main cause of death among CKD patients. Endothelial injury and 
dysfunction are critical steps in atherosclerosis, a major CVD. Oxidative 
stress (increased level of reactive oxygen species, ROS) has been 
associated with CVD development. Intravenous (IV) iron preparations are 
widely used in the management of CKD mediated anaemia, and have been 
associated with increased oxidative stress and cellular dysfunction. 
          This study examined the effect of pharmacologically-relevant 
concentrations of IV Venofer (iron sucrose) or IV Ferinject (Ferric 
carboxymaltose, FCM) on primary human umbilical vein endothelial cell 
(HUVEC) activation/damage and on intracellular ROS generation as well as 
studying the potential mechanisms responsible. Data from TUNEL assay and 
Annexin V-FITC/PI staining showed that, IV FCM had no effect, but IV iron 
sucrose increased HUVEC apoptosis at 24hr. IV iron sucrose inhibited cell 
proliferation and reduced cell viability. Both compounds induced EC 
activation through sustained activation of p38 MAPK and up-regulation of 
ICAM-1 and VCAM-1. Additionally, the compounds induced significant 
increase in total ROS and superoxide anion production, which was 
attenuated by the anti-oxidant N-acetylcysteine (NAC). P38 MAPK showed 
up-regulation of pro-apoptotic protein Bax and down-regulation of anti-
apoptotic Bcl-2 protein in HUVEC treated with IV iron sucrose and p38 
inhibition reversed these effects.  
           In summary, these results suggest that IV iron sucrose causes more 
severe EC injury than IV FCM. However, both IV iron preparations induced 
intracellular ROS and superoxide anion generation in HUVEC leading to EC 
activation/dysfunction, providing a potential explanation for vascular damage 
in CKD patients. 
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1.1. The kidney 
1.1.1. Kidney structure 
The kidneys are the main part of the renal system, a pair of organs located in 
a retroperitoneal position on the posterior abdominal wall around the 12th 
thoracic vertebra. Each kidney about the size of a fist, measuring 10-12 cm 
in length, 5-7 cm wide, and 2-5 cm thick, and both are identical in structure 
and function (Snell, 1992). 
Each kidney is surrounded by a fibrous capsule and comprises an outer 
cortex and an inner medulla and contains about one million fundamental 
structural and functional units called nephrons as shown in Figure 1.1. All 
nephrons originate in the cortex and consist of glomerular capsule (renal 
corpuscle) and a tubule system which are related structurally and functionally 
(Mezzogiorno et al., 2002). The glomerulus consists of a network of 
capillaries situated within Bowman’s capsule. The glomerular membrane or 
glomerular filtration membrane is thought to function primarily as a charge-
selectivity filter, allowing proteins to cross on the basis of charge (Steffes et 
al., 2001). The glomerular filtration membrane consists of three layers; a 
single layer of flattened capillary endothelial cells perforated by fenestrae, a 
cellular gelatinous layer of basement membrane and an inner epithelial layer 
of the Bowman’s capsule consisting of podocytes which interdigitate to form 
slits along the capillary wall. These layers of the capillary loop function 
in parallel, restricting the passage of cells and limiting filtration of 
macromolecules on the basis of charge, shape, and size  (Kitamura 
and Fine, 1999). Filtered fluid passes into the renal tubule which is divided 
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into, the proximal tubule within the cortex, the U-shaped loop of Henle 
extending into the medulla and traversing back into the cortex to form the 
distal tubule. The latter coalesce to form the collecting ducts which pass 
through the cortex and medulla and empty into the renal pelvis (Ganong, 
2005).  
1.1.2. Kidney function 
The kidneys are essential organs in the body, controlling the concentration of 
body fluids. They control water and ionic balance by regulating excretion of 
water, sodium, potassium, chloride, calcium, magnesium, phosphate, and 
many other substances, and regulate electrolyte balance of the body (Hsu et 
al., 2011). Also it maintains a stable extracellular environment, which 
supports the function of all body cells by managing acid-base status. Kidneys 
produce important hormones such as erythropoietin (EPO), which have a key 
role in stimulating the bone marrow to produce red blood cells. Furthermore, 
they produce the enzyme renin, which plays roles in the regulation of blood 
pressure and kidney function. Another important function is the metabolism 
of vitamin D to its active form (Parker, 1998; Ferguson and Waikar, 2012). 
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Figure 1.1: Shows the kidney anatomy, taken from Marsh, 1983. 
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1.1.3. Chronic kidney disease (CKD) 
According to the World Health Organisation (WHO, 2005) there were around 
58 million deaths worldwide, with 35 million attributed to chronic diseases 
(World Health Organization, 2005). CKD is increasingly recognized as a 
major and growing global public health problem which affects about 1 in 10 
adults in developed countries (Coresh et al., 2007), affecting more than fifty 
million people around the world with increasing incidence and prevalence, 
and with both poor outcomes and high cost (Coresh et al., 2003; Eknoyan et 
al., 2004). In 2010, it was estimated that CKD cost around £1.45 billion or 
1.3% of all the National Health Services (NHS) spending in England (Kerr et 
al., 2012). Approximately, 20 million people or 13% of the general population 
in America were reported to have CKD (Ardhanari et al., 2014) whereas 
8.5% of the population in the UK were affected (McLaughlin and Courtney, 
2013). In addition, in 2010, the Health Survey for England showed that 6-7% 
of population over the age of 18 were diagnosed with stage 3 to 5 of CKD. 
However, there was a clear variation by age and gender as the survey 
showed that the prevalence of CKD increased to 30% in men and 35% in 
women aged 75 and over (NICE, 2012). CKD is a complex disease which 
refers to chronic renal failure or insufficiency, characterized by progressive 
and irreversible loss of kidney function, usually accompanied by an 
imbalance of metals, nutrients and electrolytes, eventually leading to total 
kidney failure also known as end stage renal disease (ESRD) (Oliveira et al., 
2005). Although, ESRD is a prominent and much feared complication of 
renal disease, the high mortality rate associated with CKD is mainly due to 
increased incidence of cardiovascular disease (CVD) (Levey et al., 2007), 
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and is discussed in more detail in section 1.1.5. Blood vessels within the 
kidney are particularly sensitive to damage so main causes of CKD are 
atherosclerosis, hypertension and diabetes, which will be discussed in more 
details in sections 1.1.5.1- 1.1.5.3. However, there are other conditions which 
can cause CKD such as obesity, inflammatory mechanisms, smoking, 
infection, family history of kidney disease, age and some medications 
(McClellan and Flanders, 2003; Ardhanari et al., 2014).  
1.1.4. CKD stages and classifications 
CKD is defined as the presence of kidney damage, and is classified 
according to the level of kidney function. In 2002, the American National 
Kidney Foundation (NKF) published the Kidney Disease Outcome Quality 
Initiative (K/DOQI™) providing guidelines for the evaluation, classification 
and stratification of CKD (National Kidney Foundation, 2002). Thus, the 
disease is categorized into five stages of increasing severity, based upon 
abnormalities of kidney structure or function for more than three months with 
or without decrease in glomerular filtration rate (GFR), which describe the 
volume of filtered fluid passing through each kidney functional unit 
(glomerulus) per unit time with albumin creatinine ratio (ACR) of 30 mg/mmol 
or higher (Levey et al., 2005). However, in order to define an increased risk 
of adverse results, the UK National Institute for Health and Care Excellence 
(NICE) advised and updated two important elements of CKD classification 
that had been published originally by NKF. Firstly stage 3 was divided into 
two subdivision, stage 3a and 3b as shown in table 1.1. Secondly, NICE also 
recommended the addition of albuminuria stage after each CKD stage to 
denote the occurrence of albuminuria, which is defined as ACR of 30 
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mg/mmol or protein creatinine ratio (PCR) of 50 mg/mmol or higher (NICE, 
2014). The subdivision of NICE guideline on classification of CKD has been 
accepted by the Kidney Disease: Improving Global Outcomes (KDIGO). 
However, in 2013 KDIGO suggested three categories of ACR for each GFR 
category as shown in table 1.2 (NICE, 2014). 
Table 1.1: The five stages of CKD defined by estimated GFR, taken from 
NICE, 2014.  
 
Stage 
 
Description 
 
GFR ml/min/1.73m2 
1 kidney damage with normal / 
increased GFR 
Normal/increased 
GFR≥90 
2 Kidney damage with mildly 
decreased GFR                       
60 to 89 
3a Mildly to moderately decreased 45 to 59 
3b Moderately to severely decreased 
GFR 
30 to 44 
4   Severely decreased GFR 15 to 29 
5   Kidney failure ≤ 15 
 
Table 1.2: The three categories of albumin creatinine ratio suggested by 
KDIGO, taken from NICE, 2014. 
 
ACR category                           
 
ACR (mg/mmol)                             
 
Terms 
A1 <3                   Normal to mildly 
increased 
A2 3-30                        Moderately increased 
A3 >30 Severely increased 
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1.1.5. Cardiovascular disease in CKD 
It is generally accepted that, CVD is a major cause of death globally, 
affecting both the hearth and blood vessels by atherosclerosis (Perk et al., 
2012; NICE, 2014). CVD causes 17.3 million deaths annually worldwide and 
contribute to nearly one third of deaths in England and Wales equating to 
191,000 deaths per year (Smith et al., 2012). Almost 50% of UK deaths are 
from coronary heart disease (CHD) also known as coronary artery disease 
(CAD) and 25% are from stroke; both represent the most clinically significant 
forms of CVD (Scarborough et al., 2010). Furthermore, CVD has a major 
cost effects on the UK economy and was estimated to cost the NHS almost 
£6,940 million in 2003, which increased to £7,900 million in 2010 according 
to the UK national statistics (NICE, 2014). However, because CVD is 
frequently associated with CKD, the prevalence of CKD among patients with 
CVD is even higher than those who do not suffer only from CVD, and many 
studies have demonstrated that CKD is multiplier for CVD (Go et al., 2004). It 
has been shown that the increased risk of CVD can occur even in early 
stages of CKD (Di Angelantonio et al., 2010). Likewise, CKD is a major, 
serious and independent risk factor for CVD. It is increasingly apparent that 
patients with CKD are more likely to die, principally from CVD, than to 
develop kidney failure or to obtain renal replacement treatment (Keith et al., 
2004; Rahman et al., 2006).  
According to the NKF Task Force recommendation, individuals with CKD 
were to be considered in the “highest risk group” for cardiovascular events, 
and be treated accordingly for their high risk status (Levey et al., 1998). The  
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NKF Task Force on CVD in CKD issued a report in 1998 showed that, there 
was high prevalence of CVD in CKD and death from CVD was 10 to 30 times 
higher in patients with CKD, especially in dialysis patients than in the general 
population (Foley et al., 1998; Foley et al., 2005). In addition, patients with 
combined CVD and CKD have approximately 44% higher mortality rate than 
patients suffering from CVD (Tonelli et al., 2006; Hemmelgarn et al., 2009) 
Furthermore, in patients undergoing dialysis, CVD was shown to be the 
major cause of death affecting 40% of patients on haemodialysis (HD) 
(Coronado et al., 1998; Al-Dadah et al., 2012). Both the morbidity and 
mortality of CVD are associated with decline in kidney function, as estimated 
glomerular filtration rate (eGFR) falls, the incidence and severity of CVD 
dramatically increases two to fourfold (Chonchol et al., 2008; Nakano et al., 
2010; Gansevoort et al., 2013). In addition, higher incidence of CVD is also 
associated with increased rate of albuminuria (Schmieder et al., 2011). Up to 
80% of patients with ESRD are expected to die within three years once 
diagnosed with CHD (Trespalacios et al., 2003; Bagshaw et al., 2010). 
Studies showed that Left ventricular hypertrophy (LVH) considered as very 
strong predictor of CV mortality, is increasingly prevalent in CKD patients 
even at early stages of the disease due to the high prevalence of 
hypertension in these individuals (Zoccali et al., 2002; Coresh et al., 2007). 
LVH showed an association with decreased eGFR <30 mL/min/1.73 m2, and 
estimated as 75% in patients undergoing dialysis (Park et al., 2012; 
Ardhanari et al., 2014). 
Considerable efforts worldwide are targeted towards characterising the 
extent of the risk factors associated with CVD, to reduce its impact (Pearson, 
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1999). The etiology of the increased risk of CVD in CKD is unknown. 
However, both disorders have shared CVD risk factors, most notably 
atherosclerosis, hypertension and diabetes (Bleyer et al., 2000) and these 
may play a role in the increased severity of CVD in CKD. Furthermore, 
inflammation is common in patients with CKD and showed to play 
pathophysiological role in the pathogenesis of atherosclerosis via 
contributing to the development of vascular calcifications and EC 
dysfunction, which can contribute to CVD progression in CKD (Silverstein, 
2009). Thus, in order to allow early intervention it is important to assess CVD 
risk factors in individuals with kidney disease as early as possible after 
diagnosis (Larson et al., 2004).  
1.1.5.1. Atherosclerosis in CKD 
Atherosclerosis is a disease of the arterial wall, the prevalent form of CVD, 
and the primary cause of ischaemic heart disease, namely, angina and 
myocardial infarction. In 2001, a study of mortality in patients with ESRD 
showed that 20.4% of these patients died of ischaemic heart disease (Rocco 
et al., 2002). Atherosclerosis has been recognized as a common and serious 
complication in CKD patients (Koike and Nitta, 2011). Additionally, 
atherosclerotic plaque formation is considered as predictor of CV events in 
ESRD, and these plaques are present in up to 30% of patients with CKD 
(Amann et al., 2003; Benedetto et al., 2008). Furthermore, these plaques 
contribute to ventricular hypertrophy and heart failure through the association 
with events, such as arterial stiffness. 
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1.1.5.2. Hypertension in CKD 
Hypertension is a major risk factor, which contribute to cardiovascular risk 
associated with CKD (Thomas et al., 2008) with incidence increasing as 
eGFR declines (Coresh et al., 2001). The prevalence of hypertension among 
patients with CKD is approximately 70% higher than in the general 
population and is found in up to 90% of dialysis patients over the age of 65 
(Agarwal et al., 2003; Coollins et al., 2009; Banach and Rysz, 2010). The 
prehypertensive state is commonly associated with increased presence of 
inflammatory markers such as C-reactive protein (CRP) and albumin linked 
to atherosclerosis. Hypertension can damage kidney blood vessels and 
favours atherosclerosis progression primarily by accelerating the conversion 
of fatty streaks to raised lesions (McGill et al., 1998). Eventually, vascular 
lesions can progress to vessel wall necrosis (fibrinoid necrosis, necrotizing 
arteriolitis, and hyperplastic arteriolosclerosis), which may extend to the 
glomerulus (necrotizing glomerulitis) (Kumar et al., 2003). Both hypertension 
and atherosclerosis can be closely linked to each other through their effects 
on EC function due to altered hemodynamic (Chrysohoou et al., 2004), and 
as a consequence of this, ECs become dysfunctional which leads to 
recruitment of monocytes into the sub-endothelial space where they convert 
to macrophages full of lipids leading to consequent chemotaxis and 
aggregation of inflammatory cells (Chrysohoou et al., 2004).  
1.1.5.3. Diabetes and CKD 
Diabetes is a well-known risk factor for CVD with excessive cardiovascular 
morbidity and mortality, and is associated with adverse outcomes in all 
stages of CKD, accounting approximately 30% to 40% of patients with CKD 
12 
 
and up to 45% in ESRD (Lea and Nicholas, 2002; Middleton et al., 2006). 
CVD, diabetes and CKD share many risk factors, such as hypertension and 
obesity. Diabetes patients tend to have higher levels of blood pressure and 
abnormal cholesterol level, both considered to increase the risk of 
atherosclerosis, which will increase mortality and morbidity among these 
patients. Atherosclerosis develops faster and earlier in diabetic patients and 
affects the systemic and renal large and microvessels (Stout, 1993). In 
addition, diabetic nephropathy, resulting from high blood glucose levels can 
lead to abnormal kidney function by damaging the blood-filtering capillaries 
(Graham et al., 2010).  
1.1.6. Anaemia and CKD  
Anaemia, as defined by the National KDOQI is a haemoglobin (Hb) level of 
less than 12g/dl for women and less than 13.5g/dl for men (Macdougall et al., 
2007). It is a relatively common complication of CKD, affecting more than 
half of all CKD patients (McClellan et al., 2004). The 5 stages classification of 
CKD described above based on the amount of kidney function (glomerular 
filtration) remaining is very useful because the onset and severity of anaemia 
has been well correlated with the decline in glomerular filtration rate (GFR). 
Anaemia occurs in the early stages of CKD patients, such as stage 1 and 
worsens in those who are in ESRD. In one study, 26.7% of patients with 
stage 1 of CKD were shown to have anaemia, while 75% with stage 5 CKD 
were anaemic (Levin et al., 1999). In addition, a recent study showed that the 
prevalence of anaemia increases with progressive stages of CKD, Mehdi and 
Toto found nearly 8.4% of patients with CKD at stage 1 had anaemia 
compared with the general population figure of 6.3%, while the percentage of 
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anaemia was 50.3% and 53.4% in patients with CKD at stages 4 and 5 
respectively (Stauffer and Fan, 2014). Furthermore, anaemia in patients with 
CKD and diabetes was 10 fold higher and more severe than in patients with 
other causes of CKD (Mehdi and Toto, 2009). It is important to identify 
anaemia in CKD patients because relatively safe and effective therapies are 
available to correct anaemia and its complications. There are several factors 
which are likely to contribute to development of anaemia in CKD, such as 
iron deficiency, decreased production of red blood cells, blood loss and 
inflammation (Thomas et al., 2008; Fishbane et al., 2009). However, the 
primary and important cause is believed to be EPO deficiency (McFarlane et 
al., 2008; Babitt, and Lin, 2012). EPO is a glycoprotein hormone, produced 
mainly by peritubular capillary lining cells of the kidney cortex (Thomas et al., 
2007). Under physiological conditions, a basal level of EPO is produced to 
regulate proliferation, differentiation, and maturation of red blood cells 
(RBCs) (Thomas et al., 2007). Under conditions of hypoxia, kidneys produce 
EPO to increase RBC production, leading to more oxygen being delivered to 
tissues (Hodges et al., 2007). Anaemia is not only prevalent in patients with 
CKD but also in patients with diabetes and could significantly contribute to 
individual’s outcomes (Vlagopoulos et al., 2005). In addition, low levels of Hb 
increased risk for development of cardiovascular injury and death in CKD 
(New et al., 2008). Anaemia may potentiate the adverse effects of LVH on 
cardiovascular outcomes. Anaemia is associated with LVH because LVH 
increases oxygen demand and anaemia may limit supply (Joss et al., 2007). 
Thus, treating anaemia improves quality of life in patients of CKD, leading to 
improvements in many areas such as sleep, sexual function, physical 
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performance and social activities (Lawrence et al., 1997; Moreno et al., 2000; 
Dharawhat et al., 2009). 
1.2. The endothelium 
1.2.1. Endothelial cells (ECs) 
At one time researchers commonly thought these cells to be simply a non-
stick lining of blood vessels, which was believed to function only as anti-
blood coagulation and, hence a barrier to diffusion of solutes and nutrients. 
However, in the last three decades, science has shown that ECs are critical 
to health; in fact they are now considered to be an active cardiovascular 
paracrine, autocrine and endocrine organ (Pearson et al., 1999; Libby, 
2002). The endothelium’s location is ideal and considered as an integral part 
of the vascular system (Davies and Hagen, 1999). ECs are a single layer of 
cells located at the interface between blood and tissues, separating the 
vascular wall from the circulating blood and its components, controlling the 
movement of cells, fluid and small and large solutes such as plasma proteins 
from the blood to interstitial space and lining of the inner surface of blood 
vessels as shown in Figure 1.2 (Augustin et al., 1994). The layer of ECs 
constitutes approximately 1013 cells, totalling a surface area of 1-7 m2 and 
mass of 1 kg in adults (Galley and Webster, 2004). In addition, the 
endothelium plays an active role in inflammatory reactions, immunity, platelet 
activity, leukocyte adhesion and regulates vascular homeostasis, through the 
expression and release of a large number of factors that influence vasomotor 
tone, fibrinolysis, thrombosis and vascular growth (Vita and Keaney, 2002). 
Furthermore, the endothelium has emerged as a key regulator of vascular 
homeostasis particularly in cardiovascular physiology and pathology, in that it 
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acts as an active single transducer for circulating influences that modify the 
vessel wall phenotype (Vita and Keaney, 2002). The endothelium is involved 
in many biochemical pathways in health and disease. EC is able to respond 
to physical and chemical stimuli, by releasing a wide range of substances 
such as Nitric oxide (NO), reactive oxygen species (ROS) and angiotensin II 
and expressing adhesion molecules such as vascular adhesion molecule-1 
(VCAM-1), intracellular adhesion molecule-1 (ICAM-1), and E-selectin (Esper 
et al., 2006). Some of these secreted substances maintain and regulate 
vascular flow and vasomotor tone. The ability of endothelium to express 
antioxidant enzymes such as superoxide dismutase and catalase helps to 
maintain cellular integrity and function (Leopold and Loscalzo, 2009). The 
importance of the endothelium in vascular tone was first recognized and 
confirmed following the discovery that EC produce and release several 
vasoactive molecules including bradykinin and thrombin that relax or 
constrict vascular smooth muscle cells, modulating blood flow to any organ 
(Highsmith, 1998). Vasomotion is modulated by endothelium either by 
releasing vasodilator substances such as NO and prostacyclin or by an 
increase in constrictor tone via generation of endothelin (ET) and via 
conversion of angiotensin I to angiotensin II, a potent vasoconstrictor at the 
EC surface (Kinlay et al., 2001). This vasomotion plays important and direct 
roles in the balance of tissue oxygen supply and metabolic demand by 
regulation of vessel tone and diameter, and is also involved in the 
remodelling of vascular structure and long-term organ perfusion (Schechter 
and Gladwin, 2003). The endothelium plays a central role in maintaining 
vascular health by its vital anti-inflammatory and anti-coagulant properties. 
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Many of these characteristics are mediated by NO, which plays a vital role in 
EC function (Cines et al., 1998). 
 
 
Figure 1.2: Cross-sectional view of endothelium, adapted from Ang and 
Lumsden, 2001. 
 
1.2.1.1. Endothelial cell adhesion molecules (CAMs) 
CAMs are cell surface glycoproteins involved in the binding of cells to each 
other or to proteins in the extracellular matrix (Cronstine and Weissman, 
1993). These molecules are involved in the modulation of leukocyte 
recruitment and platelet adhesion during thrombosis and inflammation 
(Springer, 1994). Adhesion molecules are also involved in a number of 
cellular processes such as, cell growth, differentiation, embryogenesis and 
cancer metastasis (Bevilacqua et al., 1994). 
There are a wide range of these molecules expressed by resting and 
activated ECs, including members of the selectin family both P-selectin and 
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E-selectin and immunoglobulin (Ig) super family intercellular adhesion 
molecule-1, intercellular adhesion molecule-2  (ICAM-1, ICAM-2), vascular 
cell adhesion molecule-1 (VCAM-1) and platelet endothelial cell adhesion 
molecule (PECAM-1) (Kobayashi et al., 2007).  
P-selectin is located in granules in ECs and activated platelets. During 
inflammation, P-selectin can be expressed and moves from the internal 
location to the surface of the ECs stimulated by a number of inflammatory 
and thrombogenic mediators such as, histamine, lipid peroxidase and 
thrombin (Chamoun et al., 2000).  
E-selectin is a glycoprotein which is not present on un-stimulated ECs. 
However, is expressed by activated endothelium, synthesized and expressed 
in response to bacterial toxin and interleukin-1 (IL-1) or tumour necrosis 
factor-α (TNF-α). E-selectin supports the rolling and initial adhesion of 
leukocytes, neutrophils, monocytes, eosinophils and some lymphocytes 
along the endothelium as shown in Figure 1.3 (Xu et al., 2000). E-selectin 
binds to specific ligands located on the surface of the leukocytes such as the 
tetra saccharide and carbohydrate (Chamoun et al., 2000).  
ICAM-1 and VCAM-1 belong to the immunoglobulin (Ig) superfamily of 
proteins (Zhang et al., 2010; Cook-Mills et al., 2011). The expression of 
these two molecules is regulated at the level of gene transcription, and is 
induced by exposure of ECs to stimuli such as IL-1, or bacterial 
lipopolysaccharide, which are mediated by the transcription factor nuclear 
factor-kappa B (NF-κB) (Frank and Lisanti, 2008). A low level of ICAM-1 is 
normally present on healthy resting ECs under basal conditions as well as on 
lymphocytes and platelets, and in vitro study showed that its up-regulation 
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following stimulation peaks at 12 to 24hr, and persists for 72hr or days as 
long as the cytokine remains in the culture medium (Rothlein et al., 1986; 
Bevilacqua et al., 1994; Frank and Lisanti, 2008). ICAM-1 is also up-
regulated in response to oxidative stress such as hydrogen peroxide (H2O2), 
which increases the expression of ICAM-1 mRNA on HUVEC surface (Lo et 
al., 1993). The mechanism was shown to be due to the involvement of H2O2 
in tyrosine kinase activation, increasing the phosphorylation of Src tyrosine 
kinase, the initial step in the activation of the MAP kinase pathway upstream 
of the activation of the transcription factors include activator protein-1 (AP-1) 
and NF-kB, which results in increased EC permeability (Voelkel and Rounds, 
2009). In contrast to ICAM-1, VCAM-1 is expressed only on activated EC, 
macrophages and myoblasts, stimulated by high levels of oxidative stress 
and cytokines (Cybulsky et al., 1991; Cook-Mills et al., 2011). Similar to 
ICAM-1, VCAM-1 on activated EC appears at 24hr and persists for at least 
72hr (Zhang et al., 2010). ICAM-1 and VCAM-1 play an important role in the 
adhesion of leukocytes to EC, which is considered as a crucial step in the 
initiation of chronic inflammatory diseases such as atherosclerosis (Brooks et 
al., 2002; Van Buul et al., 2010). There are a number of steps involved in the 
adhesion of leukocyte to EC including, capture, rolling, tethering, firm 
adhesion, and transmigration as shown in Figure 1.3 (Frank and Lisanti, 
2008). The main function of ICAM-1 is to facilitate the firm adhesion step 
while VCAM-1 participates in the slow rolling of leukocytes and 
transmigration step through binding to very late antigen-4 (VLA-4), a cognate 
ligand of VCAM-1 expressed on the surface of leukocytes (Frank and Lisanti, 
2008). As a result of leukocyte activation both ICAM-1 and VCAM-1 bind to 
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the up-regulated Leukocyte integrins of the β 1 and β 2 integrin class, this 
causes the leukocyte to move over the endothelial surface to intercellular 
junctions where they pass between the ECs and enter the interstitial tissue at 
the initial stage of inflammation (Van Buul et al., 2010). 
Up-regulation of both ICAM-1 and VCAM-1 induces intracellular signalling, 
which results in production of reactive oxygen species (ROS) such as, H2O2 
and p38 MAPK pathway phosphorylation (Van Buul et al., 2010). A study by 
Deem et al showed that, binding of lymphocyte to VCAM-1 across ECs, 
leads to the activation of endothelial NADPH oxidase for ROS generation 
(Deem et al., 2007). In plasma, both ICAM-1 and VCAM-1 exist as a soluble 
form (sICAM-1 and sVCAM-1), which can be used as predictive biomarker of 
disease and correlate with EC dysfunction, atherosclerosis and CHD 
(Kannel, 2005; Jha et al., 2010). Elevated level of sICAM-1 or sVCAM-1 can 
reflect EC activation and vascular inflammation (Lake and Ridker, 2002), and 
have been shown to be present in patients with CVD and CKD on HD and 
with decreased GFR (Stancanelli et al., 2010). Furthermore, both sICAM-1 
and sVCAM-1 have shown to be independent predictors of mortality in CKD 
(Suliman et al., 2006). sICAM-1 has been shown to be regulated by a 
number of intracellular signal transduction pathways including the mitogen-
activated protein (MAP) kinases (ERK, JNK and p38), and NF-kB (Roebuck 
and Finnegan, 1999). Elevated sICAM-1 has been found in patients with 
CKD who have clinical signs of CVD (Colombo et al., 2012). In addition, in 
vivo study showed that sICAM-1 and sVCAM-1 were present on EC in 
atherosclerotic plaques (Mestas and Ley, 2008). 
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Figure 1.3:  Steps of leukocyte-endothelium interaction in inflammatory 
response: capture (1), rolling (2), tethering (3), firm adhesion (4) and 
transmigration (5), taken from Warboys et al., 2011.  
1.2.2. Nitric oxide (NO)  
NO officially called nitrogen monoxide is a hydrophilic (Kelm, 1999), and a 
gaseous lipophilic molecule which as it is uncharged, diffuses across cell 
membrane (Shimokawa, 1999). NO is a free radical species with an unpaired 
electron and a very short half-life of 6-10 seconds in physiological media 
(Burney et al., 1999). NO is one of the main vasorelaxing factors and it is 
considered as an important signalling molecule which can protect the body 
against high blood pressure, heart failure and thrombosis. In addition, NO 
has been shown to inhibit adhesion of leukocytes to the vessel wall, which 
can protect the body against the onset of atherogenesis (Förstermann and 
Münzel, 2006). NO can be produced by different cell types. However, it is 
released by ECs mainly in response to shear stress stimuli, triggering 
21 
 
vascular smooth muscle relaxation through activation of soluble guanylate 
cyclase (sGC), leading to an increase in the intracellular levels of cyclic 3,5- 
guanine monophosphate (cGMP) and vasorelaxation (Schlossmann et al., 
2003). NO has also a protective role against atherosclerosis because it 
inhibits platelet aggregation and adhesion to vascular wall as well as 
inhibiting vascular smooth muscle cell (VSMC) proliferation through 
preventing release of platelet-derived growth factors (Napoli et al., 2006). 
1.2.2.1. Nitric oxide synthase (NOS) 
NO is one produced by a family of Nitric oxide synthases (NOSs) enzymes 
(Loscalzo and Welch, 1995). NOS exists as three isoforms, endothelial NOS 
or (eNOS) in ECs, neuronal NOS or (nNOS) in the brain and inducible NOS 
or (iNOS) in macrophages and other cell types (Alderton et al., 2001; Napoli 
et al., 2006), all of which convert the amino acid substrate L-arginine to L-
citrulline and NO in the presence of several cofactors, including nicotinamide 
adenine dinucleotide phosphate (NADPH), Oxygen (O2), flavin 
mononucleotide (FMN), haem, flavin adenine dinucleotide (FAD) and 
tetrahydrobiopterin (BH4) (Ignarro et al., 1999). BH4 is an essential cofactor 
for all NOS isoforms and is involved in the reduction of the haem iron of the 
enzyme to ultimately form an iron-oxy species that hydroxylates L-arginine to 
produce NO (Li et al., 2011). All NOS enzymes are synthesized as 
monomers with both reductase domain and oxygenase domain as shown in 
Figure 1.4A. In the presence of haem, both monomers and reductase 
domains have the ability to transfer electron from the flavin to the haem of 
the opposite monomer. NOS couple their haem and start synthesizing NO 
and L-citrulline when sufficient cofactor BH4 and substrate L-arginine are 
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present. However, monomers can bind neither the substrate L-arginine nor 
the cofactor BH4 as shown in Figure 1.4 (Förstermann and Münzel, 2006). 
Meaning the enzyme is only active as a dimer. eNOS is a tightly regulated 
enzyme, constitutively expressed in ECs and considered a major weapon of 
vascular EC to fight vascular diseases (Viaro et al., 2000; Ding et al., 2007). 
eNOS can be reduced by cellular metabolism such as increase ROS 
generation, which the latter will lead to the reduction of NO bioavailability 
(Ding et al., 2007). 
 
23 
 
 
Figure 1.4: The structure of NO production in mammalian cells. (A): 
monomeric structure, each monomer consists of a reductase domain and 
oxygenase domain. (B): dimeric structure, in the presence of haem both 
monomers and reductase domains have the ability to transfer electron from 
the flavin to the haem of the opposite monomer. NOS then couple their haem 
and start synthesizing NO and L-citrulline when sufficient cofactor BH4, O2 
and substrate L-arginine are present,  
24 
 
1.2.2.2. eNOS function and dysfunction (uncoupling)  
In the absence of or decreased level of BH4, NOS transfers electrons to 
molecular oxygen producing superoxide anion (O2
.-) and H2O2 at the 
expense of NO, this phenomenon termed eNOS uncoupling (Landmesser et 
al., 2003; Kim et al., 2006). Thus, under certain pathophysiological 
conditions, eNOS can paradoxically become a source of ROS. Generation of 
superoxide anion by eNOS showed to be involved in a number of 
experimental and clinical vascular disease states including diabetes, 
hypertension, and atherosclerosis (Förstermann and Li, 2011). NO can react 
with superoxide anion to produce the potent oxidant peroxynitrite ONOO-, 
which is a destructive molecule causing oxidative damage, nitration and S-
nitrosylation of nearly all organic molecules such as proteins, lipids and DNA 
as shown in Figure 1.5  (Förstermann and Li, 2011). ONOO- in sequence 
oxidizes the cofactor BH4 to the inactive by-product trihydrobiopterin radical 
(BH3), and then to BH2 as shown in Figure 1.5 (Najjar et al., 2013). The 
chemical reactivity of peroxynitrite (-O-O-N=O) is due to its easy protonation 
and the O-O bond cleavage in the trans configuration of its acid form (Ullrich 
and Bachschmid, 2000). ONOO- is converted in the presence of excess NO 
to Nitrogen dioxide (NO2) and Dinitrogen trioxide (N2O3). These species are 
particularly thiophilic and impact thiol-mediated signalling pathways (Wink 
and Mitchell, 1998). 
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Figure 1.5: The potential mechanisms by which endothelial eNOS 
uncoupling leads to oxidative stress and EC dysfunction.  
1.2.3. Reactive oxygen species (ROS) 
Oxygen is a vital component of cellular metabolism (Woodrow, 2007a). 
However, any defect which results in acute or chronic over consumption of 
oxygen can lead to the production of free radicals, molecules containing one 
or more unpaired electrons which have high degree of reactivity, termed 
ROS. ROS formed by reduction of one or two electrons of the oxygen 
molecule (Sies, 1986). ROS are oxygen centred molecules which include the 
radicals such as, superoxide anion, hydroxyl radicals (HO.) and NO and non-
radicals which act as oxidising agents and/or are easily converted into 
radicals like, H2O2, hydroxyl anion (HO-) and singlet O2 (Folkes et al., 1995). 
ROS are produced continuously as by-products of many aerobic cellular 
metabolic pathways that are localized in different cellular compartments such 
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as mitochondria and peroxisomes (Cerutti, 1985), and are part of the 
unspecific defence system. In mammalian cells, ROS can be produced by 
enzymatic reactions including mitochondrial electron transport chain, the 
cytochrome P450s, xanthine oxidase, NADPH oxidases and uncoupled 
eNOS (Elahi et al., 2009). ROS can be beneficial to living systems as at low 
concentrations they are necessary for the regulation of several key 
physiological mechanisms (Valko et al., 2006), for instance cell 
differentiation, regulation of redox-sensitive signal transduction pathways. In 
immune defence, inflammatory cells such as neutrophils and macrophages 
have evolved a mechanism to use ROS as a powerful weapon against 
pathogens (Touyz and Schiffrin, 2004). One further beneficial example of 
ROS at low concentrations such as superoxide anion or H2O2, is the 
induction of a mitogenic response in variety of cells, resulting in increased 
rates of DNA replication and cell proliferation (Forkink et al., 2010). However, 
overproduction of ROS clearly can be toxic and damage cellular DNA, lipids 
and protein (Allen et al., 2011). Superoxide anion is considered to be the 
primary and most important ROS with a unique electronic configuration 
which has both reducing and oxidizing properties (Miller et al., 1990).   
Superoxide anion is produced by the addition of one electron to molecular 
oxygen either through metabolic processes or following oxygen activation by 
physical irradiation. Superoxide anion causes contraction of smooth muscle 
cells (SMC); it also rapidly scavenges NO within the vascular wall to reduce 
its biological half-life (Hattori et al., 1991), combining to form ONOO-. While 
the addition of two electrons yields the peroxide ion (O2
2-) which in biological 
systems is protonated to give H2O2, the latter does not contain an unpaired 
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electron and therefore is classified as stable ROS (Halliwell et al., 2000). In 
addition, H2O2 is not a free radical and does not necessarily interact with 
tissue through radical reaction directly (Keher, 1993).  
Cells contain antioxidant enzymes to keep levels of ROS under control as 
reviewed by Förstermann (2008), and Nordberg and Arner (2001). These 
cellular antioxidant enzymes include superoxide dismutase (SOD), catalase 
and glutathione peroxidase (GPx). All of these enzymes can reduce ROS 
toxicity either by forming a less active radical or by quenching the damaging 
free radical chain reaction on substrates like proteins, lipids and DNA 
(Dekkers et al., 1996). SOD represents a group of enzymes that catalyse the 
dismutation of superoxide anion into O2 and H2O2. Catalase is present in 
every cell in particular within the peroxisomes. Catalase has the ability to 
transfer H2O2 to water and O2 and also bind NADPH, which protects the 
enzyme from inactivation and increases its efficiency. GPx is present in cell 
cytosol and mitochondria, GPx converts H2O2 to water using secondary 
enzyme such as glutathione reductase (GR) and cofactors such as 
glutathione (GSH) and NADPH to function as shown in Figure 1.6 (Jones et 
al., 1981). 
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Figure 1.6: The enzyme system involved in the generation of ROS. (A): 
Number of enzymes involved in the production of ROS. (B): Overproduction 
of ROS results in oxidative stress and SOD catalyses dismutation of 
superoxide into H2O2. (C): H2O2 can be converted to the OH• in the presence 
of a transition metal, such as iron. (D):  Catalase has the ability to transfer 
H2O2 to water and O2. (E):  H2O2 can be detoxified via GPx.  
1.2.3.1. Mechanisms of ROS toxicity 
When free radicals react with non-radicals, other free radicals can be formed. 
This enables induction of chain reactions that may be thousands of events 
long, for instance hydroxyl radicals induces lipid peroxidation of 
polyunsaturated fatty acids via H2O2 abstraction (Kanner et al., 1987). 
Furthermore, the reaction of the hydroxyl radical with aromatic compounds, 
such as the purine base, guanine in DNA, is processed via H2O2 (Mello Fiho 
et al., 1984). Thus, ROS can react as both oxidising and reducing agents. 
Although the initial free radical produces only local effects, secondary 
radicals and degradation products can have biological effects distant from 
the site where the first free radical was formed. However, when two free 
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radicals react with each other, a stable molecule may be formed (Cheesman 
and Salte, 1993). These explain the eventual termination of free radical-
induced chain reactions. 
Superoxide anion is potentially toxic. It may directly influence local 
homeostasis by oxidising catecholamines, or it can be transformed into the 
hydroxyl radical via the Haber-Weiss reaction (Folkes et al., 1995). In 
contrast, H2O2 per se, is not especially toxic to cell macromolecules. 
However, it can cross the membranes of cells, which is potentially essential 
because the extracellular environment possesses few antioxidant defence 
mechanisms (Flora, 2009). In the presence of low concentrations of 
transition metal ions, such as iron and copper, hydroxyl radicals are formed 
from H2O2, via the Fenton reaction as described below. Alternatively, H2O2 
can interact with superoxide anion to produce the hydroxyl radical, by Haber-
Weiss type reaction. 
Ferric iron (Fe3+)/ Cu (II) + •O2
− → Ferrous iron (Fe2+) + O2 
Fe2+/Cu (I) + H2O2 ----> Fe
3+ + HO. + OH- 
Due to the charged nature of the superoxide anion it is more concentrated in 
the intracellular compartment. As a result, hydroxyl radicals are produced 
predominantly from H2O2 by Haber-Weiss reaction in the intracellular 
compartment whereas the Fenton reaction is more important in extracellular 
compartments (Fridovich, 1983).  
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1.2.3.2. Sources of ROS in the Endothelium 
ROS such as H2O2 and superoxide anion may be produced within the 
endothelium similar to other non-phagocytic cells such as SMC and 
fibroblasts, at relatively low levels in response to extracellular signals or 
stimuli. The principal sources of ROS in ECs are the mitochondria-specific 
manganese-dependent superoxide dismutase (MnSOD), NADPH oxidase, 
uncoupled eNOS (described in section 1.2.3.2), xanthine oxidase and 
cytochrome P450 (Li and Shah, 2004; Holley et al., 2011). 
1.2.3.2.1. The mitochondria as a generator of ROS 
Oxidative phosphorylation is the most critical function of mitochondria. This 
system contains four large multi-enzyme complexes, known as complexes, I, 
II, III, IV. Mitochondrial oxidative chain is a process in which electrons are 
extracted from NADH and FADH and transferred to molecular O2 through the 
chain of the four enzymes which is subsequently used to ensure the 
phosphorylation of adenosine diphosphate (ADP) to adenosine triphosphate 
(ATP). ATP production requires molecular O2 reduction to H2O2 (Li and Shah, 
2004). These enzymes transfer electrons along the electron transport chain 
(ETC) which generate a proton gradient, enabling generation of ATP 
(Turrens, 2003). Under physiological conditions, the mitochondria respiratory 
chain is the major source of ROS, namely superoxide anion generated as a 
by-product (Puddu et al., 2005). Superoxide anion has been implicated in the 
pathophysiology of CVD (Kovacic et al., 2005).  
 
e-+ O2→O2
- 
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2e-+ O2 +2H
+→H2O2
 
Since the mitochondria represent the most powerful cellular source of ROS 
in the body, it appears that mitochondria are primary target for their 
deleterious effects (Dröge, 2002). Mitochondrial DNA (mtDNA), which 
encodes for the majority of protein products that are essential components of 
the mitochondrial respiratory chain, is particularly sensitive to oxidative 
damage. Exposure of ECs to H2O2 or ONOO
- results in preferential damage 
to mtDNA over nuclear DNA, leading to mitochondrial dysfunction with 
decreased mitochondrial protein synthesis (Ballinger et al., 2002). Oxidative 
damage to the mitochondria can lead to decreased oxidative energetic 
capacity via impaired oxidative phosphorylation and enhanced generation of 
intracellular ROS.  
1.2.3.2.2. NADPH oxidase  
In the vasculature and kidneys, NADPH oxidases are the primary source of 
ROS (Babior et al., 2002; Feng et al., 2010). These are a family of multiple 
subunit complex enzymes that generate superoxide by the reduction of O2 
using NADPH or NADH as the electron donor, and the superoxide anion can 
be converted to H2O2 by SOD or to highly reactive hydroxyl radical or to 
peroxynitrite by reacting with NO. NADPH oxidase was originally discovered 
in phagocytes (neutrophils), where it plays an essential role in non-specific 
host defence against microbial organisms (Babior et al., 2002). Vascular 
NADPH oxidase consists of membrane integrated cytochrome b558 
(Griendling et al., 2000), and comprises seven isoforms, Nox1, Nox2, Nox3, 
Nox4, and Nox5, and Duox1 and Duox2 (BelAiba et al., 2007). In addition to 
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this membrane- associated catalytic core, the four cytosolic subunits 
(p40phox, p47phox, p67phox and the small GTP-binding protein Rac1or (Rac2)), 
are essential for the regulation of oxidase activity (DeLeo et al., 1998).  
Cytochrome b558 is comprised of two subunits, p22
phox and the catalytic 
gp91phox also known as Nox2 (Babior, 2004). In unstimulated cells, p40phox, 
p47phox and p67phox exist in the cytosol, whereas p22phox and the catalytic 
gp91phox are in the membrane, as a heterodimeric flavoprotein, cytochrome 
b558 (Paravicini and Touyz, 2008). However, on stimulation, p47
phox becomes 
phosphorylated and cytosolic subunits form a complex that translocates to 
the membrane, where it associates with cytochrome b558 to assemble the 
active oxidase, which transfers electrons from the substrate to molecular O2, 
forming superoxide anion and secondary ROS (Paravicini and Touyz, 2008). 
Although initially thought to be limited to phagocytes, it is now appreciated 
that many components of this oxidase including the catalytic Nox2 are 
expressed in non-phagocytes. For instance, Nox2, p47phox, p67phox and 
p40phox, and Pac1 are all expressed in ECs (Geiszt, 2006). In the vascular 
wall, CVD risk factors such as hypertension and diabetes, which are known 
to contribute to CKD stimulate ROS production, particularly of superoxide 
through the increase activity of NADPH oxidase, producing ONOO_ as 
described in section 1.2.3 (Förstermann and Münzel, 2006; González et al., 
2014). This uncouples eNOS and increases oxidative stress, which can 
contribute to vascular damage due to reduced bioavailability of NO shown in 
Figure 1.7 (Kuzkaya et al., 2003; Förstermann and Münzel, 2006; Joshi et 
al., 2013).  
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Figure 1.7: The role of CVD risk factors such as, hypertension and diabetes 
in NADPH-induced ROS generation, adapted from Förstermann and Münzel, 
2006. 
1.3. Oxidative stress, EC dysfunction and atherosclerosis development  
The term oxidative stress defined as high levels of ROS, which can cause 
cells and tissue damage (Sies, 1997; Dayem et al., 2010). High oxidant 
stress occurs when the formation rate of ROS exceeds the capacity of 
physiological antioxidant defence mechanisms (Higashi et al., 2009). The 
extent of oxidative stress has been variably determined by measurement of a 
decrease in total antioxidant capacity, through depletion of individual 
antioxidants such as vitamin E, vitamin C or GPx (Ogino and Wang, 2007). 
Atherosclerosis is a chronic low grade inflammatory disease (Ross, 1995; 
Dessì et al., 2013), and EC dysfunction occurs at an early stage (Totoson et 
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al., 2014). EC dysfunction involves abnormalities in the homeostatic function 
of vascular endothelium including disturbed vascular tone, haemostasis, and 
inappropriate inflammation (Cai and Harrison, 2000). It is evident that during 
CVD process, ROS overcome antioxidant defences, leading to oxidative 
stress (Davidson and Duchen, 2007). EC dysfunction is initiated or defined 
by reduced NO bioavailability and increase in endothelium-derived 
contracting factors like endothelin-1 (ET-1) due to increased oxidative stress, 
which  plays a key role in the reduction of NO biological activity via the up-
regulation of eNOS uncoupling as described in section 1.2.3.3 (Tziomalos et 
al., 2010; Cavieres et al., 2014). These abnormalities lead to impairment of 
endothelium-dependent relaxation of blood vessels, eventually resulting in 
cardiovascular disorders (Messner and Bernhard, 2014). In addition, under 
inflammatory conditions, such as atherosclerosis, activated leukocytes are 
attracted to the site of injury and facilitate the production of ROS which 
worsen the injury (Papatheodorou and Weiss, 2007). Furthermore, oxidative 
stress has been shown to increase vascular endothelial permeability, and 
this was supported by in vitro study in which direct treatment of bovine 
pulmonary artery ECs with H2O2 increased trans-endothelial permeability. 
H2O2 altered the vascular permeability via increased phosphorylation of 
tyrosine kinases, which potentiated binding of neutrophils on endothelium 
(Usatyuk et al., 2003; Vogiatzil et al., 2009). The early events of 
atherosclerosis include sublethal changes in EC, where the endothelium 
shows increased permeability to plasma proteins and lipoproteins, like low 
density lipoprotein (LDL), albumin and fibrinogen (Phinikaridou et al., 2012). 
LDL can be a target for ROS which is very cytotoxic for EC, and induces 
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inflammatory cells recruitment to the endothelium, a key event in 
atherogenesis (Spickett et al., 2013). LDL binds to extracellular matrix 
proteins of the sub-endothelial space and accumulates in the artery wall, 
where it can be oxidised (oxLDL) (Milioti et al., 2008). EC and leukocytes 
release chemokines that cause proliferation and migration of SMC from the 
media to the intima (Gosmanova and Le, 2011). SMC help in accumulation 
of collagen and proteoglycan which are essential factors for the plaque 
stability (Braunersreuther et al., 2007). Two phenotypes of plaque have been 
identified, those with thick fibrous cap and small lipid core and termed stable 
plaques which do not pose much danger of rupture inducing atherosclerotic 
complications. In contrast, unstable plaques are characterized by large lipid 
core and thin fibrous cap and are prone to rupture, inducing thrombosis 
leading to acute vascular events (Fuster et al., 1999; Mallat and Tedgui, 
2006).  
Oxidative stress is implicated in atherosclerosis (Hilliwell and Gutterige, 
1999; Son et al., 2011). Several lines of evidence indicate that oxidative 
stress induces EC activation and dysfunction by altering different pathways 
(Cai and Harrison, 2000). In the presence of increased ROS, ECs lose their 
protective phenotype and express proinflammatory molecules such as ICAM-
1, monocyte chemotactic protein-1 (MCP-1) and VCAM-1, which are 
regulated or controlled by a redox-sensitive transcriptional regulatory protein 
NF-κB as described in section 1.2.1.1 (Gosmanova and Le, 2011). In ECs, 
NF-κB is a prime target for ROS, has been shown to be redox sensitive and 
to be regulated by intracellular redox state (Meyer et al., 1994; Joshi et al., 
2013). In EC, oxidative stress particularly H2O2 plays a regulatory part in 
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other aspects of intracellular signalling, and has been shown to mediate 
activation of Mitogen activated protein kinase (MAPK) family members like 
p38 MAPK, which play a role in the activation of NF-κB (Ushio-Fukai et al., 
1998; Foncea et al., 2000). Growing evidence indicates that exposure of ECs 
to ROS induces apoptosis, leading to EC loss and results in atherogenesis 
and a procoagulative state (Dimmeler and Zeiher, 2000). Mechanisms of 
apoptosis are regulated by ROS through a variety of stimuli in EC including, 
oxidized LDL, angiotensin II, high glucose, and TNF-α, which are inhibited by 
N-acetyl cysteine (NAC), vitamins C and E, which will be discussed in detail 
in section 1.5 (Dimmeler and Zeiher, 2000). There is a well-established 
relationship between both oxidative stress and hypertension as angiotensin II 
signalling is also an important inducer of superoxide production in the 
vascular wall through up-regulation and activation of NADPH oxidase (Zalba 
et al., 2001). 
1.4. Role of oxidative stress and EC dysfunction in CKD 
As described in section 1.1.5, CKD patients are at greater risk of CVD and 
these patients are more likely to die from CVD than to develop to ESRD 
(Dhaun and Webb, 2013). Both dysfunction of ECs and oxidative stress are 
present in patients with moderate to severe CKD, which may explain the 
increased cardiovascular risk in CKD patients (Martens et al., 2011). 
Vascular cells, activated macrophages and glomerular cells are renal source 
of ROS, which all can play a role in renal diseases such as 
glomerulonephritis and tubulointerstitial nephritis; these suggest that the 
kidney may be particularly susceptible to oxidative stress (Ichikawa et al., 
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1994). A number of oxidative stress biomarkers such as lipid peroxides, 
malondialdehyde (MDA) and oxLDL (Agarwal, 2004; Diepeveen et al., 2004), 
and advanced oxidation protein products (AOPPs) were shown to be 
increased in plasma of CKD patients as a well as in those on dialysis 
(Stenvinkel et al., 2008). A study by Costa-Hong et al showed that, oxidative 
stress markers correlate with EC dysfunction in patients at stage 5 of CKD 
who have no sign of CVD. The results showed significant increases in 
thiobarbituric acid-reactive substances (TBARS), a marker of lipid 
peroxidation and a reduction of brachial-artery flow-mediated dilation, which 
indicate that increased oxidative stress could adversely affect endothelial 
function, and eventually cause CVD in CKD patients (Costa-Hong et al., 
2009). Furthermore, increased signs of oxidative stress and EC dysfunction 
are implicated with decreases in renal function, and showed to be present in 
early stages 1 and 2 of CKD (Tsuchikura et al., 2010). A study showed that 
levels of AOPP was significantly increased in early stages of CKD, and was 
gradually elevated with renal failure progression, as GFR was inversely 
associated with plasma concentrations of AOPP (Witko-Sarsat et al., 1998; 
Tsuchikura et al., 2010), suggesting that decline in renal function may have 
direct effect on worsening of endothelial function (Khaira et al., 2011). 
Moreover, perfused mesenteric arteries from rats that underwent renal mass 
reduction have impaired vasodilation in response to acetylcholine within 3-10 
days after surgery. This impairment was restored by treatment with SOD, 
indicating that at early stages of CKD, oxidative stress plays a role in EC 
dysfunction (Martens and Edwards, 2011). 
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One of the major effects of oxidative stress is the reduction in NO biological 
activity (Costa-Hong et al., 2009). Reduced NO bioavailability has been 
shown to contribute to glomerular hypertension and accelerate renal damage 
leading to more rapid progression of CKD (Baylis, 2008). Cross et al 
investigated the contribution of oxidative stress to the decreased NO 
bioactivity detected in ESRD patients, and the authors found there was a 
decrease in acetylcholine-induced forearm blood flow in these patients, 
which was improved by infusion of antioxidant vitamin C, demonstrating EC 
dysfunction was due to increased oxidative stress (Cross et al., 2003). The 
presence of inflammation is a well-documented factor influencing the 
development of oxidative stress in dialysis patients through the promotion of 
hypertension which is known as risk factor of both CVD and CKD, causing 
EC dysfunction (Samouilidou et al., 2003).  
Asymmetric dimethylarginine (ADMA) is a naturally occurring amino acid that 
circulates in blood and is excreted in urine, and is an endogenous inhibitor of 
all types of NOS (Memon et al., 2013). Some of ADMA is cleared by renal 
excretion from the circulation (Jacobi et al., 2014), However, it has been 
reported that, dimethylarginine dimethylaminohydrolase (DDAH) enzyme 
which contain two isoforms DDAH 1 and DDAH 2, is responsible for the 
clearance of the vast majority of ADMA extracting it from the circulation, 
through metabolizing it to L-citrulline and dimethylamine and therefore DDAH 
is able to determine NO bioavailability (Janssen et al., 2013). Reduced 
clearance of ADMA in renal failure is associated with EC dysfunction (Lin et 
al., 2002). Elevated ADMA levels have been linked with an increased risk of 
CVD events and total mortality (Sibal et al., 2010). Oxidative stress may 
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increase synthesis of ADMA by stimulating the expression of methyl 
transferases or by reducing DDAH activity (Zhang et al., 2010). In addition, it 
was reported that increased levels of plasma ADMA were present in patents 
with CKD and were associated with higher intima-media thickness and 
cardiovascular events (Zoccali et al., 2001). 
Both elevated ADMA and high oxidative stress have been reported to be risk 
factors for EC dysfunction as a result of reduced activity of NOS 
(Hackenhaar et al., 2014). In human ECs such as HUVEC, oxidative stress 
has been shown to decrease the activity of DDAH, resulting in an increase in 
ADMA concentrations. Therefore, an increased production of ROS could be 
the reason for increased ADMA levels (Sibal et al., 2010). In CKD, levels of 
plasma ADMA may increase from 3 to 9 fold, which leads to inhibition of NO 
production by 30-70% (Lu et al., 2011). The reduction of NO production and 
impairment of DDAH ability to metabolize ADMA, leading to impaired 
endothelium-dependent vasodilation and elevated platelet aggregation may 
explain why ADMA can be used as a cardiovascular marker, and may predict 
cardiovascular events in ESRD patients as shown in Figure 1.8 (Lu et al., 
2011).  
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Figure 1.8: Potential mechanism for EC dysfunction in CKD. Inhibition of 
endothelial eNOS by ADMA occurs via competitive inhibition of L-arginine 
binding, resulting in reduced NO production and EC dysfunction, CVD events 
and CKD progression. 
Elevated ADMA plasma level has also been reported in various CKD models 
(Halliwell, 1993). In a model of mouse CKD, high levels of ADMA caused 
impairment of endothelial function via impairment of eNOS function (Kajimoto 
et al., 2012). This was confirmed by Kajimoto et al who used rat model of 
CKD and showed that, treatment with intravenous DDAH 1 reduced 
circulating plasma levels of ADMA and oxidative stress, which in turn release 
the inhibition of eNOS, and consequently reversing CKD-induced EC 
dysfunction (Pacurari et al., 2013).  
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1.5. Antioxidant treatment  
Levels of ROS are maintained by the balance between ROS-generating 
mechanisms and the efficiency of antioxidant enzymes. Antioxidants are 
divided into two major groups, enzymatic section 1.2.3, and non-enzymatic 
antioxidants. Non-enzymatic antioxidants treatment for instance, vitamin C 
and NAC, have been extensively used both in vivo and in vitro studies of 
CKD and CVD, and are designed to reduce ROS and the associated 
vasculopathy (Kerkeni et al., 2006; Takacs et al., 2001). Because the level of 
oxidative stress is high in patients with CKD particularly those on dialysis 
(Jun et al., 2012), antioxidant treatment may potentially offer benefits for 
these patients, and this section will discuss the available evidence regarding 
the effect of non-enzymatic antioxidants in modifying oxidative stress in CKD 
patients. 
1.5.1. Vitamin C (ascorbic acid)  
Vitamin C/ascorbic acid is water soluble and represents one of the most 
essential antioxidants, and can be administrated orally or intravenously 
(Rahman, 2007). Doses at 100-200 mg/day of oral vitamin C or 300-500 mg 
thrice weekly of intravenous vitamin C are considered adequate and safe in 
HD patients (Kalantar-Zadeh et al., 2005; Zhang et al., 2013). In CKD and 
HD patients, 60-100 mg per day of vitamin C are recommended clinically and 
suggested to exert positive effects by inhibition of lipid peroxidation and 
decreasing endothelial damage (Biniaz et al., 2014). However, this 
recommendation might not be ideal since on a single dialysis, patients can 
lose over 100 mg of vitamin C, subsequently causing deficiency of vitamin C 
(Zhang and Zuo, 2014). In vivo oral vitamin C at doses greater than 500 mg 
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per day showed significant improvement of endothelial function in patients 
with coronary and peripheral vascular disease as assessed by flow-mediated 
dilation (FMD), forearm blood flow (FBF), and pulse wave analysis (PWA) 
(Ashor et al., 2014). In addition, vitamin C suppressed endothelial apoptosis 
mediated by inflammatory cytokines and oxLDL and, therefore, may prevent 
atherogenesis (Mallat et al., 2000). Vitamin C enhances NO synthesis in ECs 
and in vivo it has shown sustained beneficial effects on endothelial-derived 
NO-dependent flow-mediated dilation (Raitakari et al., 2000). However, 
vitamin C at high concentrations also can act as a pro-oxidant and produce 
hydroxyl free radicals by participating in the Fenton reaction as shown in the 
equation below (Cai et al., 2001; Zhang et al., 2014), causing severe side 
effects such as elevated generation of oxidative stress when used in the 
presence of IV iron preparations in CKD patients (Sturm et al., 2005). 
Moreover, because vitamin C is a reducing agent it therefore has the 
capacity to release iron from ferritin and activate iron from the 
reticuloendothelial system to transferrin, this in turn leads to increased iron 
availability and may prevent tissue iron overload further increasing oxidative 
stress (Sturm et al., 2005).  
 
    Reaction 1:  Ascorbate (AscH-) + Fe3+     Fe2+ + Ascorbate radical (Asc-) +H+ 
 
    Reaction 2:  Fe2+ + H2O2         Fe
3++ OH• +OH- 
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1.5.2. N-acetyl Cysteine (NAC) 
NAC could be derived from food or produced within the human body from 
cysteine and is rapidly metabolized to intracellular glutathione, which acts as 
a powerful antioxidant in the body (Atmaca, 2004). Glutathione is 
synthesised in the body via three amino acids, glutamic acid, glycine and 
cysteine. Both glutamic acid and glycine are plentiful in cells and therefore 
the availability of Cys controls glutathione production (Atmaca, 2004). In 
clinical practice, NAC can be orally administered at dose 600 to 1200 mg 
twice daily where GFR is less than 60 ml/min per 1.73 m2 (Rehman et al, 
2008). NAC has been shown to inhibit NF-κB activation in HUVEC cultured 
with plasma from women with severe preeclampsia (Takacs et al., 2001). 
The effect was shown to be through scavenging ROS which are known to 
activate NF-κB and also block the expression of ICAM-1 mediated by NF-κB. 
Furthermore, NAC was shown to reduce H2O2-induced p38 MAPK activation 
in lung microvascular EC (Peter et al., 2003). NAC has been shown to be 
effective in reducing several of cardiovascular events and oxidative stress in 
HD patients (Tepel et al., 2007; Coombes and Fassett, 2012). Following 
exposure of human proximal tubule epithelial cell line to H2O2, NAC 
decreased lipid peroxidation and maintained the mitochondrial membrane 
potential, thus preventing apoptosis (Ye et al., 2010). In diabetic mouse 
model of CKD, NAC also reduced level of kidney MDA (Ribeiro et al., 2011). 
In addition, NAC has been previously shown to decrease the plasma level of 
ADMA (Tepel et al., 2003). Furthermore, administration of NAC at 1200 mg 
twice a week for 15 days, significantly improves renal function in HD patients 
(Feldman et al., 2012). In vivo study by Swarnalatha et al (2010) showed that 
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treatment with NAC (600 mg twice daily for 10 days) prior to IV iron therapy 
with IV iron sucrose reduced EC dysfunction and MDA as a marker of 
oxidative stress in CKD patients.  
1.6. Iron 
1.6.1. Iron function and metabolism 
Iron is vital for life and an essential trace metal required for almost all living 
organisms, participating in a wide variety of metabolic and physiological 
processes in every living cell these include, DNA synthesis, electron transfer 
reactions, gene regulation, binding and transport of oxygen, and regulation of 
cell growth and differentiation (Andrews, 1999). In addition, iron is 
considered as an essential component of many proteins and enzymes that 
maintain good health. Iron is also essential for expression of protein kinase 
C-β, a member of the protein kinase C family of intracellular signalling 
pathways required for cell growth and differentiation (Boldt, 1999). 
Furthermore, several enzymes including NOS, oxidases, cytochromes, 
catalases and peroxidises, which are critical in many basic cellular process 
like DNA and RNA synthesis, and also contribute to the development of a 
number of diseases contain iron as a key component of these enzymes 
(Boldt, 1999). The total serum iron levels in the body for adults who ingest a 
diet free of iron are between 3-4 g (Weinberg, 1990), and its level in the body 
must be tightly regulated because excessive iron leads to tissue damage. 
Roughly 60 to 70% of total body iron is bound to as well as being component 
of Hb which is circulating in the RBCs (Conrad et al., 1999). Another 10% is 
a constituent of myoglobin, cytochromes, and other iron-containing enzymes 
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amounting to no more than 0.4-0.8 mg of iron. In healthy individual, the 
remaining 20 to 30% is bound to the iron storage proteins, ferritin and 
hemosiderin (Cheng and Li, 2007). Although only 0.1% (approximately 4 mg) 
of the total body iron is transported in plasma complexed with transferrin, it is 
the most significant iron pool and has the highest turnover. The turnover of 
the iron bound to transferrin is about 25 mg/day. 80% of transferrin bound-
iron is transported to bone marrow for the synthesis of the Hb in developing 
erythroid cells (Conrad et al., 1999). From these sites, immature RBCs or 
reticulocytes are released into the circulation and within one day, they 
develop into mature RBCs (Bottomley et al., 1995). Hb is the primary protein 
in RBCs, transports oxygen form the lung to the tissues and transport back 
the carbon dioxide to the lung. Hence, iron plays a crucial role in proteins 
involved in oxygen transport and any deficiency in iron can limit oxygen 
delivery to cells which results in fatigue and decreases immunity (Andrews, 
1999).  
1.6.2. Iron chemistry and its role in the human body 
1.6.2.1. Iron and oxidative stress 
Iron is required for diverse cellular functions. The biological importance of 
iron is in its chemistry. Iron occurs in oxidation states Fe2+ and Fe3+, and is 
capable of accepting and donating electrons readily. This capacity makes it 
an important component of molecules that bind to oxygen such as 
haemoglobin and myoglobin (McCord et al., 1998). However, iron is also 
biochemically dangerous and toxic when present in excess as a result of the 
formation of free radicals which can damage the cells (Lee et al., 2006a). 
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It is believed that high levels of iron generate oxidative stress due to an 
increase in the steady state of ROS concentration, both H2O2 and superoxide 
anion raise the toxicity from their iron-dependent transformation into the 
highly reactive OH∙ and this can lead to severe damage to proteins, 
membrane and DNA (Halliwell et al, 1984). Under normal conditions, this 
threat is reduced by the fine regulation of iron metabolism, which prevents 
the production of ROS. However, under certain pathological conditions, the 
metabolism of both iron and superoxide are clearly interactive. Each can 
exacerbate the toxicity of the other (Lipinski and Drapier, 1997). Several 
studies have demonstrated that, mutations in antioxidant SOD and ferric 
uptake regulator (fur), which is a protein responsible for coordinating the 
expression of iron uptake and storage function may lead to excess level of 
superoxide and iron overload (Iolascon et al., 2009). Through these 
conditions, redox active iron can participate in stimulating lipid peroxidation 
and the formation of OH∙ canalization with subsequent tissue damage 
(Iolascon et al., 2009).  
Free iron plays a crucial role in oxidative stress (Gutteridge and Halliwell, 
1994). Free iron is controlled by a number of automatic mechanisms in the 
body, which is immediately chelated in cells by compounds such as citrate or 
ADP and renders it non-toxic or inactive (Prousek, 2007). This unbound or 
free iron could generate high reactive OH∙ by participating in the Haber-
Weiss reaction, a reaction where OH∙ generated from an interaction between 
H2O2 and superoxide and catalysed by iron as described below (Prousek, 
2007). In the first step of this reaction superoxide anion reduces Fe3+ ion to 
Fe2+. 
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                                          Fe3+ + O2
.-→ Fe2+ + O2 
The second step of the reaction is the Fenton reaction, where the H2O2 is 
reduced to form hydroxyl radical and hydroxyl ion. 
 Fe2+ + H2O2 ----> Fe
3+ + OH∙ + OH- 
Net reaction 
                                    O2
.-+ H2O2 → OH∙ + OH
- + O2 
OH∙ is highly reactive with a half-life of approximately 10-9 seconds and has 
the capacity to abstract a hydrogen atom from polyunsaturated fatty acids 
(LH) to initiate lipid peroxidation, once lipid hydroperoxide (LOOH) 
accumulate. An additional lipid peroxidation may be directly initiated by the 
unbound iron, which will destroy membrane structure and function (Nelson 
and McCord, 1998). 
. 
OH° + LH → H2O + L° 
L° + LH → LOO° 
LOO° + LH → LOOH + L° 
Fe2+ + LOOH → Fe3+ + LO° + OH− 
 
OH- can damage lipids, proteins, DNA, sugars, and generally all organic 
molecules. Hence, high amounts of unbound iron play a crucial role in 
oxidative stress and can have deleterious effects, especially in case of 
48 
 
overproduction of superoxide, like during inflammatory reactions (Kakhlon 
and Cabantchik, 2002). 
1.6.3. Iron therapy 
1.6.3.1. Intravenous iron preparations and CKD 
Anaemia is considered one of the major co-morbidities linked to patients with 
CKD on HD (Besarab, 1999). There are several causes of anaemia in CKD 
patients, such as poor nutrition, frequent blood loss, vitamin deficiencies 
(B12 and folate) and inflammation (Koshy et al., 2008). However, the primary 
cause is an inadequate quantity of endogenous EPO. In addition, the vast 
majority of patients with CKD can already have iron deficiency which is also 
a common cause of anaemia as a result of low protein diet or gastrointestinal 
bleeding (Eschbach and Adamson, 1985). EPO is a glycoprotein hormone 
produced by the peritubular capillary cells in the kidney. It promotes the 
formation of red blood cells in the bone marrow. Therefore, optimal 
management of anaemia associated with CKD can be efficiently corrected by 
recombinant human erythropoietin (rhEPO), widely and routinely used 
instead of transfusion of blood, which was formerly used (Nissenson, 1991). 
In CKD patients, in order to avoid iron deficiency, maintain adequate iron 
stores (serum ferritin > 100 μg/L or TSAT > 20%) and support erythropoiesis, 
iron replacement therapy should be administered therefore reducing 
consumption of the highly cost rhEPO and to achieving haemoglobin target 
level in order to manage the anaemia (Hasegawa et al., 2011). Iron can be 
given either orally or intravenously, and because oral iron is adequate for the 
treatment of many iron-deficient patients poorly absorbed in CKD patients 
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due to gastrointestinal upset (diarrhoea and constipation) or due to the 
inflammation associated with these patients (Spinowitz et al., 2008). 
Therefore, IV iron is better choice than oral iron and considered as the key 
component of anaemia management for CKD patients. IV iron is 
administered frequently (≤200 mg), needing from 5 to 8 visits for the 
administration of 1 g or it can be administered as a large dose depending on 
IV iron type (Silverberg et al., 1999; Van Wyck et al., 2005; Spinowitz et al., 
2008). IV iron was first introduced for human use in the early 20th century 
(Heath et al., 1932; Garneata, 2008). There are a variety of IV iron products 
used in treatment of iron deficiency anaemia in CKD such as low molecular 
weight iron dextran, ferric gluconate, iron sucrose, ferric carboxymaltose 
(FCM) and ferric chloride hexahydrate (Moore et al., 2011). Iron dextran was 
commonly used from 1950 to 2000, however has subsequently been largely 
replaced worldwide by ferric gluconate and iron sucrose (Wang et al., 2008). 
IV iron preparations have formulations that consist of an iron core 
surrounded by a stabilized carbohydrate shell to encapsulate the bioactive 
iron; this was because of the instability of the compound, permitting iron to 
dissociate in the circulation causing toxicity (Danielson, 2004). Each one ml 
of IV iron sucrose solution contains 20 mg of iron as iron sucrose (iron (III)-
hydroxide sucrose complex), where one mL of IV FCM solution contains 50 
mg of iron as ferric carboxymaltose. These types of IV iron preparations all 
differ in core size and identity of the shell, which determine the 
pharmacological properties of the agent such as stability and iron release 
(Danielson, 2004). In addition, pharmacokinetic properties vary between 
these compounds, where IV iron sucrose has the lowest molecular weight 
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(140 KDa), shortest half-life (6hr) and lowest stability compared with IV FCM 
which has higher molecular weight of (233 KDa), half-life of (7-12hr) and is 
more stable (Jahn et al., 2011; Geisser and Burckhardt, 2011; Nordfjeld et 
al., 2012). All these differences suggest that IV FCM may have a safer profile 
and may induce less toxicity than IV iron sucrose (Funk et al., 2010; Toblli et 
al., 2011; Prats et al., 2013). Iron dextran can be administered as a single 
dose, but this requires administration over a period of 4 to 6 hr, but has been 
associated with hypersensitivity reactions that have limited its use (Bailie et 
al., 2005; Gisbert and Gomollón, 2008). IV iron sucrose is given as 1000 mg 
in divided doses, as a slow push injection or 15 to 30 min infusion in doses of 
100-200 mg, which require multiple outpatient visits and repeated 
intravenous access. IV FCM can be administered as a large replenishment 
dose (1000-1500 mg of iron) over a short infusion in 15-30 min; however, 
only doses up to 1000 mg are currently approved (Lyseng-Williamson and 
Keating, 2009). It has been documented that parenteral iron administration is 
efficient and safe (Chertow et al., 2006). However, because of iron’s potent 
oxidant activity, concerns have been raised about parenteral iron leading to 
over saturation of transferrin, producing iron overload and potentially 
increasing oxidative stress which is already a factor in CKD patients (Deicher 
and Horl, 2002). Following injection, IV iron supplementations are initially 
processed in the reticuloendothelial system (RES) of the liver and spleen but 
large amounts of these compounds are distributed to RES of the bone 
marrow, where phagocytes liberate iron to be stored in ferritin or released 
back to the circulation as transferrin-bound iron (Beshara et al., 1999; 
Beshara et al., 2003). Large doses of IV iron can exceed storage capacity 
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leading to non-transferrin-bound-iron (NTBI) being released into the 
circulation. In addition, some iron can directly bind to transferrin without 
passing through RES as shown in Figure 1.9; this unbound iron via the 
Fenton reaction can produce the potent hydroxyl radical (Kalyanaraman, 
2013), as described in section 1.2.3. All these factors are believed to 
increase oxidative stress, thereby worsen the cardiovascular outcome of 
CKD patients, leading to EC dysfunction and inflammation as shown in 
Figure 1.9. Furthermore, in vivo and in vitro studies have shown that IV iron 
administration increases oxidative stress biologic markers; iron sucrose 
increases oxidative stress markers of lipid peroxidation such as MDA and 
free iron in dialysis patients. Iron sucrose can also be associated with EC 
injury and dysfunction, promoting apoptosis and inhibiting proliferation in 
cultured ECs (Kartikasari et al., 2006). Zager et al found that all the three IV 
iron preparations mentioned above led to some degree of lipid peroxidation 
(Zager et al., 2002). In a study in 2004 on 20 patients at stages 3-4 of CKD, 
who were injected with 100 mg IV iron sucrose over 5 min, increased plasma 
and urine levels of MDA occurred after 15-30 min of administration, and 
returned to baseline after 24hr (Agarwal et al., 2004). Leehey et al found that 
IV administration of ferric gluconate to CKD patients, increases oxidative 
stress, assessed by increased level of plasma and urine MDA (Leehey et al., 
2005). In 2007, another study was carried out to investigate the effect of IV 
iron administrations on markers of oxidative stress. This study, involved 12 
patients undergoing HD, who each received 100 mg/ml IV iron sucrose, iron 
dextran or ferric gluconate consecutively with 14 days washout stage 
between each IV iron compound administration. It was found that IV iron 
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sucrose and ferric gluconate were associated with greater NTBI levels 
compared with iron dextran. In addition, all three compounds induced 
oxidative stress as reflected by increased level of MDA (Pai et al., 2007).  
 
 
Figure 1.9: Metabolism of IV iron preparation. Once administered IV iron is 
processed in the RES, where phagocytes liberate iron to be stored in ferritin 
or released back to the circulation as transferrin-bound iron. IV formulations 
can deliver a small amount of iron directly to transferrin without being 
processed in the RES. There is concern that oversaturation of transferrin 
results in increased extracellular iron bound to negatively charged 
compounds and is accessible for generation of free radicals via the 
Fenton/Haber–Weiss reactions. This unbound iron or NTBI via the Fenton 
reaction can produce the hydroxyl radical, resulting in EC dysfunction and 
subsequently CVD in CKD patients. 
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1.7. Apoptosis 
Apoptosis or programmed cell death was coined by Kerr et al. in 1972, and 
can be distinguished from necrosis through different morphological and 
biological features such as, cell shrinkage, membrane blebbing, nuclear and 
cell fragmentation as shown in Figure 1.10 (Ding et al., 2007). Apoptosis is 
an essential biological and tightly regulated process for normal development 
to maintain cell populations in tissues and maintenance of homeostasis also 
occurs as a protective mechanism such as in immune reactions or when 
cells are damaged by disease including cancer and CVD (Norbury and 
Hickson, 2001). A key feature that differentiates apoptosis and necrosis is 
that apoptosis does not induces an inflammatory reaction (Rock and Kono, 
2008). In mammals, initiation and regulation of apoptosis can be through one 
of two major signalling pathways the intrinsic pathway, which depends on the 
participation of mitochondria and is mediated by Bcl-2 family members, and 
the extrinsic pathway which occurs through death-receptor interactions, 
principally those involving the tumour necrosis factor-receptor (TNF-R) 
family, including TNF receptor-1 or the Fas receptor (Zimmermann and 
Green 2001). These two pathways are responsible for the activation of 
cysteine protease enzymes known as caspases. There are three types of 
caspase and initially all are present as inactive pro-enzymes that require 
dimerization including, initiator caspases (2, 8, 10 and 9), effector caspases 
(3, 6 and 7) and inflammatory caspases (1, 4 and 5) (Cohen, 1997; Strasser 
et al., 2000).  
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Figure 1.10: Image shows different morphological and biological features of 
apoptosis such as, cell shrinkage, membrane blebbing, nuclear and cell 
fragmentation. 
1.7.1. Extrinsic pathway apoptosis 
In the extrinsic pathway, the death receptor Fas recruits Fas-associated 
death domain (FADD) to the death-inducing signalling complex (DISC) 
through interaction with death effector domain (DED) of pro-caspase-8, 
which in turn result in its autocatalytic activation (Ashkenazi, 2002). The 
initiator caspase-8 activates further caspases (including the effector 
caspases-3, 6 and 7), which are critical in cell death (Yang et al., 2005) as 
shown in Figure 1.11.  
1.7.2. Intrinsic pathway apoptosis 
The mitochondrial apoptotic pathway is triggered by numerous stimuli 
including DNA damage, cytotoxic drug, oxidative stress and pro-apoptotic 
signal-transducing molecules which act on mitochondria to induce outer 
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mitochondrial membrane permeabilization (Chipuk and Green, 2008; Muñoz-
Pinedo, 2012). This permeabilization is regulated by pro-apoptotic proteins 
from the B cell lymphoma-2 (Bcl-2) family such as Bax (Fulda and Debatin, 
2006). Upon disruption of the outer mitochondrial membrane, proteins 
normally found in the space between the inner and outer mitochondrial 
membranes are released, including cytochrome c (Loreto et al., 2014). When 
released from mitochondria into the cytosol, the cytochrome c promotes the 
assembly of apoptosome (Rowinsky, 2005; Loreto et al., 2011). The 
apoptosome is a multimeric protein complex involving apoptotic protease 
activating factor-1 (Apaf-1) where the cytochrome c binds to Apaf-1 and 
caspase-9, and forms a complex which becomes activated in the presence of 
ATP or Deoxyadenosine triphosphate (dATP) (Yu et al., 2005). The activated 
caspase-9 subsequently cleavages other downstream caspases like 
caspase-3, which result in cell apoptosis (Li and Yuan, 2008; Tan et al., 
2014).  
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Figure 1.11: Representative image shows the apoptosis pathways (intrinsic 
and extrinsic). 
 
1.7.3. Bcl-2 Family proteins 
Bcl-2 was first identified as a gene product that causes resistance to 
apoptosis in lymphocytes (Bakhshi et al., 1987). The Bcl-2 family proteins 
are key regulators of apoptosis and can be divided into three main 
subfamilies based on their function and the number of BCL-2 homology (BH) 
domains. Family members include, anti-apoptotic proteins (Bcl-2, Bcl-xL,A1 
and Mcl-1), which are characterized by the BH1-4 domains, and two pro-
apoptotic protein groups (Bax and Bak), and (Bim, Puma, Noxa, Bid, Bad, 
Bik, Bmf, Hrk), which are characterized by the presence of BH1-3 domains 
and BH3-only group (containing only the BH3 domain) (Wang et al., 1996;  
Brunelle and Letai, 2009) as shown in Figure 1.12. In normal viable cells, the 
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majority of Bax exists as a monomer in the cytosol or attached to the outer 
mitochondrial membrane, and translocate to the mitochondria in response to 
apoptotic signals (Wolter et al., 1997). Bax and Bcl-2 play an essential role in 
regulating the changes in mitochondrial outer membrane permeability 
(MOMP) (Youle and Strasser, 2008). The anti-apoptotic Bcl-2 promotes cell 
survival by preventing changes in MOMP by neutralizing the activity of both 
pro-apoptotic members BH3 only protein and multi domain members (Youle 
and Strasser, 2008), while activation of pro-apoptotic protein Bax and Bak 
can strongly influence the progression of cells towards death via apoptosis 
through the release of apoptogenic factors, such as cytochrome c and Smac 
from mitochondrial intermembrane space (IMS) into the cytosol (Wei et al., 
2001; Wang, 2001). Cytochrome c is a water soluble protein and considered 
as the main mediator of apoptosis, which can be inhibited by overexpression 
of Bcl-2 protein (Yang et al., 1997; Pellegrini and Scorrano, 2007). Once 
released, cytochrome c promotes the formation of the apoptosome that 
includes pro-caspase-9 and its adaptor Apaf-1 (apoptotic protease-activating 
factor-1), transforming pro-caspase-9 into its active form, which in turns 
proteolytically activates the effector caspases (3, 6 and 7) to initiate the 
execution of apoptosis (Degterev et al., 2003). 
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Figure 1.12: The Bcl-2 protein family members. Anti-apoptotic Bcl-2-family 
members contain all four BH domains. Pro-apoptotic Bcl-2-family members 
can be separated into multi-domain or BH3-only proteins. Some pro-
apoptotic proteins (BH3-only proteins) do not have a transmembrane Domain 
(TM), such as Bid, Puma, Bad and Noxa. 
1.8. Mitogen activated protein kinase (MAP kinase) 
Mitogen activated protein kinases (MAPKs), are a family of serine-threonine 
kinases that mediate important cellular functions and responses including 
proliferation, differentiation, development, transcription, stress response, and 
apoptosis (Plotnikov et al., 2011). They mediate cellular responses to 
external stimuli, including soluble factors such as, growth factors, hormones 
and cytokines (Barr and Bogoyevitch, 2001). MAPKs require dual threonine 
and tyrosine phosphorylation in an activation loop (Thr‐Xaa‐Tyr motif), in 
which MAPKK Kinase (MAPKKK or MAP3K) phosphorylates and activate 
MAPKK or (MAP2K). This MAPKK in turn phosphorylates and activates 
MAPK, which phosphorylate and activate their specific target proteins both 
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cytosolic proteins and transcription factors such as C-myc (Huang and 
Ferrell, 1996; Barr and Bogoyevitch, 2001; Roux and Blenis, 2004). The 
MAPK signalling cascades are often initiated by receptor-mediated activation 
of members of the small monomeric G protein family, such as Ras, Rac or 
Rho (Loirand et al., 2013). The MAP kinase pathway consists of four 
families, which are referred to as extracellular signal-regulated kinases 
(ERKs) consisting of two proteins: ERK1 and ERK2, p38 MAPK: p38α, p38β, 
p38γ and p38δ MAPK, Jun‐N‐terminal kinases (JNKs): JNK1, JNK2 and 
JNK3 (also known as stress-activated protein kinases, SAPKs). There is also 
ERK5 as shown in Figure 1.13 (Sebolt‐Leopoldm and Herrera, 2004; Wagner 
and Nebreda, 2009). In mammals, there are seven MAPKKs, which have 
some specificity towards MAPKs as shown in Figure 1.13 (Rose et al., 2010). 
These MAPKKs consist of, MEK1 and MEK2 which activate ERK 1 and 
ERK2, MEK5 for activation of ERK5, MKK4 and MKK7 activate JNKs, and 
MKK3 and MKK6 to activate p38 MAPKs as shown in Figure 1.13 (Rose et 
al., 2010). In addition, there are at least twenty MAPKKK, of which six 
regulate the ERK1 and 2 pathways, twelve regulate the JNK pathway and 
ten MAP3Ks regulate the p38 MAPK pathway as shown in Figure 1.13 
(Cargnello and Roux, 2011). 
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Figure 1.13: The Schematic of MAPK signalling pathways. Activation 
pathway of all MAPK family members is composed of three consecutive 
kinases (MAPKKK, MAPKK, and MAPK). 
ERK1 and ERK2 pathway can be activated in response to growth factors, 
cytokines, certain stresses, ligands for small G protein-coupled receptors 
(GPCRs), and are involved in cell proliferation and survival (Svensson et al., 
2011). JNK and p38 MAPK can be activated in response to a number of 
exogenous stimuli like growth factor deprivation, pro-inflammatory cytokines 
such as TNF-α, and have been shown to be implicated in apoptosis, 
proliferation and survival, depending on the stimuli and cellular conditions 
(Junttila et al., 2008; Schutters and Reutelingsperger, 2010). P38 MAPK will 
be discussed in more detailed in section 1.8.1. 
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1.8.1. Role of p38 MAP kinase in apoptosis  
There are three isoforms expressed in ECs, p38α, p38β and p38δ (Cuenda 
and Rousseau, 2007). Isoforms p38α and p38β are ubiquitously expressed 
at significant levels in ECs and they are sensitive to pharmacological 
inhibitors such as SB203580, which act as specific inhibitors of p38 MAPK 
signalling pathway (Kumar et al, 1997; Porras et al., 2004), p38α is also the 
most abundant p38 MAPK family member, while p38γ and p38δ are 
differentially expressed depending on the tissue (Porras et al., 2004). P38 
MAPK signalling pathways are activated by phosphorylation on both tyrosine 
(Tyr182) and threonine (Thr180) residue, which is mediated by the upstream 
activation of MEK3 and MEK6 (Derijard et al., 1995; Banh and Hales, 2013). 
In addition, MAP3Ks shown to trigger the activation of p38 MAPK pathway 
include ASK1 (apoptosis signal kinase 1), TAK1 (transforming growth factor 
β-activated kinase 1) and TPL2 (tumour progression loci 2) as shown in 
Figure 1.13. P38 MAPKs are activated in response to different inflammatory 
cytokines, hormones, stress factors, ligands that activate GPCRs and 
physical stresses such as, osmotic and heat shock leading to the regulation 
of cellular functions such as proliferation, differentiation and survival 
(Pearson et al., 2001). P38 MAPK is also activated in response to elevated 
oxidative stress and this activation was shown to be associated with 
apoptosis (Callsen and Brune, 1999). Role of p38 MAPK in the regulation of 
apoptosis is dependent on the cell type and stimuli. In neuronal cells, p38α 
MAPK was shown to mediate apoptosis (Wang et al., 1998), and in cardiac 
cells upon stimulation with TNF-α (Ghatan et al., 2000).  
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P38 MAPK was shown to mediate Bcl-2 protein phosphorylation in growth 
factor-starved memory B lymphocytes, which caused apoptosis (Torcia et al., 
2001). In addition, up-regulation of both Bax protein expression and Bax 
mRNA has been reported to be mediated by p38 MAPK in a cardiomyocyte 
derived cell line, leading to apoptosis (Porras et al., 2004). Furthermore, in a 
study by Grethe et al (2004) showed that treating an endothelial cell line 
(EA.hy926) with TNF-α induced phosphorylation of p38 MAPK which in turn 
led to the activation of caspase 3, and treatment with p38 MAPK inhibitor 
(SB203580) caused 50% reduction of TNF-induced activation of caspase-3 
and cell death, indicating that p38 MAPK play an important role in the 
apoptosis of ECs. As overproduction of ROS plays major role in the initiation 
and progression of CVD, its role as a second messenger to activate p38 
MAPK and its associated downstream transcription factors such as NF-κB 
and AP-1, which then can regulate the expression of numerous pro-
inflammatory genes, results in cell injury (Sun et al., 1996; Dröge, 2002). 
Accumulation of intracellular ROS disrupt the mitochondrial membrane 
potential, release of cytochrome c with subsequent activation of the caspase 
cascade, and, ultimately, leads to apoptosis (Jabs, 1999; Jing et al., 1999). 
ROS such as H2O2 was shown to induce apoptosis of ECs via activation of 
p38 MAPK (Natarajan et al., 2001). Recently generation of ROS in EBV-
transformed B cells was shown to activate p38 MAPK, resulting in up-
regulation of Bax and activation of caspase-9 and caspase-3, and 
subsequent apoptosis (Park et al., 2014). 
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1.9. AIMS  
As has been reviewed in the introduction, vascular damage in CKD is a 
major problem. The reliance on IV iron treatment means it is important to 
investigate the mechanisms and extent by which different iron treatments 
induce activation and damage to EC, leading to dysfunction. Thus, fully 
understanding the mechanisms leading to vascular damage by IV iron 
preparations can be beneficial in designing treatment regimens to reduce 
development, progression and early morbidity and mortality of CVD in 
patients with CKD. Due to lack of availability of ECs from CKD patients, 
clinical iron preparations will be used in vitro with primary EC from healthy 
sources (HUVEC). Treatment of healthy EC with the clinically IV iron 
preparations used for CKD patients will be critical to understand the 
mechanisms that lead to EC dysfunction and which can then be extrapolated 
to effects in the kidney of patients with CKD. The project has a number of 
objectives: 
 Study the ability of IV iron sucrose or IV FCM to alter the growth 
characteristics, morphology and viability of HUVECs. 
 Assessment of the extent to which each IV iron preparations induce 
endogenous ROS generation in HUVEC by the measurement of 
intracellular superoxide anions and total intracellular ROS production 
in HUVEC with the aim of correlating with differential EC damage and 
CV risk in CKD patients. 
 Determine extent of functional changes seen in the EC in response to 
IV iron sucrose or IV FCM exposure. Both EC activation by the 
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assessment of endothelial adhesion molecule expression (ICAM-1 
and VCAM-1) and apoptosis will be quantified. This in vitro data links 
the role of ROS to functional changes in EC which importantly can be 
correlated with increased CVD, the primary cause of death in patients 
with CKD. 
 Importantly the in vitro system allows direct assessment of the 
mechanisms important in driving these functional changes, something 
difficult to assess in vivo and signalling pathways with a role in 
apoptosis such as Bcl-2/Bax and p38 MAP kinase will be identified. 
 Evaluation of the role of IV iron compounds in EC apoptosis, which 
may be a promoter of atherosclerosis. Specifically of interest is p38 
MAPK pathway and associated proteins, such as Bcl-2 and Bax.  
 Investigation of the benefit of treatment with antioxidants such as NAC 
in reducing oxidative stress generated by IV iron preparations and 
their downstream ability to cause EC dysfunction, therefore giving an 
indication of potential therapeutic strategies for preventing or 
decreasing EC dysfunction/damage and CVD in patients with CKD.  
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CHAPTER 2 
THE EFFECT OF INTRAVENOUS IRON PREPARATIONS ON GROWTH 
OF HUMAN ENDOTHELIAL CELLS  
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2.1. INTRODUCTION 
CKD is a worldwide health concern, affecting approximately 5-7% of world 
population (Couser et al., 2011) and over 13% of the western population 
(Coresh et al., 2007). CKD is recognised as an important risk factor for CVD 
development (Moe et al., 2003). Particularly, patients in early stages of this 
complex disease have a higher risk of death due to CVD, than they are to 
progress to ESRD or renal transplantation (Schiffrin et al., 2007). In addition, 
CVD is considered as the main cause of death among CKD patients, with the 
rate of CVD being twice as common compared with the general population 
(Collins et al., 2003). The risk of death from CVD in dialysis patients is 9% 
per year of haemodialysis (Coen et al., 2007), and 30% of all deaths 
worldwide among general population (Anderson and Chu, 2007). A study by 
Keith et al (2004), on CKD patients at stages 2, 3 and 4 showed that, death 
due to CVD occurred before the patients had the opportunity to receive renal 
replacement therapy. Furthermore, a UK study found that only 4% of 
individuals progressed to ESRD over a 5.5 year follow-up period, whilst 69% 
had died at the end of follow-up; the cause of death was cardiovascular in 
46% of cases (Drey et al., 2003). Atherosclerosis is an inflammatory vascular 
disease, characterized by the accumulation of lipids, inflammatory cells, and 
connective tissue within the intima-media layer of the arterial wall (Libby, 
2002). Atherosclerosis is frequently associated with CVD and has been 
recognized as one of the most serious and frequent complications occurring 
in patients suffering from CKD (Luczak et al., 2011). In addition, these 
patients have a 20 fold higher prevalence of premature arterial 
atherosclerosis compared with general population (Luczak et al., 2011). 
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Atherosclerosis is considered as the leading cause of ischemic heart disease 
in dialysis patients (Luczak et al., 2011). ECs act as a barrier (the 
endothelium) between tissue and the blood constituents (Belle et al., 1998; 
Bonetti et al., 2003). ECs plays critical role in overall homeostasis by the 
synthesis of various paracrine substances that regulate vascular tone and 
permeability, coagulation and fibrinolysis, and inflammatory responses in the 
vessel wall, including NO, angiotensin II and ROS. ECs also interact with 
other cell types such as VSMC, platelets, and leukocytes (Pober and Sessa, 
2007). Due to these roles anything that causes EC dysfunction could be 
considered among the primary causes of atherosclerosis (Davignon and 
Ganz, 2004). 
Iron deficiency is found in most CKD patients particularly in patients on 
haemodialysis, and is a frequent cause of anaemia in these patients 
(McClellan et al., 2002; Yessayan et al., 2014). The first recourse is iron 
supplementation, either oral or parenteral, and since oral iron is poorly 
absorbed, and is not well tolerated because of adverse gastrointestinal 
effects (Kulnigg and Gasche, 2006; Rozen-Zvi et al., 2008). IV iron 
preparations were developed to overcome these problems in CKD patients 
(Bailie et al., 2005; Gisbert and Gomollón, 2008). IV iron preparations used 
clinically have included iron as high or low-molecular-weight iron dextran, 
ferric gluconate, IV iron sucrose and IV FCM (Kulnigg et al., 2008; Dillon et 
al., 2012). These compounds are widely used in the treatment of anaemia by 
improving serum haemoglobin in CKD patients and to lower the requirement 
of the high cost erythropoiesis-stimulating agents or rhEPO in these patients 
(Besarab et al., 2000; Dillon et al., 2012). However, all of these compounds 
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despite their differences can lead to saturation of transferrin and, 
consequently, to elevated significant blood levels of NTBI or free iron due to 
the rapid release of iron from its complex, particularly if high doses are 
administered (Kooistra et al., 2002; Schaller et al., 2005). Functional and 
structural disintegration of ECs due to impaired NO bioavailability, is a key 
element in the progression of CKD, and may explain the increased 
cardiovascular risk in these patients (Fliser et al., 2011). EC is frequently 
observed in CKD and it may be further aggravated by IV iron 
supplementation (Cross, 2002; Shah and Alam, 2003). There is abundant 
evidence that IV iron administration, including IV iron sucrose can inhibit EC 
proliferation and mediate damage of ECs in vitro (Zager et al., 2002; 
Kamanna et al., 2012) and in vivo (Rooyakkers et al., 2002; Zheng et al., 
2006), which is likely to be a key step in accelerated atherogenesis since EC 
represent the primary site for the initiation of atherosclerosis, which would 
finally lead to plaque progression and occurrence of atherosclerotic 
complications (Davignon and Ganz, 2004). In contrast, IV FCM is a new 
preparation of non-dextran iron which, can be administered as a large 
replenishment dose over 1000 mg of iron over a short infusion in 30 min. IV 
FCM has been shown to induce less toxicity and less cellular damage than 
other IV iron compounds, due to its robust iron-carbohydrate complex 
stability and pharmacokinetics properties (Funk et al., 2010; Toblli et al., 
2011; Prats et al., 2013). However, to our knowledge the effect of this 
compound on EC proliferation, injury and damage in vitro has not been 
tested. Therefore, two IV iron preparation were chosen in this study, IV iron 
sucrose as the commonest and agent with most published literature and IV 
69 
 
FCM. The effect of these compounds on in vitro growth characteristics, 
viability and proliferation rate of human ECs was studied. 
2.2. MATERIALS AND METHODS 
2.2.1. Materials 
2.2.1.1. Cell culture 
All tissue culture reagents used were of tissue culture grade. All tissue 
culture plastics used (T75 cm2) flasks, 96-well plates and 6 well plates were 
either from Corning Incorporation (Corning, NY 14831, USA) or Becton-
Dickinson (Falcon), (Leeds, England UK). Disposable sterile pipettes of 
volume 5, 10 and 25 ml were from Costar Corporation, Cambridge or from 
LIP Equipment & Services Ltd, (Shipley, UK). Disposable syringes were 
purchased from National Health Supplies (Leeds, UK). 
Human umbilical vein endothelial cells (HUVEC) were obtained from several 
sources: Ethical Tissue Bank (University of Bradford, UK), Promocell, 
Sickingenstrasse, Germany catalogue number C-12250 or from Caltag-
Medsystems, Buckingham, UK catalogue number ZHC-2106. HUVEC used 
throughout all this study, were from a number of individual donors as shown 
in table 2 .1.  
All cell culture plastics used for the culture of HUVEC were coated in 10% 
(v/v) bovine gelatin in PBS prior to use for at least 30 min and rinsed with 
PBS prior to addition of cells. All cell culture procedures were performed 
using aseptic techniques in biological safety cabinet. All culture were 
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preserved in a humidified in 5% Carbon dioxide (CO2), 95% humidified air 
and at 370C.  
Table 2.1: List of primary HUVEC with catalogue number, source materials, 
passage number and the providers. 
Catalogue 
number 
Source 
materials 
Tissue / 
Material 
Passage 
number/Comments 
 
Provider 
ET-10-3595 
 
1 HUVEC 1x106 P1/single donor 
 
Ethical Tissue 
Bank University 
of Bradford 
ET-10-3429 
 
1 HUVEC 1x106 P1/single donor  Ethical Tissue 
Bank University 
of Bradford 
ET-11-3738 
 
1 HUVEC 1x106 P1/single donor  Ethical Tissue 
Bank University 
of Bradford 
ET-11-3742 
 
1 HUVEC 1x106 P1/single donor  Ethical Tissue 
Bank University 
of Bradford 
ET-12-4314 
 
1 HUVEC 1x106 P1/single donor  Ethical Tissue 
Bank University 
of Bradford 
ET-12-4739 
 
1 HUVEC 1x106 P1/single donor  Ethical Tissue 
Bank University 
of Bradford 
ZHC-2106 
 
5 HUVEC 5x105 P1/single donors Caltag 
Medsystems 
C-12250 
 
5 HUVEC 500,000 proliferating 
cells/single donors 
 
Promocell 
 
2.2.1.2. Reagents 
Penicillin/streptomycin (15140-115), trypsin/ethylenediaminetetraacetic acid 
(EDTA) (E5134), Fungizone (15290-026) and L-glutamine (25030-024) were 
obtained from Gibco (Paisley, Scotland, UK). Trypan blue (T6146), gelatin 
(G1393), dimethyl sulfoxide A.C.S spectrophotometric grade (DMSO, D-
8779), Fluorescein-conjugated mouse monoclonal antibodies against human 
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CD31 (PECAM-1) (F8402), paraformaldehyde (P6148), Triton X-100 (T9284) 
and Thiazolyl Blue Tetrazolium Bromide (MTT) (M2128) were all purchased 
from Sigma-Aldrich Chemical Company (Poole Dorset, UK). IV iron sucrose 
(Venofer) 100 mg in 5 ml and IV ferric carboxymaltose (FCM) or (Ferinject) 
100 mg in 2 ml (DVF04499) were purchased from Bradford (Hospitals NHS 
trust, UK). Dulbecco’s Phosphate Buffer Saline (DPBS) (SH 3026401) and 
Lab-Tek™ II Chamber Slide™ System (154534) were purchased from 
Thermo Scientific (Nottingham, UK). Phenol red-free M199 media (11043-
023) was supplied by Invitrogen (Paisley, UK). Endothelial cell growth 
medium (C-22020) was purchased from Promocell (Sickingenstrasse, 
Germany). Human large vessel endothelial cell growth medium (ZHM-2953) 
were obtained from Caltag-Medsystems (Buckingham, UK). TrypLE™ 
Express enzyme (1X), phenol red free (12604-013) was purchased from Life 
Technologies Ltd (Paisley, UK). Foetal bovine serum (FR-1090) was 
obtained from Biosera (East Sussex, UK).  
2.2.2. Methods 
2.2.2.1. Culture of HUVECs 
HUVEC were maintained in endothelial cell growth medium supplemented 
with (100U/100 mg/ml) penicillin-streptomycin and supplement mix (0.02 
ml/ml foetal calf serum and 0.004 ml/ml endothelial growth supplement), L-
glutamine (2 mM) and Fungizone (2.5 μg/ml) and cultured at 370C in a humid 
atmosphere containing 5% CO2 in 95% air. Cells were then grown in 
endothelial cell growth medium (C-22020) or (ZHM-2953) and were 
propagated in gelatin coated plastic tissue culture T75 cm2 flasks. After 
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reaching confluence, the cells were sub-cultured and reseeded. Subsequent 
to trypsinization by trypsin/EDTA (0.05%/0.02%), the cells considered to be 
round in shapes and in suspension. After 24hr the medium was discarded, 
and cells were washed twice with warm phosphate buffer saline (PBS) to 
remove cell debris and any dead cells. Upon confluence, HUVEC were 
passaged at ratio of 1:3 up to passage number 4, as they have been 
characterized within the lab (Sarkanen et al., 2010) to respond to stimuli in a 
manner consistent with newly isolated endothelium until passage 4. HUVEC 
which were not able to adapt to culture conditions were discarded. All cell 
culture plastics (flasks or plates) used for the culture of HUVEC were coated 
in 10% v/v gelatin in PBS prior to use for at least 30 min and rinsed with PBS 
prior to addition of cells. 
2.2.2.2. Immunocharacterisation of HUVEC 
Cells were seeded at a concentration of 2 x 105 cells per ml (500 μl/chamber) 
in chamber slides and cultured at 370C in a humid atmosphere containing 5% 
CO2 in 95% air. Once HUVEC reached the confluence state, the media was 
discarded and HUVEC were fixed using 4% w/v paraformaldehyde (in PBS) 
for 10 min at room temperature. Subsequently, the fixative was discarded 
and cells were washed thoroughly three times with PBS. Fixed HUVEC were 
then permeabilized with PBT (0.1% (v/v) Triton X-100 in PBS) for 10 min. the 
cells were blocked with blocking buffer (1% w/v BSA in PBS) for 90 min and 
then they were incubated with 200 μl mouse monoclonal anti human CD31 
antibodies (1:20) overnight at 4°C. HUVEC from same donors were 
incubated with PBS and considered as negative control. Cell nuclei were 
counterstained by Vectashield with 4’, 5-Diamidino-2-phenylindole (DAPI). 
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Images were obtained using an Eclipse TE2000 inverted research 
microscope (Nikon DS-U1, Tokyo, Japan) version 5.03 and photographed 
with a cooled Hamamatsu digital camera (Hamamatsu, Japan) using 20x 
objective. Photos of randomly chosen fields were taken in each experiment 
using the FITC- filter and DAPI- filter for antibodies-treated and non-treated 
cells and compared to check the basal level. 
2.2.2.3. Expansion of cultures 
After the cells become confluent, cells were passaged at a ratio of 1:3 to 
expand the cultures. The previous culture media was discarded from the 
flask and the cells were rinsed twice with pre-heated PBS. To detach the 
confluent cultured cells from the flask, trypsin/EDTA (0.05%/0.02%) was 
added for less than 1 min and the cells observed microscopically. The cells 
started rounding up i.e. losing cell-cell contacts. Then trypsin was removed. 
The flasks were then incubated at 370C for 1-2 min. Following incubation, the 
side of the flask was tapped against the palm in order to separate the cells 
from the surface of the flask. Detached cells were re-suspended in an 
appropriate volume of complete endothelial cell growth medium, cells then 
were seeded into the appropriate container T75 cm2 flasks and returned to 
the incubator at 370C, 24hr later cells were washed with warm PBS and the 
medium was changed. All these steps were repeated once again when the 
cells reached confluence state. 
2.2.2.4. Cryopreservation of cell stocks 
In order to keep HUVEC from the same donor for future works, cells were 
cryopreserved between passage 2 and 4. After trypsinization as described 
above, cells were re-suspended in complete endothelial cell growth media 
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and centrifuged at 560g for 5 min at room temperature to sediment the cells. 
The cell pellet was re-suspended in 40C foetal bovine serum containing 10% 
v/v DMSO. Cells were frozen at a density of 1x106 cells per ml. Cells were 
placed in cryovial and placed immediately on ice. The cryovials were 
wrapped in layers of tissue paper and placed into -800C for 24hr, and then 
the cryovials were transferred to liquid nitrogen Dewar flasks and stored until 
required. 
2.2.2.5. Thawing and maintenance of HUVEC 
The cryopreserved vial of HUVEC was removed from the liquid nitrogen 
storage tank and the cells thawed by placing the lower half of the vial in a 
370C water bath for approximately 1 min. The vial was removed from the 
water bath and wiped dry. The cell suspension of 1 ml was removed from the 
vial into the T75 cm2 flask which contained 10 ml of endothelial cell growth 
medium, and was incubated overnight to allow cell adhesion. 
After 24hr, the culture media was discarded and the flask rinsed two times 
with 5 ml of pre-heated PBS, added to the side of the flask opposite the cells 
to avoid dislodging the cells and to remove any remaining media or detached 
cells. After this step, complete media was then added to the flask which was 
then returned to the cell incubator for further 48hr to allow the cells to 
become confluent. 
2.2.2.6. Determination of cell concentration and cell viability 
When required, the concentration of cells in suspension was determined by 
counting in a haemocytometer under an inverted phase contrast microscope. 
Cells were trypsinised off the T75 cm2 flask, as described above and the 
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trypsinization was halted by adding 5-10 ml of complete media. Cell 
suspension was centrifuged at 560g for 5 min, after centrifugation the cell 
pellet was re-suspended in 5 ml fresh culture media. 10 µl of the cell 
suspension was removed from the 5 ml universal tube and was loaded into 
each chamber of a standard haemocytometer in order to allow the cells 
resolve on the grid, by using the inverted microscope as mentioned above. 
Cells were counted within four corners of the grid and the average was 
found. The cell concentrations were determined by using this formula:  
Cell concentration (cells/ml) = total cell number (TC) / 4XDilution factor X 104 
Total cells in the flask could then be determined by multiplying the total 
volume added to the culture media tube. 
Trypan blue, a vital dye, was used to detect cell viability in HUVEC 
suspension. Viable cells exclude the trypan blue whilst this dye enters to the 
non-viable cells and which are easily identified during counting in the 
haemocytometer. Dyed cells and non-dyed cells were counted and the 
percentage viability was calculated as follows: 
% viability = Unstained cells (viable)/total cells (viable and non-viable) x 100 
2.2.2.7. Treatment of HUVEC with IV iron preparations 
To investigate clinically relevant effects of IV iron preparation and to 
determine the effective concentration on HUVEC in culture, a dose response 
study was performed. HUVEC (2 × 105 cells per well) were cultured in 
complete endothelial cell growth medium and treated with three different 
concentrations of IV iron sucrose or IV FCM, which are known to be in the 
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clinically relevant range (50, 100, and 200 µg/ml) (Gupta et al., 2010; 
Kamanna et al., 2012; Martin-Malo et al., 2012) for 24hr at 370C in 5% CO2. 
These concentrations were chosen and calculated based on the anticipated 
plasma concentrations that are achieved in CKD patients after 100 to 1000 
mg IV iron sucrose injection which is close to 600 to 6000 µmol/l or 33 to 330 
µg/ml plasma respectively and plasma concentrations close to 672 to 6720 
µmol/l or 37 to 370 µg/ml respectively in patients injected with 100 to 1000 
mg IV FCM (Van Wyck et al., 2004; Kamanna et al., 2012; Praschberger et 
al., 2013). After 24hr incubation, the number of viable cells was determined 
using trypan blue exclusion assay.  
2.2.2.8. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide 
(MTT) assay for HUVECs proliferation 
To determine the HUVEC growth rate, an MTT assay was conducted. A 
solution of MTT is yellowish was widely used to measure cell viability and 
proliferation (Mosmann, 1983). Mitochondrial dehydrogenase of viable cells 
cleaves the Tetrazolium ring of MTT, yielding purple MTT formazan crystals. 
These crystals can be dissolved in DMSO and the resulting colour read 
spectrophotometrically giving absorbance proportional to cell number. 
However, MTT assay have HUVEC from passage 2-4 were used in this 
assay. Confluent HUVEC were trypsinised as mentioned above and were 
seeded in triplicate into gelatine-coated 96 well plates 1x104 cells per well. 
Endothelial cell growth medium was added to three wells of the plate to act 
as a cell blank control. Cells were incubated overnight at 370C and 5% CO2 
in a humidified atmosphere to allow the cells attach to the surface of the 
plate. After 24hr, culture medium was changed and replaced with medium 
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containing 50 µg/ml IV iron sucrose or IV FCM. Plates were incubated at 
370C and 5% CO2 in a humidified atmosphere for 96hr and media was 
changed once after 48hr. Following incubation, MTT solution (5mg/ml) was 
added aseptically in an amount equal to 10% of the culture volume and 
plates were incubated for 3 to 4hr at 370C and 5% CO2 in a humidified 
atmosphere. Subsequently, the media was discarded and the crystals 
formed were dissolved in 150 µl DMSO. The resulting purple colour was read 
within 1hr using Microplate reader MRX II (Dynex Technologies, Chantilly, 
USA) at a wavelength of 570nm and blank readings were subtracted from 
those samples, giving a proliferation curve over 96hr. This technique was 
also carried out every 24hr for 4 days to measure the daily proliferation rate 
of non-treated and IV iron preparations-treated HUVEC. 
 2.3. Statistical analysis 
Excel and SPSS software 21.0 packages were used for the statistical 
analysis. For normally distributed values, all data analysis was carried out 
using paired t-test unless specified. Differences were examined for statistical 
significance using the one-way analysis of variance (ANOVA). The same 
statistical analysis was carried out in this chapter and all the following 
chapters unless specified. The differences were considered significant if p 
values were (< 0.05). Significant differences are marked with (*) p< 0.05, (**) 
p< 0.01 and (***) p< 0.001. 
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2.4. RESULTS 
2.4.1. Culture of primary HUVEC  
Under phase contrast microscopy, newly cultured HUVECs looked like small 
clumps of round cells, they adhered within 12hr to the gelatin coated flasks 
and under phase contrast microscope, they had a small clusters of elongated 
cells with thin peripheral cytoplasm, centrally located nucleus and indistinct 
borders (Figure 2.1A). These cells proliferated and became confluent within 
3-4 days in 6 well plates and 7-9 days in T75 cm2 flasks depending on the 
growth rate (Figure 2.1B). The growth rate was variable between cells from 
different donors. Total contact inhibition was not observed. However, cells 
proliferated very slowly when they reached confluence and the number of 
floating dead cells was higher in confluent flasks then non-confluent ones.  
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Figure 2.1: Morphology of HUVECs in culture. A: primary HUVEC after 24h 
of harvesting. B: confluent monolayer of HUVEC. (Original magnification is 
100x). 
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2.4.2. Characterization of primary HUVEC  
HUVEC phenotype was visualized using phase-contrast microscopy and 
immunostaining for CD31 (PECAM-1) in addition to the distinct cobblestone 
like arrangement of the cells at confluence as shown in (Figure 2.2). A FITC-
tagged antibody against CD31 was used to visualise their expression on the 
HUVEC surface. Expression of CD31 molecule presented high fluorescence 
on surface of HUVEC, representing a basal expression of this molecule as 
shown in (Figure 2.2b). In contrast, HUVEC which were incubated with only 
FITC secondary mouse antibody (negative control) showed no fluorescence 
as shown in (Figure 2.2 (2b)).  
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Figure 2.2: Representative images of the expression of CD31 on HUVEC 
surface. HUVEC were cultured in complete endothelial growth medium and 
then were fixed and immunostained with FITC-tagged antibodies against 
CD31. Clear specific detection seen for CD31. The upper row is 
immunofluorescence microscopy detection of DAPI. The middle row is 
immunofluorescence microscopy detection of CD31-FITC. The bottom one is 
a merge of the two. (Original magnification: 400X). 
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2.4.3. Treatment with IV iron preparations 
Following 24hr of incubation with 50, 100 and 200 µg/ml of IV iron sucrose or 
IV FCM, whilst IV FCM demonstrated negligible toxicity at all concentrations, 
the IV iron sucrose was toxic to the HUVEC at both 100 and 200 µg/ml as 
shown in Figure 2.3. Some reduced viability was also seen at 50 µg/ml. 
Hence, 50 µg/ml was used in subsequent assays for both compounds.  
    
Figure 2.3: Dose response of IV iron preparations on cell viability. HUVECs 
were cultured in endothelial cell growth media in 6 well plates until cells 
attain about 80% confluent. Cells were treated with 50, 100 and 200 µg/ml IV 
iron sucrose for 24hr. Cellular viability was measured by trypan blue under 
phase contrast microscopy. The results are expressed as mean (+/- SEM) 
from 3 different donors (n=3). 
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2.4.4. Morphological changes in HUVEC cultured in IV iron preparations 
To investigate the effect of IV iron preparations on HUVEC, we first observed 
the cell morphology of the HUVEC after exposure to two different types of IV 
iron preparations. Non-treated HUVEC showed normal morphology with 
typical cobblestone appearance as shown in Figure 2.4A. Following 24hr of 
incubation with 50 µg/ml of IV iron sucrose or IV FCM, the morphological 
changes in the HUVEC were observed as indicated in Figure 2.4C and 2.4B 
respectively. Obvious morphological changes were observed in the HUVEC 
compared with non-treated cells, the majority of the cells in the IV iron 
sucrose-treated HUVEC became shrunk and star-shaped with sharp 
outlines. These results suggest that IV iron sucrose causes cell 
rearrangement in HUVEC. 
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Figure 2.4: Morphological changes in HUVEC cultured with two different 
types of IV iron preparations (sucrose or FCM). A: cells were grown in 6 well 
plates in complete endothelial growth medium and considered as a control. 
B: HUVECs were incubated with 50 µg/ml of IV FCM for 24hr. C: HUVECs 
incubated with 50 µg/ml of IV iron sucrose for 24hr. (Original magnification: 
100X). 
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2.4.5. Effects of IV iron preparations on HUVEC viability 
There have been previously published reports that human arterial ECs 
(HAECs) treated with 10-100 μg/ml IV iron sucrose 4-24hr, causes 
decreased cell viability (Kamanna et al., 2012). However, to our knowledge 
there have not been any in vitro published studies that investigate the effect 
of IV iron sucrose or IV FCM on HUVEC viability. Therefore, this test was 
performed to directly determine the effect of the two commercially IV parental 
iron preparations, IV iron sucrose or IV FCM on cellular viability of HUVEC 
under our laboratory conditions. HUVEC from the same donor were either 
treated with 50 µg/ml IV iron sucrose or IV FCM for 24hr or left untreated and 
considered as control. Trypan blue dye exclusion was used to distinguish 
between live and dead cells, and the percentage of live cells was more than 
95% in all non-treated cells (Figure 2.5). However, percentage of live cells 
treated with 50 µg/ml of IV FCM or IV iron sucrose was 92% and 61% 
respectively after 24hr (Figure 2.5). Indicating that IV iron sucrose had toxic 
effects on HUVEC leading to reduced cell viability. 
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Figure 2.5: Effect of IV iron sucrose or IV FCM on HUVEC viability. Trypan 
blue dye exclusion test to show residual cell viability, HUVECs were cultured 
in endothelial cell growth media in 6 well plates for 2 days until cells attain 
about 80% confluent. Cells were treated with 50 µg/ml IV iron sucrose or IV 
FCM for 24hr or left untreated and considered as control. Cellular viability 
was measured by trypan blue under phase contrast microscopy. The results 
are expressed as mean (+/- SEM) from 3 different donors (n=3). **p<0.01 
compared with non-treated cells. 
 
 
 
 
87 
 
2.4.6. Characterization of IV iron preparation effects on HUVEC 
proliferation 
The effects of IV iron preparations on HUVEC proliferation were evaluated by 
assessing mitochondrial dehydrogenase activity, using the MTT assay. Cell 
proliferation was assessed by monitoring the conversion of MTT to formazan 
(Figure 2.6). The reduction of MTT is catalysed by mitochondrial 
dehydrogenase enzymes and is therefore a measure for cell proliferation 
(Mosmann, 1983). HUVEC were seeded in 96 well plates at a concentration 
of 1x104 cells per well in triplicate and incubated at 370C in 5% CO2 for 96hr. 
The MTT assay was then conducted and the relationship between cell 
number and absorbance was determined (Figure 2.7). In addition, the MTT 
assay was repeated at 24hr intervals up to 96hr. There was a significant 
difference in the proliferation rate between non-treated cells and IV iron 
sucrose-treated cells (p<0.01 and p<0.001) at 48, 72 and 96hr respectively, 
while no significant difference was observed between IV iron sucrose-treated 
cells and non-treated cells at 24hr (Figure 2.8). HUVEC incubated with IV 
FCM at both 24 and 48hr showed no significant reduction in the growth rate 
compared with non-treated cells (Figure 2.8). In contrast, the growth rate of 
cells treated with IV FCM at 72 and 96hr did increase but was significantly 
lower than non-treated cells (p<0.05) (Figure 2.8). 
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Figure 2.6: Representative image showing the reduction of yellow MTT to 
purple MTT formazan, was taken from Mosmann, 1983. 
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Figure 2.7: The effects of IV iron preparations on cell proliferation rate. 
HUVEC were treated with 50 µg/ml of IV iron sucrose or IV FCM. HUVEC 
were seeded in 96-well plates at density 1x104 cells per well in triplicate and 
MTT assays were conducted after 96hr. Non-treated HUVECs from the same 
donor were used in each experiment as negative controls. The results are 
expressed as mean (+/- SEM) from 3 different donors (n=3). Non-treated 
absorbance values were defined as 100% and other values were adjusted 
accordingly. *p<0.05 and ***p<0.001 versus non-treated cells respectively. 
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Figure 2.8: The effects of IV iron sucrose or IV FCM on HUVEC proliferation 
rate over 4 days. Cells were seeded in triplicate in 96 well plates at density 
1x104 cells per well. HUVECs were incubated for 96hr in the absence non-
treated (control) or presence of 50 µg/ml IV iron sucrose or IV FCM. MTT 
assay was performed every 24hr for four days. Data are expressed as 
(mean+/- SEM) from 3 different donors (n=3). *p<0.05, **p<0.01 and 
***p<0.001 compared with non-treated cells. 
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2.5. DISCUSSION 
The results in this chapter showed that, IV iron sucrose induced 
morphological, functional changes include induced marked decrease 
proliferation and inhibited  the survival of the HUVEC when compared with 
non-treated cells. In contrast, exposure of HUVEC to IV FCM did not 
promote EC dysfunction compared with non-treated cells.  
Due to the limited availability of human vascular endothelial tissue and HAEC 
(Romanoski et al., 2010; Mäkinen et al., 2014), in vitro studies have used EC 
from a variety of sources to study the mechanisms of EC dysfunction that lie 
behind atherosclerotic plaque formation (Zhang et al., 2001a; Lee et al., 
2002; Dalal et al., 2003; Ferretti et al., 2004). HUVEC represent one easily 
accessible in vitro model mainly because of umbilical cords availability and 
have played a major role as a model system for the study of the regulation of 
EC function which have been used successfully in a large number of studies 
(Outinen et al., 1999; Xu et al., 2000; Dong et al., 2005). HUVECs also 
represent a more relevant model than murine or bovine arterial EC which 
have been used by some groups (Weiss et al., 2002; Jin et al., 2007). This is 
because the umbilical vein carries oxygenated blood which delivers oxygen 
and nutrition to the placenta and HUVEC exposed to the same growth 
factors, cytokines and other factors to which arterial EC are exposed. 
Therefore, HUVEC physiology closely approaches that of arterial cells 
(Kivetys and Granger, 1997). In addition, the role of venous EC in acute 
inflammation is well established, as veins are the major site of leukocyte 
recruitment. In CKD there is systemic inflammation (Machowska et al., 2015) 
and therefore all types of ECs are likely to be activated. All these make the 
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use of HUVEC in these studies a convenient approach for investigating and 
determining the mechanism for IV iron preparation-induced EC damage 
important in CKD.  
Characterization of HUVEC used in this study showed that these cells retain 
important endothelial characteristics until at least passage number four as 
defined by their basal expression of CD31 (PECAM-1) on their surface 
(Figure 2.2), and is in agreement with the findings of other researchers who 
showed that, these cells retain important endothelial characteristics in culture 
(Varani et al., 1995; Kaushal et al., 2001). Due to the possibility that, HUVEC 
may lose characteristic morphologic features, characteristics of apoptosis 
and DNA fragmentation, once passaged in culture for a longer time, cells 
were not used beyond this number of passage in culture in all studies for this 
thesis. Iron is important for the proliferation and survival of all cells and 
required to catalyse various redox reactions (Ganz, 2005). IV iron 
supplements are widely used to maintain adequate iron stores and manage 
to reduce the anaemia in CKD patients (Hörl, 2007). However, these 
compounds including IV iron sucrose has been shown inhibit proliferation 
and to cause EC injury, otherwise known as EC dysfunction, representing a 
key early step in the development of atherosclerosis (Agarwal et al., 2004; 
Kamanna et al., 2012; Masuda et al., 2013). Atherosclerosis is defined as a 
chronic inflammatory response in the walls of arteries (Lusis, 2000; Galkina 
and Ley, 2009), patients with CKD have higher risk of developing CVD, 
which is associated with atherosclerosis and is the major cause of death in 
patients treated with CKD (Ardhanari et al., 2014).  
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The initial aim of this study was to confirm the hypothesis that IV iron sucrose 
produces alterations on HUVEC morphology, viability, and growth as has 
been previously shown in other in vitro EC culture models and compare to 
treatment with the same clinically relevant concentrations of the more 
recently developed  IV iron preparation, FCM. Figure 2.3A showed normal 
morphology of non-treated HUVEC with typical cobblestone appearance. 
However, HUVEC treated with 50 µg/ml IV iron sucrose for 24hr had lost 
their normal morphological characteristics, shrunk and were detached from 
the plates compared with non-treated cells (Figure 2. 4C). Data from trypan 
blue exclusion to determine cell viability and MTT assays confirmed these 
effects (Figures 2.4 and 2.7). In contrast, IV FCM-treated cells showed 
normal morphological characteristics compared with non-treated cells (Figure 
2. 4B), and less severe effects on cell proliferation with little reduction in cell 
viability suggesting that HUVEC are more sensitive to damage by IV iron 
sucrose than IV FCM. This is consistent with a published study by Kamanna 
et al (2012) which showed that, treatment of HAEC with 50 and 100 µg/ml IV 
iron sucrose for 4hr had detrimental effects on cell morphology as the cells 
shrunk and detached from the plates, and the monolayer was disrupted. In 
addition, many cells exhibited typical features of apoptosis including 
condensed and fragmented nuclei when compared to non-treated cells. 
These authors suggested that, alteration of ECs morphology could be due to 
the increased in plasma level of catalytically active NTBI or free iron after IV 
iron being administered. This NTBI in turn is capable of generating oxidative 
stress, which causes endothelial injury and dysfunction, and triggers 
inflammation via activation of NF-ĸB. Interestingly, from Kamanna study it 
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seems that HAEC were more sensitive to IV iron sucrose than our model of 
HUVEC. The authors showed that the morphology was altered at 4hr of 
treatment with 50 µg/ml iron sucrose, and the cells exhibited typical features 
of apoptosis such as, condensed or fragmented nuclei as compared with 
non-treated cells. However, our data is similar to earlier published work by 
Kamanna and others, that treatment with IV iron sucrose caused shrunk and 
star-shaped with sharp outlines in HUVEC morphology (Figure 2. 4C). In 
addition, IV iron sucrose significantly reduced the viability of HUVEC by 
almost 40% compared with non-treated cells at 24hr (p<0.01) (Figure 2.5), 
which indicate that IV iron sucrose was toxic to HUVEC. This is another 
evidence shows that HAEC is more sensitive to IV iron sucrose compared to 
our data of HUVEC, as 61% of HUVEC were viable after treatment with IV 
iron sucrose for 24hr. A study by Masuda et al (2014) showed that, treatment 
of isolated pancreatic islet cells with 20, 100 and 200 mg/l IV iron sucrose 
resulted in significant decrease in cell viability using tetramethylrhodamine 
ethyl ester (TMRE) methods. These authors reported that the reduction in 
islet cell viability occurs as a result of increased oxidative stress. Kamanna et 
al (2012) also showed that treating HAEC with 10, 50 and 100 µg/ml IV iron 
sucrose for 24hr, significantly decreased cellular viability using MTT assay 
compared with non-treated cells  with viability being reduced to 20% on 
treatment with 50 and 100 µg/ml for 4hr. In contrast, cells treated with 50 
µg/ml of IV FCM showed that this component was not cytotoxic to cells since 
the viability of cells was always greater than 92% with the number of dead 
cells similar to that observed in non-treated (Figure 2.4). Thus, not all ECs 
have the same response to IV iron compounds and this may explain the 
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differences in the results between diverse studies from the literature. These 
differences in cell survival over 24hr may result from pharmacokinetic 
differences such as molecular weight, reactivity, thermodynamic stability and 
half-lives between IV iron sucrose or IV FCM, which differ in their 
carbohydrate ligands as discussed in section 1.6.3.1. These differences 
result in a substance-specific kinetic of NTBI release from iron complexes 
(Fell et al., 2014). 
Fell et al., (2014) examined the effect of 100, 200 and 500 µg/ml IV iron 
sucrose or IV FCM for 3hr, on monocyte cell viability by Annexin V binding 
buffer using flow cytometry method. The authors found a significant reduction 
in cell viability with IV iron sucrose treatment versus non-treated cells, which 
was not the case in cell treated with IV FCM, as there was no significant 
decrease in the cell viability compared with non-treated cells. Fell and others 
suggested that the reduction of cell viability by IV iron sucrose was due to the 
differences between IV iron sucrose and IV FCM in term of properties such 
as carbohydrate ligands, molecular weight and half-lives. IV iron sucrose has 
the lowest molecular weight, the shortest half-life and the lowest stability 
compared with  IV FCM, which lead to the release of higher levels free iron 
or NTBI (Jahn et al., 2011; Geisser and Burckhardt, 2011; Nordfjeld et al., 
2012). This in turn may induce distinct toxic effects such as ROS production 
and subsequently DNA damage (Fell et al., 2014).  
There are numerous methods available to study cell proliferation including 
MTT assay and [3H] thymidine incorporation. However, [3H] thymidine 
incorporation has many limitations compared to MTT assay including 
dependence upon cellular uptake, extra nuclear binding of thymidine, 
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problems with the physiochemical properties of the radioactive [3H] 
thymidine as reviewed by Maurer (1981). Thus, in order to confirm our 
finding by trypan blue method, the proliferation of HUVEC treated with IV iron 
preparations was investigated using MTT assay. The significant increased 
reduction of MTT by treated cells provide a sign of the disrupted 
mitochondria function, which in turn can lead to apoptosis of ECs. Although 
we know that MTT results depend on mitochondrial function and oxidative 
stress can compromise that, the data in our lab by Sultan and others showed 
hyperglycaemia induced oxidative stress but effects on proliferation were 
similar when measured by MTT or manual counting (Sultan et al., 2015).  
Consistent with our findings, other studies showed that IV iron sucrose 
reduced EC proliferation using either [3H] thymidine incorporation or MTT 
methods. Zager et al (2002) showed that IV iron sucrose inhibits HAEC 
proliferation when these cells were treated with 60 and 1000 µg/ml for 72hr 
using MTT assay. In addition, another study was done by Carlini et al (2006), 
who agreed with the finding of Zager et al and Carlini and others, treating 
bovine aortic ECs (BAECs) with 500 and 1000 µg/ml IV iron sucrose for 24 
and 48hr showed that this complex significantly decreased BAEC 
proliferation compared with non-treated cells using [3H] thymidine 
incorporation assay. These groups suggested that impaired mitochondria 
function was the cause for inhibition of HAEC proliferation by this compound. 
All the previous studies reflect the complex biochemical events initiated by 
the iron preparation on the cells, which could include the loss of mitochondria 
integrity and the production of oxidative stress. This needs further 
investigation which will be carried out in the next chapters to confirm and 
97 
 
quantify the generation of oxidative stress by IV iron sucrose or IV FCM. It 
has been shown that the majority of patients with CKD die due to CVD. 
The key early role of EC dysfunction in generating atherosclerosis is a 
contributing factor to CV disease. The findings of this study showed that both 
IV iron compounds have the capacity to reduce HUVEC proliferation and this 
could be contributing factor to CVD leading to CKD death but the extent and 
mechanisms responsible for the damage require further investigation. 
2.6. CONCLUSION 
IV FCM has been shown to be less harmful than IV iron sucrose at 
pharmacologically relevant concentrations and did not kill HUVEC in culture. 
However, our study is the first in vitro study to show that IV FCM still caused 
decreased EC proliferation rate especially when incubated with cells for 
longer time (72 and 96hr). In contrast, IV iron sucrose significantly induced 
changes in cell morphology and inhibited proliferation of cultured HUVEC 
compared with untreated cells. These factors need to be taken into account 
when administering iron preparations to patients with CKD. Based on these 
findings our study went to investigate mechanisms which may be responsible 
for altered HUVEC morphology and growth.  
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CHAPTER 3 
THE ROLE OF OXIDATIVE STRESS IN IV IRON PREPARATION-
MEDIATED EC DYSFUNCTION 
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3.1. INTRODUCTION 
Oxidative stress is a cellular condition which results from high levels of ROS 
such as superoxide anion and/or either impaired or defective function of 
antioxidant defence, such as SOD and GPx (Sies, 1997; Schnabel and 
Blankenberg, 2007), and it has been shown in many studies to be associated 
with CVD (Cai and Harrison, 2000; Schnabel and Blankenberg, 2007). Under 
physiological conditions, ROS production is tightly regulated to participate in 
the regulation of cellular activities and functions such as cell proliferation, 
differentiation and cell signalling (Kamata and Hirata, 1999; Trachootham et 
al., 2008) as described in chapter 1 (section 1.2.3). However, overproduction 
of ROS can generate oxidative stress, which leads to cellular damage and 
CV remodelling (Hamza and Dyck, 2014).  
Because anaemia is a significant source of morbidity and mortality in ESRD 
patients (Kausz et al., 2000), iron deficiency is an important clinical concern 
which is prevalent in patients with CKD and contributes to anaemia 
(Eschbach et al., 1977). Iron can exert potent pro-oxidant effects due to its 
ability to donate or accept an electron (Flora, 2009). In the Fenton reaction, 
H2O2 a relatively innocuous and easily containable ROS, is converted by iron 
to the hydroxyl radical, which is the most reactive and cytotoxic ROS 
(Kamanna et al., 2012). Therefore IV iron preparation administration can 
induce the formation of ROS in CKD  patients and cause oxidative stress 
producing inflammation, endothelial injury and dysfunction (Duffy et al., 2001; 
Pai et al., 2011; Brissot et al., 2012; Kamanna et al., 2012), which may be 
partially mediated by LDL oxidation and antioxidant depletion (Valenti et al., 
2007). Oxidative stress in patients with CKD can cause progression of renal 
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disease and cardiovascular morbidity and mortality (Himmelfarb et al., 2002; 
Agarwal et al., 2004). Several in vivo (Zager et al., 2002; Agarwal et al., 
2004; Bishu and Agarwal, 2006), in vitro (Shah, 2001) and clinical studies 
(Lim et al., 1999; Herrera et al., 2001; Showkat et al., 2014), have 
demonstrated that IV iron preparations increase oxidative stress biomarkers 
such as MDA, AOPP, SOD, glutathione peroxidase and lipid hydroperoxide 
(LHP). In addition, oxidative stress was shown to be increased after IV iron 
sucrose was administered in CKD patients at stage 3 and 4, which resulted 
in increase in proteinuria and tubular injury (Agarwal et al., 2004). It has been 
found that, within 15 to 30 min after 100 mg of IV iron sucrose administration 
to CKD patients, a rapid increase of MDA resulted (Showkat et al., 2014). 
Furthermore, in patients with CKD, markers of oxidative stress such as 
LOOH and diene conjugates (DC) have been found to correlate with EC 
dysfunction, an early critical step in the pathogenesis of atherosclerosis and 
CVD (Annuk et al., 2001).  
Additionally, IV iron preparation can cause renal injury due to direct drug-
induced toxicity including changes in glomerular hemodynamics, tubular cell 
toxicity, inflammation, crystal nephropathy, rhabdomyolysis, and thrombotic 
microangiopathy (Kim and Moon, 2012). This injury induced by IV iron 
preparation per se can cause the production of oxidative stress (Bhandari, 
2011). IV iron can cause oxidative stress induction in a number of cell types 
for instance; an in vitro study by Sturm et al showed that IV iron sucrose, 
ferric gluconate and iron dextran can all increase ROS production in HepG2 
cells (Sturm et al., 2010). Zager et al have shown in vitro that, IV iron 
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preparations can induce production of ROS in cultured human proximal 
tubular cells and proximal tubular segments (Zager et al., 2004).  
Increased ROS mediated endothelial injury can be possibly improved using 
an antioxidant treatment such as NAC (Lim et al., 1999; Agarwal et al., 
2004). NAC has been found to reduce EC dysfunction by the reduction of 
ROS-dependent activation of NF-kB which was caused by uraemic toxins 
(Tumur et al., 2010). Furthermore, NAC has been found to reduce levels of 
the kidney oxidative stress marker MDA in a mouse model of diabetic 
nephropathy (Ribeiro et al., 2011). To our knowledge ROS production in vitro 
in HUVEC treated with IV iron preparations (either iron sucrose or FCM) 
have not previously been investigated.  
Therefore, the aim of this chapter is to investigate the relative abilities of IV 
iron sucrose or IV FCM to induce ROS production in both an endothelial cell 
line (EA.hy926 cell line) and primary HUVEC by measurement of oxidant 
stress using DCFH-DA staining by flow cytometry method. In addition, NBT 
assay method was used to quantify superoxide anion generation in primary 
HUVEC. Furthermore, the ability of antioxidant treatment to reduce levels of 
IV iron induced superoxide anion and total ROS in HUVEC will be examined.  
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3.2. MATERIALS AND METHODS 
3.2.1. Materials 
3.2.1.1. Reagents 
Dulbecco’s modified eagle’s medium (D-6546) and N-acetyl cysteine (NAC) 
(A7250) were purchased from Sigma-Aldrich Chemical Company (Poole 
Dorset, UK). 2′, 7′-Dichlorofluorescin Diacetate (DCHF-DA) (287810) and p-
Nitroblue Tetrazolium Chloride (NBT) (484235) were supplied by Calbiochem 
(La Jolla, USA). Phenol red-free M199 media (11043-023) was supplied by 
Invitrogen (Paisley, UK). Dulbecco’s Phosphate Buffer Saline (DPBS) (SH 
3026401) was purchased from Thermo Fisher Scientific (Hemel Hempstead, 
UK). Foetal Bovine Serum (FB-1090) was purchased from Biosera (East 
Sussex, UK). Sample Test Tubes for Flow Cytometers, 12 x 75 mm 
(2523749) were purchased from Beckman Coulter (High Wycombe, UK).  
3.2.1.2. Cell culture 
All tissue culture reagents used were of tissue culture grade. All tissue 
culture plastics used (T75), 96 multi-well plates and 6 well plates were 
obtained from (corning, incorporated, costar, USA). Disposal sterile pipettes 
of volume 5, 10 and 25 ml from (Sarstedt company, France). 
EA.hy926 cell lines were kindly provided by Dr. Anne Graham (University of 
Bradford). All cell culture procedures were performed using aseptic 
techniques in biological safety cabinet. All culture were preserved in a 
humidified in 5 % CO2, 95% humidified air and at 37
0C.  
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All cells culture materials of HUVECs were as described in chapter 2 in 
(section 2.2.1.1).  
3.2.2. Methods 
3.2.2.1. Endothelial cell culture 
3.2.2.1.1. Culture of EA.hy926 cell line 
EA.hy926 cell lines were first established by Edgell and colleagues and were 
generated by fusing primary HUVECs with the human lung carcinoma cell 
line (A549) (Edgell et al., 1983). EA.hy926 cells were a generous gift from 
Dr. Anne Graham (University of Bradford). EA.hy926 cells were maintained 
and grown in DMEM media (catalogue number D6546; Sigma Aldrich), 
propagated in plastic tissue culture flasks T75 cm2  supplemented with 10% 
foetal bovine serum (v/v), penicillin/streptomycin (100U/100 mg/ml) and L-
glutamine (2 mM), cultured at 370C in a humid atmosphere containing 5% 
CO2 in air. After reaching confluence, the cells were sub-cultured and 
reseeded. After 24hr the medium was discarded, and cells were washed 
twice with warm PBS to remove any dead cells. The cultures were then 
successfully grown in vitro using conditions above. When confluence was 
achieved, cells were passaged (every 5-7 days).  
3.2.2.1.2. Culture of primary HUVEC 
HUVEC were cultured as previously described in chapter 2, section (2.2.2.1).  
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3.2.2.2. Measurement of oxidative stress in ECs 
3.2.2.2.1. Total ROS detection in EA.hy926 by flow cytometry using 
DCFH-DA staining 
EA.hy926 cells were seeded into 6 well plates in complete medium at a 
density of 2x105 cells per well and cultured until they reached 70-90% 
confluence. Media was aspirated and cells were washed twice with PBS to 
remove any dead cells from the plate. Cells were then treated with 100 or 
500 µg/ml IV iron sucrose or IV FCM for 2, 6 and 24hr. Subsequently, media 
was discarded and cells were washed once with DPBS. Media without 
phenol red containing 10 µM DCFH-DA was added and cells were incubated 
at 370C and 5% CO2 for 30-45 min. Subsequently, Media aspirated and cells 
were washed once with DPBS. Cells were then harvested in trypsin/EDTA 
(0.05%/0.02%) at 370C and 5% CO2 for 2-3 min, the cells then were re-
suspended in 1 ml ice-cold PBS in flow cytometry test tube on ice in the dark.  
DCFH-DA is commonly used to measure oxidative stress in cells due to the 
high sensitivity of fluorescence-based assays, is non-fluorescent lipid 
compound and membrane–permeable, once it gets into the cell; it is 
converted into non-fluorescent DCFH through the action of cellular 
esterases, which stay trapped within the cells (Tarpey and Fridovich, 2001). 
However, in the presence of ROS such as H2O2, superoxide anion, hydroxyl 
and NO, DCFH is speedily oxidized to its fluorescent derivative 2’, 7’-
dichlorofluorescin (DCF) (Royall and Ischiropoulos, 1993) as shown in 
(Figure 3.1). The fluorescence intensity of DCF was read at 535 nm emission 
when excited at 488nm by flow cytometry (Beckman Coulter, Inc. UK).  
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3.2.2.2.2. Total ROS detection in HUVEC by flow cytometry using DCFH-
DA staining 
HUVEC were seeded into gelatin coated 6 well plates in complete 
endothelial cell growth medium at a density of 2x105 cells per well and 
cultured until they reached 80-90% confluence. Culture medium was 
aspirated and the cells were washed twice with PBS. HUVEC were then 
treated with 50 µg/ml IV iron sucrose or IV FCM for 2, 6 and 24hr. 
Subsequently, endothelial growth media was discarded and cells were 
washed once with DPBS. Media without phenol red containing 10 µM DCFH-
DA was added and cells were incubated at 370C and 5% CO2 for 30-45 min. 
Subsequently, Media aspirated and cells were washed once with PBS. 
HUVEC were then harvested in trypsin/EDTA (0.05%/0.02%) at 370C and 
5% CO2 for 2-3 min, the cells then were re-suspended in 1 ml ice-cold PBS 
in flow cytometry test tube on ice in the dark. All individual donor samples 
were prepared and analysed in triplicate. 
 3.2.2.2.3. Detection of intracellular superoxide anion production in 
HUVEC by p-Nitro Blue Tetrazolium (NBT) assay 
The NBT reduction assay was used to demonstrate whether IV iron sucrose 
or IV FCM, induce the generation of superoxide anions intracellularly in 
HUVEC. NBT forms a water-insoluble blue formazan crystal when it reacts 
with intracellular superoxide anion demonstrating the degree of superoxide 
formation within the cell (Auclair and Voisin, 1985). The formed crystals are 
trapped within the cell, however, can be released by directly lysing the cells 
with lysis solution. The formation of blue formazan can be measured 
spectrophotometrically at 570 nm.  
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Briefly, HUVEC were plated into gelatin coated 24 well cell culture plates in 
complete endothelial cell growth medium at a density of 5x104 cells per well 
and incubated at 370C and 5% CO2, medium was changed every 48hr until 
cells were 80-90% confluent. The cells were washed twice with warm PBS to 
remove any dead cells from the plate then HUVEC were treated with 50 
µg/ml IV iron sucrose or IV FCM for 2, 6 and 24hr. Media then was aspirated 
and replaced with phenol red-free media (M199) containing 1 mg/ml NBT 
with and without 50 µg/ml of IV iron sucrose or IV FCM, the cells then were 
incubated at 370C and 5% CO2 for 90 min. Preparation of cell lysate is a 
critical step and, therefore, it was essential to optimise the protocol to get the 
right lysis buffer. Thus, the first protocol used was as follow: HUVEC were 
harvested in 1 ml PBS by gentle scraping using a sterile scraper. The cell 
pellet was collected by centrifuging at 13000x g for 5 min. Pellets were lysed 
vigorously in 500 μl 100% pyridine and then cell lysis vortexed thoroughly 
before heating in a heating block at 95°C for 20 min. Absorbance was 
measured using a spectrophotometer at a wavelength of 570nm. However, 
this protocol did not work and no results were obtained. Subsequently, 
another lysis buffer recommended by Eligini et al (2005) was used, which led 
to the final data of NBT assay presented. HUVEC were directly lysed with 
lysis solution (90% DMSO, 0.1% SDS and 0.01 M of NaOH) (Eligini et al., 
2005). The resulting blue coloured solution was measured 
spectrophotometrically at a wavelength of 750nm using Microplate reader 
MRX II (Dynex Technologies, Chantilly, USA). The production of intracellular 
superoxide anion was proportional to the absorbance values at 750nm. All 
samples were prepared and analysed in triplicate.  
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3.2.2.3. Treatment with antioxidants  
Previously published work has shown that, co-treatment with antioxidant 
such as, NAC can effectively reduce ROS production in cells and patients 
treated with IV iron sucrose (Lim et al., 1999; Agarwal et al., 2004).  
In order to investigate the role of antioxidant treatment on oxidative stress 
generated by IV iron sucrose or IV FCM, obtained by NBT assay or DCFH-
DA staining cells were treated with NAC in the presence of absence of IV 
iron preparations. For DCFH-DA staining by flow cytometry, HUVEC were 
cultured for 6 and 24hr in complete endothelial cell growth medium 
containing 50 µg/ml either IV iron sucrose or IV FCM alone or in the 
presence of 2 mM NAC. For NBT assay, HUVECs were cultured for 2, 6 and 
24hr in complete endothelial cell growth medium containing 50 µg/ml either 
IV iron sucrose or IV FCM alone or in the presence of 2 mM NAC. HUVEC 
isolated from the same patient were cultured for 24hr in complete medium 
alone, and were considered as a control for both NBT assay and DCFH-DA 
staining method as described in sections 3.2.2.2.2 and 3.2.2.2.3.  
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Figure 3.1: The mechanism of DCFH-DA staining, taken from Takanashi et 
al., 1997. 
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3.3. RESULTS 
3.3.1. Detection of total intracellular ROS production in EA.hy926 using 
DCFH-DA staining  
In order to investigate the role of IV iron sucrose or IV FCM on the 
generation of total ROS production in ECs, EA.hy926 cell line were initially 
used to optimize the methods of flow cytometry using DCFH-DA staining and 
determining dose response effects. Whether the EA.hy926 cell line can be a 
good model compared with primary HUVEC for studying the effect of these 
compounds on oxidative stress generation in cultured ECs was also a key 
consideration and is discussed later in the chapter. Figures 3.2B, 3.3B and 
3.4B showed that non-treated cells at 2, 6 and 24hr showed very low levels 
of DCF fluorescence intensity. EA.hy926 cells treated with 100 µg/ml IV FCM 
or IV iron sucrose at 2hr showed a slight increase in ROS production 
compared with non-treated cells, however this increase was not significantly 
different compared with non-treated cells (Figure 3.2B). In contrast, cells 
treated with 500 µg/ml IV iron sucrose or IV FCM for 2hr showed significant 
increases in ROS production compared to non-treated cells (p<0.05) (Figure 
3.2B). Figure 3.3B showed significant increase in ROS production in cells 
treated with 100 or 500 µg/ml IV iron sucrose or IV FCM at 6hr compared 
with non-treated cells (p<0.05) and (p<0.01) respectively. Furthermore, 
EA.hy926 cells which had been treated with 100 µg/ml IV iron sucrose or IV 
FCM, and those treated with 500 µg/ml IV FCM at 24hr showed significant 
increase in ROS production compared with non-treated cells (p<0.01) (Figure 
3.4B).  
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Additionally, EA.hy926 cells treated with 500 µg/ml IV iron sucrose for 24hr 
showed  a significant increase in ROS formation compared with non-treated 
cells (p<0.001) (Figure 3.4B). There was also a significant difference 
between those cells treated with 500 µg/ml IV iron sucrose and cells treated 
with IV FCM at 24hr (p<0.05) (Figure 3.4B). All these observations indicate 
that IV iron sucrose or IV FCM significantly induce oxidative stress 
generation in EA.hy926.  
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Figure 3.2: The effects of IV iron administrations on intracellular total ROS 
production in cultured EA.hy926 endothelial cell line at 2hr. EA.hy926 cells 
were washed with PBS and incubated with 10 µM DCFH-DA for 30-45 min. 
Then cells were either non-treated or treated with 100 or 500 µg/ml IV iron 
sucrose or IV FCM for 2hr. Non-treated cells were considered as negative 
control. (A): representative flow cytometry histogram of EA.hy926 cell line 
labelled with DCFH-DA staining. (B): DCF fluorescence intensity obtained 
from the histogram statistics. The results are expressed as mean (+/- SEM) 
from 3 different experiments (n=3). Fluorescence intensity of DCF was 
determined at 535nm emission when excited at 488nm by flow cytometry. 
*p<0.05 compared with non- treated cells.  
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Figure 3.3: The effects of IV iron administrations on intracellular total ROS 
production in cultured EA.hy926 endothelial cell line at 6hr. EA.hy926 cells 
were either non-treated or treated with 100 or 500 µg/ml IV iron sucrose or IV 
FCM for 6hr. Then cells were washed with PBS and incubated with 10 µM 
DCFH-DA for 30-45 min. Non-treated cells were considered as negative 
control. (A): representative flow cytometry histogram of EA.hy926 cell line 
labelled with DCFH-DA staining. (B): DCF fluorescence intensity obtained 
from the histogram statistics. The results are expressed as mean (+/- SEM) 
from 3 different experiments (n=3). Fluorescence intensity of DCF was 
determined at 535nm emission when excited at 488nm by flow cytometry. 
*p<0.05 and **p<0.01 compared with non-treated cells. 
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Figure 3.4: The effects of IV iron administrations on intracellular total ROS 
production in cultured EA.hy926 endothelial cell line at 24hr. EA.hy926 cells 
were either non-treated or treated with 100 or 500 µg/ml IV iron sucrose or IV 
FCM for 24hr. Then cells were washed with PBS and incubated with 10 µM 
DCFH-DA for 30-45 min. Non-treated cells were considered as negative 
control. (A): representative flow cytometry histogram of EA.hy926 cell line 
labelled with DCFH-DA staining. (B): DCF fluorescence intensity obtained 
from the histogram statistics. The results are expressed as mean (+/- SEM) 
from 3 different experiments (n=3). Fluorescence intensity of DCF was 
determined at 535nm emission when excited at 488nm by flow cytometry. 
**p<0.01 and ***p<0.001 compared with non-treated cells. *p<0.05 IV iron 
sucrose compared with IV FCM treated cells at 24hr.  
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3.3.2. Detection of total intracellular ROS production and the effect of 
NAC on ROS generation in primary HUVEC using DCFH-DA staining 
In addition to superoxide anion, EC can produce different types of ROS such 
as H2O2 and peroxides (Dröge, 2002). In order to investigate whether IV iron 
sucrose or IV FCM might induce increases in the generation of total 
intracellular ROS production, total ROS level was determined in HUVEC by 
measuring the oxidative conversion of DCFH-DA to fluorescent compound 
DCF (Jia et al., 2006; Lin et al., 2002). 
Figure 3.5B shows that non-treated cells produced small amounts of total 
ROS. IV iron sucrose or IV FCM at 2hr showed detectable increase in ROS 
level. However, this increase was not significant compared to non-treated 
cells (Figure 3.5B). IV iron sucrose or IV FCM-treated cells at 6hr showed a 
much higher production of the fluorescent dye versus to non-treated cells, 
which reflects significant increase in total ROS formation intracellularly  
(p<0.05). In addition, ROS production was significantly increased in HUVEC 
treated with IV iron sucrose or IV FCM at 24hr compared with non-treated 
cells (p<0.001) and (p<0.01) respectively (Figure 3.5B). HUVEC treated with 
IV iron sucrose or IV FCM and 2 mM NAC at 6 and 24hr showed significant 
reductions in ROS levels compared with the same cells treated with the IV 
iron sucrose or IV FCM alone at 6 and 24hr (p<0.05) (Figures 3.6B, 3.7B and 
3.8B) and (p<0.01) (Figure 3.9B). However, although there was a reduction 
in ROS in IV iron sucrose or IV FCM-treated cells with NAC, this was still 
shown to be significantly higher when compared with non-treated cells 
(p<0.05) (Figures 3.8B and 3.9B).  
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Figure 3.5: The effects of IV iron administrations on intracellular total ROS 
production in HUVECs using DCFH-DA by flow cytometry. HUVEC were 
grown in complete endothelial growth medium and either not treated or 
treated with 50 µg/ml IV iron sucrose or IV FCM for 2, 6 and 24hr. Non-
treated were considered as negative controls. These cells were washed with 
DPBS then incubated with 10 μM DCFH-DA for 30-45 min. (A): 
representative flow cytometry histogram of HUVECs labelled with DCFH-DA. 
(B): mean fluorescence obtained from the histogram statistics. The 
fluorescence intensity of DCF was read at 525nm emission when excited at 
488nm by flow cytometry. The results are expressed as mean (+/- SEM) from 
3 different donors (n=3). *p<0.05, **p<0.01 and ***p<0.001 compared with 
non-treated cells and *p<0.05 for cells treated with IV iron sucrose compared 
with cells treated with IV FCM at 24hr.  
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Figure 3.6: Representative images showing the effect of IV iron sucrose and 
NAC co-incubation on ROS generation in HUVECs using DCFH-DA by flow 
cytometry at 6hr. HUVEC were grown in complete endothelial growth 
medium and either not treated or treated with 50 µg/ml IV iron sucrose alone 
or in combination with 2 mM NAC for 6hr. Non-treated were considered as 
control. These cells were washed with DPBS then incubated with 10 μM 
DCFH-DA for 30-45 min. (A): representative flow cytometry histogram of 
HUVEC labelled with DCFH-DA. (B): quantitative analysis of the mean 
fluorescence intensity of DCF. The fluorescence intensity of DCF was read at 
525nm emission when exited at 488nm by flow cytometry. The results are 
expressed as mean (+/- SEM) from 3 different donors (n=3). *p<0.05 
compared with non-treated cells. #p<0.05 for cells treated with IV iron 
sucrose and NAC compared with HUVEC treated with IV iron sucrose at 6hr 
alone.  
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Figure 3.7: Representative images showing the effects of IV FCM and NAC 
co-incubation on ROS generation in HUVECs using DCFH-DA by flow 
cytometry at 6hr. HUVEC were grown in complete endothelial growth 
medium and either not treated or treated with 50 µg/ml IV FCM alone or in 
combination with 2 mM NAC for 6hr. Non-treated were considered as 
negative controls. These cells were washed with DPBS then incubated with 
10 μM DCFH-DA for 30-45 min. (A): representative histogram of DCF 
intensity in HUVECs labelled with DCFH-DA and measured by flow 
cytometer. (B): mean fluorescence obtained from the histogram statistics. 
The fluorescence intensity of DCF was read at 525nm emission when exited 
at 488nm by flow cytometry. The results are expressed as mean (+/- SEM) 
from 3 different donors (n=3). *p<0.05 compared to non-treated cells. 
#p<0.01 for HUVEC treated with IV FCM and NAC versus cells treated with 
IV FCM at 6hr alone.  
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Figure 3.8: Representative images showing the effect of IV iron sucrose and 
NAC co-incubation on ROS generation in HUVECs using DCFH-DA by flow 
cytometry at 24hr. HUVEC were grown in complete endothelial growth 
medium and either not treated or treated with 50 µg/ml IV iron sucrose alone 
or in combination with 2 mM NAC for 24hr. Non-treated were considered as 
negative controls. These cells were washed with DPBS then incubated with 
10 μM DCFH-DA for 30-45 min. (A): representative flow cytometry histogram 
of HUVEC labelled with DCFH-DA. (B): mean fluorescence obtained from 
the histogram statistics. The fluorescence intensity of DCF was read at 
525nm emission when exited at 488nm by flow cytometry. The results are 
expressed as mean (+/- SEM) from 3 different donors (n=3). ***p<0.05 
versus non-treated cells, ##p<0.01 for HUVEC treated with IV iron sucrose 
and NAC compared with IV iron sucrose-treated cells alone and *p<0.05 IV 
iron sucrose and NAC together versus non-treated cells.  
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Figure 3.9: Representative images showing the effect of IV FCM and NAC 
co-incubation on ROS generation in HUVECs using DCFH-DA by flow 
cytometry at 24hr. HUVEC were grown in complete endothelial growth 
medium and either not treated or treated with 50µg/ml IV FCM alone or in 
combination with NAC (2mM) for 24hr. Non-treated were considered as 
control. These cells were washed with DPBS then incubated with 10μM 
DCFH-DA for 30-45min. (A): representative flow cytometry histogram of 
HUVEC labelled with DCFH-DA. (B): mean fluorescence obtained from the 
histogram statistics. The fluorescence intensity of DCF was read at 525nm 
emission when exited at 488nm by flow cytometry. The results are expressed 
as mean (+/- SEM) from 3 different donors (n=3). **p<0.05 versus non-
treated cells, #p<0.01 for IV FCM and NAC-treated cells versus IV FCM-
treated HUVEC alone and *p<0.05 for IV cells treated with IV FCM and NAC 
versus non-treated cells.  
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3.3.3. Intracellular superoxide anion measurement in HUVEC treated 
with IV iron preparation and NAC using NBT assay 
While DCF measure all ROS (including NO), the NBT assay specifically 
measures superoxide anion generation. Similar to the results obtained from 
total ROS production by DCFH-DA staining, Figure 3.10 showed clear 
detectable production of superoxide anion in non-treated cells. Although, IV 
iron sucrose or IV FCM at 2hr show increased superoxide anion production 
compared to non-treated cells, this was not statistically significant (Figure 
3.10). In contrast, IV iron sucrose or IV FCM at 6 and 24hr incubation show 
clearly detectable production in superoxide anion, which were significantly 
increased compared to non-treated cells (p<0.05), (p<0.01) and (p<0.001) 
(Figure 3.10). In addition, HUVEC treated with IV iron sucrose showed 
significant increase compared with IV FCM-treated cells at 24hr (p<0.05) 
(Figure 3.10). Co-treatment with 2 mM NAC and IV iron sucrose or IV FCM 
resulted in significant reduction of superoxide anion compared with HUVEC 
treated with IV iron sucrose or IV FCM alone at 6hr and 24hr (p<0.05) and 
(p<0.01) respectively (Figure 3.11).  
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Figure 3.10: The effect of IV iron preparations on superoxide anion 
production in HUVEC using NBT assay. HUVEC were grown in complete 
medium and either not treated or treated with 50 µg/ml IV iron sucrose or IV 
FCM for different time course 2, 6 and 24hr. Non-treated cells from the same 
donor were considered as negative control. Media was replaced with phenol 
red-free media containing 1 mg/ml NBT and incubated at 370C in 5% CO2 for 
90 min. Cells were then lysed and absorbance was measured immediately 
with a spectrophotometer at wavelength 750nm as described in (Section 
3.2.2.2.3). The results are expressed as mean (+/- SEM) from 6 different 
donors (n=6). *p<0.05, **p<0.01 and ***p<0.01 versus non-treated cells. 
*p<0.05 for HUVEC treated with IV iron sucrose at 24hr versus IV FCM-
treated cells at 24hr. 
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Figure 3.11: The effect of IV iron preparations and NAC co-incubation on 
superoxide anion production in HUVEC using NBT assay. HUVEC were 
grown in complete medium and wither not treated or treated with 50 µg/ml IV 
iron sucrose or IV FCM alone or with 50 µg/ml IV iron sucrose or IV FCM and 
2 mM NAC for different time course 2, 6 and 24hr. Non-treated cells were 
considered as negative control. Media was replaced with phenol red-free 
media containing 1 mg/ml NBT and incubated at 370C in 5% CO2 for 90 min. 
Cells were then lysed and absorbance was measured immediately with a 
spectrophotometer at wave length 750nm as described in section (3.2.2.2.3). 
The results are expressed as mean (+/- SEM) from 4 different donors (n=4). 
*p<0.05, **p<0.01 and ***p<0.01 versus non-treated cells. #p<0.05 for IV iron 
sucrose or IV FCM at 6hr compared with IV iron sucrose or IV FCM and NAC 
treated cells at 6hr and ##p<0.05 for IV iron sucrose or IV FCM at 24hr 
compared with IV iron sucrose or IV FCM and NAC treated cells at 24hr.  
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3.4. DISCUSSION 
This chapter provides experimental support for the concept that IV iron 
administration can trigger oxidative stress, by increasing ROS production 
which may lead to endothelial injury, a factor that plays a role in development 
of CVD in CKD patients (Lahera et al., 2006). There are several different 
methods used in the literature to investigate and measure ROS production in 
the cells (Tarpey and Fridovich, 2001). Even with several methods available, 
vascular ROS formation is not easy to measure, as the cytoplasmic and 
mitochondrial SOD enzyme scavenges the intracellular low steady state of 
superoxide anion, which can leak to the extracellular spaces (Rosen and 
Freeman, 1984). Thus, efficient and sensitive methods are needed in order 
to measure the relatively short half-life of ROS (Tarpey and Fridovich, 2001). 
In this study, to measure both total ROS production in EA.hy926 endothelial 
cell line and primary HUVEC, and superoxide anion in HUVEC, cells were 
exposed to IV iron sucrose or IV FCM, and two different methods were 
preformed, the DCFH-DA staining and NBT reduction assay.  
ROS in the cells can oxidize DCFH-DA into its fluorescent derivative DCF. 
Numerous studies have shown that different types of ROS such as H2O2 or 
hydroxyl radical can oxidize DCFH-DA to DCF in BAEC (Royall and 
Ischiropoulos, 1993; Tampo et al., 2003), HUVEC (Hsieh et al., 1998) and by 
oxidants produced during the respiratory burst in inflammatory cells (Tarpey 
and Fridovich, 2001). However, Kalyanaraman et al (2011) have reviewed 
that DCFH-DA staining can not be used to measure H2O2 directly and this is 
due to its complexity and a number of limitation associated with this staining 
such as, cytochrome c have the ability either directly or indirectly to oxidize 
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DCFH to DCF (Karlsson et al., 2010; Burkitt and Wardman, 2001). Iron in its 
active state Fe2+ can promote the oxidation of DCFH to DCF in the presence 
of H2O2 (Qian and Buettner, 1999). However, all these limitations, can lead to 
incorrect fluorescence intensity of DCF.  
In order, to confirm our data obtained by DCFH-DA staining and to determine 
if superoxide anion is elevated by IV iron preparations in HUVEC, NBT assay 
was used. The data of flow cytometry using DCFH-DA staining showed that 
total ROS production was significantly induced in EA.hy926 cell line and 
primary HUVEC treated with for IV iron sucrose or IV FCM compared with 
non-treated cells (Figures 3.2B, 3.3B, 3.4B and 3.5B). This indicates that 
both IV iron supplement induced an increase in the generation of total 
intracellular ROS production in both primary HUVEC and EA.hy926 cell line. 
However, HUVEC seemed to be more sensitive to IV iron preparations 
compared with EA.hy926 cell line, as our data showed that EA.hy926 cell 
line exposed to up to 500 µg/ml of IV iron sucrose or IV FCM, and cells did 
not die and no sign of cell death such as shrinkage was observed under the 
microscope compared with non-treated cells. While, our data from chapter 2, 
showed that HUVEC treated with 50 µg/ml of IV iron sucrose significantly 
reduced cell proliferation, obvious morphological changes and cells became 
shrunk and star-shaped with sharp outlines sign of apoptosis compared with 
non-treated cells. These data are indicative that EA.hy926 cell line may have 
better antioxidant defence system than primary HUVEC, although non-
treated EA.hy926 cell line showed to generate more ROS compared with 
non-treated HUVEC.  
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Our data can be interpreted as being in line with Gupta et al (2010), who also 
used DCFH-DA staining and found that, following exposure of peripheral 
blood mononuclear cells (PBMC) to 100 µg/ml of IV iron sucrose, iron 
dextran and sodium ferric gluconate for 24hr, all three types of IV iron 
preparations significantly increased total intracellular ROS level in these 
cells. However, the concentration of IV iron preparations that was used in our 
study was half of what Gupta et al have used which suggests that HUVEC 
are more sensitive to those compounds. Kuo et al (2008) also found that, 
ROS was significantly induced in lymphocyte treated with serum from CKD 
patients who were treated with a range from 200 to 500 mg/ml IV iron 
sucrose using DCFH-DA staining analysed by flow cytometry. The authors 
assumed that this was as a result of antioxidant reduction since they found 
that plasma level of vitamin C and E were significantly reduced in the CKD 
patients. In addition, a recent in vitro study by Martin-Malo et al (2012), found 
that iron dextran, IV iron sucrose, IV FCM, and ferric gluconate significantly 
increased ROS production in haemodialysis patients. Martin-Malo and 
colleagues found that treating PBMCs from healthy donors and CKD patients 
on dialysis with 200 μg/ml IV iron sucrose, IV FCM, iron dextran and ferric 
gluconate for 2, 8 and 24hr, significantly induced total ROS production at 8 
and 24hr compared to non-treated PBMC (Martin-Malo et al., 2012). These 
authors propose that ROS increased due to the NTBI released from each IV 
iron preparation. A more recent in vitro study by Fell et al (2014) treated 
PBMCs with 133, 266 and 533 µg/mL IV iron sucrose or IV FCM for 3hr. Fell 
and others used carboxy- H2DFFDA staining by flow cytometry to measure 
ROS production and found that IV iron sucrose significantly increases ROS 
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production in these cells, while IV FCM had no significant effect. Because 
only IV iron sucrose increases ROS production, these authors suggested 
that this can be due to the pharmacokinetic differences between the two 
compounds as discussed in section 1.6.3.1. All these differences can play a 
key role in free iron released from IV iron preparations, which then leads to 
the induction of ROS production (Fell et al., 2014). However, the data of Fell 
and others study can be criticized as they incubated the cells with IV iron 
preparations only for 3hr, which could bias their results as ROS production 
by IV FCM may be evident after longer incubation period. In contrast, in vivo 
study by Malindretos et al (2007) showed that treating 20 CKD patients with 
100 mg IV iron sucrose and iron dextran has no effect on oxidative stress 
levels. Another recent in vivo study showed that, treating anaemic mouse 
model with IV FCM, no significant effects on oxidative stress induction were 
observed (Heming et al., 2012). 
Many reports in the literature have demonstrated the beneficial effect of NAC 
in the treatment of CKD patients. An in vivo study by Hsu et al showed that 
treating CKD patients with NAC improved their anaemia and decreased the 
plasma level of oxidized LDL (Hsu et al., 2010). In addition, another study on 
134 CKD patients who were treated with 600 mg NAC twice a day for a 
week, has shown significant reduction in cardiac events and ischaemic stroke 
by 30% and 36% respectively (Tepel et al., 2003). Other studies have 
documented the beneficial effect of NAC on improvement of endothelial 
function in CKD patients (Scholze et al., 2004; Libetta et al., 2011). To 
explore whether antioxidant treatment can reduce or normalize the excess 
level of ROS production, in vitro HUVEC were treated with 2 mM NAC and 
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ROS levels measured using NBT reduction assay and DCFH-DA staining. 
NAC reduced the ROS inducing effect of IV iron sucrose or IV FCM. This 
reduction was significant (p<0.05) for IV iron sucrose or IV FCM and NAC at 
6 and 24hr compared to IV iron sucrose or IV FCM at 6h and 24hr alone, 
which indicates that NAC was an efficient ROS scavenger and was able to 
attenuate IV iron preparation-induced ROS production in HUVEC. Our 
results can be in line with an in vivo study where MDA was looked at. 
Agarwal et al (2004) and Swarnalatha et al., (2010), who found that treating 
CKD patients with 100 mg of IV iron sucrose and 600 mg NAC, significantly 
reduced the amount of plasma MDA that was elevated by IV iron sucrose in 
these patients. Therefore, both our in vitro data and published in vivo data 
indicate that NAC is effective in reducing oxidative stress levels.  
Several studies have been previously published on the measurement of 
superoxide anion by NBT reduction assay (Au-Yeung et al., 2004; Eligini et 
al., 2005; Patterson et al., 1999). Superoxide anions reduce NBT to 
monoformazan (NBT+) which can be detected spectrophotometrically. From 
our data in this chapter, both treated and non-treated cells showed 
detectable production of superoxide anion. These results could be 
interpreted as being in line with other studies which documented that ECs 
produce low levels of superoxide anion as a second messenger which play 
an important role in mediating different signalling pathways under 
physiological conditions (Kunsch and Medford, 1999; Ullrich and 
Bachschmid, 2000; Zhang and Gutterman, 2007). However, IV iron-treated 
HUVEC showed increases superoxide anion production compared with non-
treated cells, and this increase was significant for cells that were treated with 
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either IV iron sucrose or IV FCM at 6hr incubation compared with non-treated 
cells (p<0.05) and for IV iron sucrose or IV FCM at 24hr incubation compared 
with non-treated cells (p<0.01). Even though both IV iron preparations induce 
superoxide anion this was not to a similar extent at different time points. IV 
iron sucrose at 24hr showed greater capacity in generating superoxide anion 
than IV FCM at the same time point. Our result are consistent with the finding 
by Rooyakkers and others who showed 100 mg/ml IV iron sucrose 
significantly induced superoxide anion production by 53-70% in healthy 
volunteers after 10 and 240 min of administration (Rooyakkers et al., 2002). 
These group suggest that increase of superoxide anion, was due to NTBI or 
free iron, which acts as a catalytic agent in the formation of oxygen radicals. 
Also consistent with the finding by Kuo et al., who showed that superoxide 
anion was significantly increased in CKD patients treated with 800 mg/l of IV 
ferric chloride hexahydrate. Kuo and others suggest that is because the high 
doses of IV iron which might increase the amount of NTBI or free iron, and 
subsequently superoxide production (Kuo et al., 2012). This indicates that IV 
iron preparation not only increase oxidative stress in CKD patients but also in 
healthy people.  
Collectively, all these findings indicate that IV iron preparations can lead to 
EC dysfunction and through overproduction of ROS generation. It is well 
known that, normal function of EC is to produce NO, and because EC 
dysfunction is associated with reduction of NO. Therefore, EC dysfunction as 
a result of IV iron preparation treatment can be due to decreased tissue 
bioavailability of NO. Together, our data obtained by both the NBT reduction 
assay and DCFH-DA probe give solid evidence that treatment with IV iron 
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preparations induced oxidative stress in HUVEC. This increased ROS could 
explain, at least partially the inhibition of ECs proliferation rate and the 
marked changes in HUVEC morphology by IV iron sucrose. In addition, IV 
FCM also showed to induce ROS generation compared with non-treated 
cells. However, IV FCM did not generate as much ROS as the IV iron 
sucrose and may explain our data from chapter 2, where IV FCM did not 
promote EC dysfunction compared with non-treated cells. Thus, the findings 
of this study suggest that increased ROS generation and superoxide anion 
induced by IV iron preparations may play a major role in EC dysfunction and 
potentially provide a fundamental mechanism linking the high prevalence of 
CVD in CKD patients. 
3.5. CONCLUSION 
In conclusion, taken together, these results indicate that IV iron sucrose or IV 
FCM exposure induces total intracellular ROS generation. This study 
documents for the first time that IV FCM compound induced superoxide 
anion production in EC. Oxidative stress, in turn can result in EC damage 
and, subsequently CVD in CKD patients. IV iron sucrose is more potent in 
generating superoxide and total ROS when compared to IV FCM. In addition, 
treatment with NAC has clear evidence in protecting EC from oxidative 
stress, which was induced by the selected IV iron preparations. 
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CHAPTER 4 
EFFECT OF IV IRON PREPARATIONS ON HUVEC DAMAGE  
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4.1. INTRODUCTION  
Apoptosis or programmed cell death is an essential part of normal 
development, and plays a role in homeostasis to control cell populations in 
tissue (Elmore, 2007). Apoptosis also works as a defence mechanism for 
instance, in the induction and generation of regulatory T- lymphocyte cells, 
which play a key role in regulating the immune system in times of infection to 
get rid of harmed cells (Norbury and Hickson, 2001). However, inappropriate 
activation of apoptosis may contribute to a variety of clinical disorders, 
including those that affect the vascular system such as atherosclerosis (Van 
Vré et al., 2012). ROS which function as regulators of subcellular events, 
when overexpressed can also induce DNA, lipid, and protein damage and 
cell death through intrinsic and extrinsic apoptotic pathways, suggesting a 
link between ROS and apoptosis (Wen et al., 2002; Uttara et al., 2009). ROS 
are known to induce apoptotic cell death in different cell types, including ECs 
(Dimmeler et al., 2000). Furthermore, in the cardiovascular system, apoptotic 
cell death following injury of vascular endothelium may play a role in initiation 
of atherogenesis as well as in the induction of acute events which trigger 
myocardial infarction (Cines et al., 1998; Dimmeler et al., 1997; Falk, 2006; 
Rudijanto, 2007). Excessive ROS production includes O2
.− and H2O2, can 
cause apoptosis in ECs (Irani, 2000; Li and Shah, 2004). EC apoptosis 
results in increased vascular permeability to cells (leukocyte) and lipids, 
smooth muscle cell proliferation, and increased coagulation, thus contributing 
to the development of atherosclerotic lesions (Pirillo et al., 2013). IV iron 
administration has been frequently used for the treatment of iron deficiency 
and for the management of anaemia in CKD as previously discussed 
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(Kamanna et al., 2012). However, several in vitro and in vivo studies showed 
that these compounds, in particular IV iron sucrose promote apoptosis in 
different cell types including, ECs and lymphocytes (Kartikasari et al., 2006; 
Carlini et al., 2006; Ichii et al., 2012; Martin-Malo et al., 2012; Kamanna et 
al., 2012;  Masuda et al., 2013). Furthermore, previous in vitro studies 
showed that IV iron sucrose causes endothelial damage through oxidative 
stress induction (Zager et al., 2002; Bishu and Agarwal, 2006; Kamanna et 
al., 2012). 
Enzymes within the p38 MAPK family are widely distributed among different 
tissues and play an important role in regulating many cellular processes such 
as differentiation, cell growth, death and DNA repair and can also contribute 
to the regulation of cell apoptosis upon stress stimuli (Ono and Han, 2000; 
Tian et al., 2012). Elevated ROS has shown to directly injure the cells by 
oxidizing DNA and protein (Klaunig et al., 2010). However, different studies 
showed that high level of ROS can also damage the cells indirectly by 
activating multiple signalling pathways, including MAPK cascades, p38 
MAPK in different tissue and in different arteries ECs from human (HAEC), 
rat (RAECs) and mouse (MAECs), and are often associated with apoptosis 
(Callsen and Brune, 1999; Osone et al., 2004; Sigaud et al., 2005; Tian et al., 
2012). Studies have shown that apoptosis can be mediated by p38 MAPK in 
EC (EA.hy926 cell line) in response to TNF-α (Yue et al., 1999; Grethe et al., 
2004). Other studies have described the anti-apoptotic effects of this 
pathway as protective on cardiac myocytes (Zechner et al., 1998). It has 
been shown that, many death and survival genes, including Bax and Bcl-2, 
which are located on the mitochondria can alter mitochondrial membrane 
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permeability and trigger apoptosis (Yuan et al., 2003). The expression of Bax 
is regulated by redox-sensitive transcription factor NF-kB, and oxidative 
stress increases Bax expression through the activation of NF-kB producing a 
pro-apoptotic state (Shou et al., 2002; Wiu et al., 2001). P38 MAPK 
activation has been shown to phosphorylate Bcl-2 and lead to its 
translocation out of the mitochondria, which seem to be essential for the 
activation of the intrinsic pathway apoptotic signal, leading to release of 
cytochrome c and downstream activation of caspase-3, resulting in apoptosis 
(Farley et al., 2006). Furthermore, in a cardiac myocyte cell line, Bax protein 
and mRNA gene expressions were also shown to be up-regulated by p38α 
MAPK, which resulted in cell apoptosis (Porras et al., 2004). Oxidative stress 
including 200 µM H2O2, induced apoptosis in rat cardiac myocyte, due to 
significant down-regulation of Bcl-2 protein expression. This down-regulation 
of Bcl-2 was attenuated by p38 MAPK inhibitor, SB203580 (Markou et al., 
2009), which indicates that p38 MAPK plays an important role in down 
regulation of Bcl-2 protein and apoptosis. In addition, p38 MAPK was shown 
to play a key role in CVD such as ischaemia reperfusion injury, through the 
induction of apoptosis, via the modulation of Bcl-2 family proteins (Kaiser et 
al., 2004).  
Chapter 2 and 3 indicated clearly that, IV iron preparations, in particular IV 
iron sucrose significantly inhibited proliferation and induced ROS generation 
in ECs. In this chapter, we hypothesise that ROS generation by IV iron 
preparations can mediate the activation of p38 MAPK and consequently lead 
to both down-regulation of Bcl-2 and up-regulation of Bax, leading to 
apoptosis in HUVEC. Therefore, this chapter aimed to investigate the in vitro 
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effect of IV iron sucrose or IV FCM on induction of EC apoptosis using 
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL 
assay) and Annexin V-FITC/PI. In addition, the work aimed to demonstrate 
whether treatment with these two compounds induce sustained activation of 
p38 MAPK via ROS elevation and whether this is responsible for the down-
regulation of Bcl-2 and up-regulation of Bax protein expressions, as two key 
anti and pro-apoptotic proteins involved in stress-induced apoptosis pathway, 
leading to apoptosis of ECs using Western blot method. The role of p38 
MAPK in apoptosis was investigated using the specific inhibitor, SB203580 
on IV iron preparation-induced apoptosis to confirm the role of p38 MAP 
kinase pathway in apoptosis. 
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4.2. MATERIALS AND METHODS 
4.2.1. Materials  
4.2.1.1. Reagents 
Sodium chloride was purchased from Sigma-Aldrich. Sodium dodecyl 
sulphate (SDS, L3771), glycine (G-8898), sodium pyrophosphate (S-9515), 
bromophenol blue (B-5525), N,N,N’,N’- tetramethylethylenediamine (TEMED, 
T-9281), Dl-dithiotheritol (D-9163),  ammonium persulfate (APS, A-3678), 
Kodak GBX developer and replenisher (P7167) and Kodak fixer and 
replenisher (P7042), Kodak X-ray film (F1274-50). HEPES (H4034) were 
purchased from Sigma-Aldrich Chemical Company (Pool Dorest, UK). 
Polyvinylidene difluoride (PVDF) membrane (Hypond-P, RPN303F) was 
purchased from GE healthcare UK limited, Buckinghamshire, UK. 
Acrylamide/bis solution (30%) (161.0156), protein assay kits (500-0120) 
were obtained from BioRad (Bio-Rad Laboratories, Hercules, California, 
USA). All reagents for enhanced chemiluminescence (ECL) were purchased 
from Amersham Life sciences (Little Chalfont, Bucks, UK). P38 MAP kinase 
inhibitor SB203580 (ab120162) was obtained from Abcam (Cambridge, UK). 
Terminal Deoxynucleotidyl Transferase, Recombinant (M1871) was obtained 
from Promega (Southampton, UK). Annexin V-FITC/PI Apoptosis Detection 
Kit (ab14085) was purchased from Abcam (Cambridge, UK). Phosphate 
buffered saline (PBS) pH 7.4. 
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4.2.1.2. Antibodies 
Rabbit polyclonal IgG phospho-p38 MAP Kinase (MAPK) (Thr180/Thr182) 
antibody (9212S), Bcl-2 Antibody (Human Specific) (2872) and Bax Antibody 
(2772) were purchased from New England Biolabs, UK. ECL anti- rabbit IgG 
horseradish peroxidise HRP linked whole antibody (NA934V) was purchased 
from GE healthcare UK limited, Buckinghamshire, UK. Biotinylated protein 
ladder (catalog No. 7727) and HRP conjugated anti biotin antibodies (catalog 
No. 7075) were purchased from New England Biolabs, UK. Prestained 
Protein Ladder (catalog No. 26616) was purchased from Thermo Fisher 
Scientific, UK. The diluent which has been used to dilute all antibodies was 
TBS-T including, 2% w/v BSA. Glyceraldehyde-3-phosphate dehydrogenase 
antibody (GAPDH) (ab9485) was purchased from Abcam (Cambridge, UK). 
4.2.2. Methods  
4.2.2.1. Determination of apoptosis in IV iron preparation treated-
HUVEC  
4.2.2.1.1. Terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL assay) 
TUNEL assay was used to demonstrate whether IV iron sucrose or IV FCM 
induces apoptosis in cultured HUVEC. Gavrieli and colleagues (1992) have 
described TUNEL as an assay for localization of apoptotic DNA 
fragmentation (Gavrieli et al., 1992). The method relies on the template-
independent identification of blunt ends of double-stranded DNA breaks, 
which can be recognised by TdT enzyme to measure the fragmented DNA of 
137 
 
apoptotic cells by catalytically incorporating fluorescein-16-dUTP (a) at 3 -́OH 
DNA ends (Kyrylkova et al., 2012), as shown in (Figure 4.1).  
HUVEC  were grown onto coverslip slides in 6 well plates at a concentration 
of 2x105 cells per well, treated with 50 µg/ml IV iron sucrose or IV FCM, and 
incubated at 370C in 5% CO2 for 2, 6 and 24hr. Cells were then fixed in 4% 
paraformaldehyde in PBS pH 7.4 for 15 min at room temperature. Then 
slides were washed twice with PBS. Apoptosis was determined using a 
terminal TUNEL assay kit (Promega, Southampton, UK) according to the 
manufacture’s protocol. Slides were incubated in a reaction mixture (30 mM 
Tris pH 7.4; 140 mM sodium cacodylate; 1 mM cobalt chloride; 5 µM biotin-
16-deoxyuridine triphosphate; 0.3 U/µl terminal deoxynucleotidyl transferase 
(TdT) at 370C for 1hr, and then were washed twice in PBS. Additionally, cells 
were treated with extravidin peroxidase solution for 30 min in a moisture 
chamber at 370C. Slides were then washed in PBS and the chromogenic 
reaction visualized by the addition of 3, 3’-diaminobenzidine (DAB) for 8-10 
min at room temperature, and contrastained with haematoxylin and 
coverslips was applied using Histomount mounting medium (Fisher 
Scientific, Fair Lawn, NJ) for light microscopic observation. Imaging and 
analyses were performed by using Olympus CKX31 microscopy (Olympus, 
Southend-on-Sea, UK). Cells incubated without TdT mixture reaction were 
considered as negative control. 
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Figure 4.1: Schematic of the TUNEL assay. Staining of single or double 
stranded DNA breaks labelling with dUTP utilizing exogenous TDT enzyme 
and analysed under microscope. 
4.2.2.1.2. Cell analysis for TUNEL assay  
HUVEC were assessed for morphology and staining according to Gold et al., 
(1994). The following findings were considered to represent apoptosis: 
marked condensation of chromatin and cytoplasm clearly staining strongly 
brown or brown/black; the TUNEL-positive cells were scored in several fields 
on each coverslip to yield a total of at least 100 cells per field (10 fields in 
each slide) under a 40x objective of an Olympus CKX31 microscope. Values 
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represent percentages from at least 100 cells from each culture. Using the 
one-way ANOVA test differences were considered as significant at p<0.05.    
4.2.2.1.3. Annexin V-FITC/PI staining method to detect apoptosis  
Phosphatidylserine (PS) is plasma phospholipid membrane component 
located inside the cell membrane envelope (Lee et al., 2013). However, on 
induction of apoptosis, PS translocate to the outer surface of the cell, acting 
as signal for macrophages to overwhelm the cell (Lee et al., 2013). Thus, 
Annexin V-FITC/PI staining is a recombinant phosphatidylserine-binding 
protein that interacts strongly with phosphatidylserine residues and can be 
used for the detection of apoptosis as shown in Figure 4.2 (Schutte et al., 
1998; Arur et al., 2003). Annexin V-FITC/PI apoptosis kit also contain 
propidium iodide (PI), which used to differentiate necrotic from apoptotic 
cells. PI is a membrane impermeant dye but once cells lose their membrane 
integrity, PI then enter and bind to nucleic acids of dead cells, which explain 
why PI-positive cells are necrotic as shown in Figure 4.2 (Riccardi and 
Nicoletti, 2006). HUVEC were grown in 6 well plates at a concentration of 
1x105 cells per well and incubated with 50 µg/ml IV iron sucrose or IV FCM 
for 24hr. Cells were trypsinised and washed with PBS, centrifuged at 13000x 
g for 5 min. Then, 1 x105 cells from each well were suspended in 100 µl 
binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM NaCl and 2.5 mM 
CaCl2). Cells were then incubated with 5 μl Annexin V-FITC/PI and 5 μl of 
propidium iodide, and incubated for 15 min in the dark at room temperature. 
Subsequently, 500 μl binding buffer was added and the fluorescence of each 
sample was quantitatively analysed at 488nm by FACScalibur flow cytometry 
(Beckman Coulter, Inc. UK). Apoptosis was expressed as the percentage of 
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cells exhibiting Annexin V-binding relative to the total cell population (Rayner 
et al., 2006; Sun et al., 2007). 
 
Figure 4.2: Schematic representation of apoptosis-induced membrane 
changes recognized by Annexin V-FITC/PI.  
4.2.2.1.4. P38 MAP kinase role in IV iron preparation-mediated EC 
activation 
4.2.2.1.5. Cell Treatment with IV iron preparations prior to Western 
blotting for phospho-p38 MAP Kinase, Bcl-2 and Bax 
HUVEC were seeded in complete endothelial growth medium in 6 well plates 
at a concentration of 2 x105 cells per well, until they were 80-90% confluent. 
Cells were stimulated with 50 µg/ml of IV iron sucrose or IV FCM for 15 min, 
30 min, 60 min, 2hr, 6hr and 24hr for detection of p38 MAPK, and 2, 6 and 
24hr for Bcl-2 and Bax, and incubated in an atmosphere of 95% air and 5% 
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CO2 at 37
0C. HUVEC left untreated were considered as negative control (0 
µM). 
4.2.2.1.6. Identification of phospho-p38 MAP Kinase, Bcl-2 and Bax by 
sodium dodecyl sulphate gel electrophoresis (SDS-PAGE) and Western 
blotting  
4.2.2.1.6.1. Preparation of samples for analysis by SDS PAGE 
Following the appropriate stimulation, the 6 well plates were removed from 
the incubator at 370C and placed on ice. Media was aspirated from each 
plate, and the cells were washed twice with 500 µl ice-cold HPFEV buffer (50 
mM Hepes, 10 mM sodium pyrophosphate Na4P2O7, 100 µM sodium fluoride 
NaF, 4 mM EDTA and 2 mM orthovanadate Na3Vo4, pH7.4) to stop the 
reaction and inhibit protein dephosphorylation. Following buffer aspiration, 
adherent cells were harvested by scraping into 400 µl hot (650C) Laemmli 
sample buffer (0.048 M Tris-HCL, pH 6.8 containing 0.8 mM sodium 
pyrophosphate, 5 mM EDTA, 2% w/v SDS, 10% glycerol, 001% w/v 
bromophenol blue, 50 mM DTT) (Laemmli, 1970) and pulling the sample 
passed repeatedly through a 23G needle. The cells were then heated at 
1000C for 5 min in a heating block, in order to denature the protein present, 
and then stored at -200C until analysis. 
4.2.2.1.6.2. Determination of protein concentration 
The amount of protein in cell lysates was quantified to ensure equal loading 
in Western blot gels. Total protein in each HUVEC sample (without 
bromophenol blue)  was analysed with Bradford protein assay kit (Bio-rad 
500-0120) according to the manufacturer’s instructions, with the detergent 
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compatible adaptation and the use of bovine serum albumin as standard 
(200, 400, 600, 800, and 1000 mg/ml). Initially, dilutions of the protein 
standard were prepared at above concentrations then 5 µl of the standard or 
cell lysate were added to individual wells of a 96 well-plate in triplicate. 25 µl 
of reagent A* (2% v/v reagent S in reagent A) was added to each well and 
then and then 200 µl of reagent B were added onto each well. The plates 
were left for 15 min at room temperature with gentle agitation to mix the 
reagents. The absorbance was read by 96 well plate reader at 750 nm, each 
sample producing a triplicate reading to allow the average of these triplicates 
to be calculated. The volume from each sample containing 30-40 µg of 
protein was then calculated and the appropriate volume of sample used for 
electrophoresis. 
4.2.2.1.6.3. Resolution of protein by SDS-PAGE 
A Bio-Rad mini protein gel electrophoresis kit (500-0120) was used to run all 
gels. Tris buffers were prepared and stored at room temperature for both 
resolving gel (1.5 M Tris base and 0.4% w/v SDS, pH 8.4) and stacking gel 
(0.5 M Tris base and 0.4% w/v SDS, pH 6.8). 10% resolving gel was 
prepared and poured in between glass plates and spacers (1.0 mm thick) to 
a level 1cm below the bottom of the comb when inserted and overlaid with 
0.1% w/v SDS solution. Once the resolving gel polymerized, SDS was 
removed and a 3% stacking gel was poured on the top and a 1mm comb 
was inserted. Following gel polymerization, they were assembled and placed 
in a Prespex tank containing electrophoresis buffer (25 mM Tris base, 192 
mM glycine and 0.1% w/v SDS). Appropriate volume from each sample 
containing 30-40 µg protein was loaded per well as well as 5 µl prestained 
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protein ladders (Thermo Fisher Scientific, UK) and biotinylated standards 
(New England Biolabs, UK). Samples were electrophoresed at a constant 
voltage of 100V for 2hr. 
4.2.2.1.6.4. Western blotting  
A Bio-Rad mini transfer Kit was used for the transfer of protein to PVDF 
membrane. PVDF membrane (GE healthcare, UK) was pre-wet in 100% 
methanol for 1-2 min and then washed with distilled water followed by 
blotting buffer (25 mM Tris base, 192 mM glycine and 20% v/v methanol) for 
5 min each. A transfer sandwich was prepared containing black cassette, 
sponge, filter paper, resolving gel; pre wet PVDF membrane, filter paper and 
white cassette. This sandwich was inserted into a transfer tank buffer filled 
with blotting buffer. The whole tank was engulfed with ice and connected to 
the power supply at 100V for 2.30hr. 
4.2.2.1.6.5. Detection of phospho-p38 MAPK, total p38 MAPK proteins, 
Bcl-2 and Bax 
A number of different protocols were attempted to produce specific p-p38 
MAPK, Bcl-2 and Bax bands as shown in Figure 4.3. Once transfer was 
completed, PVDF membrane was placed in blocking solution of either 3% 
w/v BSA or 5% w/v non-fat Milk in tris buffer saline-Tween (TBS-T) (150 mM 
sodium chloride, 20 mM Tris base pH7.4) containing detergent (Tween-20) at 
concentrations of 0.1% v/v overnight at 40C. The membrane was then 
incubated with p38 MAP kinase rabbit Ab (diluted in TBS-T,1:2000) or 
phospho-p38 MAP kinase rabbit mAb (diluted in TBS-T ,1:5000), anti-human 
Bcl-2 rabbit Ab (diluted in TBS-T,1:2000) or anti-Bax rabbit antibody (diluted 
144 
 
in TBS-T,1:2000) overnight with gentle agitation at 40C. The following day, 
the membranes were washed on a shaker 3 times for 10 min with 10ml TBS-
T and then incubated with horseradish peroxidise HRP- conjugated donkey 
anti rabbit IgG (1:5000) for 1hr at room temperature with shaking. Membrane 
was washed as previously described then prepared for ECL detection. 
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Figure 4.3: Flowchart representing developmental work that led to the final 
data of Western blot presented. 
4.2.2.1.6.6. Detection of protein by enhanced chemiluminescence (ECL) 
Following the final wash, the membrane was incubated in equal amounts of 
ECL solutions, ECL1 (250 mM luminol, 90 mM p-coumaric and 1 M tris base 
pH 8.5) and ECL 2 (30% H2O2 and 1 M tris base pH 8.5) for 3 min with gentle 
agitation and then placed in developing cassette, covered with saran wrap 
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excluding air bubbles. Kodak X-ray film was exposed to the membrane in the 
dark for 5 to 10 min. Film was immersed in developing solution for 
approximately 3 min until bands were visible, then it was washed with tap 
water before immersing it in fixing solution until the film became translucent. 
Film was rinsed thoroughly with tap water and left to air dry. 
All Western blotting experiments were performed on at least 3 independent 
samples and densitometric analysis of ECL exposure was performed using 
ImageJ 1.48 software from NIH.  
4.2.2.1.6.7. NAC treatment 
The antioxidant NAC was used to investigate the role of ROS generation in 
p38 MAP kinase activation. HUVEC were pre-treated with 2 mM NAC and 
then cultured for 60 min and 2hr in complete endothelial cell growth medium 
containing 50 µg/ml IV iron sucrose or IV FCM. HUVEC from the same 
donors cultured for 3hr in complete endothelial growth medium alone or with 
2 mM NAC and were considered as control. 
4.2.2.1.6.8. P38 MAPK inhibition  
SB203580, a specific inhibitor for p38 MAPK was used to inhibit the 
phosphorylation of p38 MAP kinase (Gum et al., 1998). HUVECs were 
cultured to reach 80-90% confluence. Cells were pre-treated with p38 MAPK 
inhibitor, SB203580 at a final concentration of 10 µM for 1hr. Then cells were 
treated with IV iron sucrose for 24hr. HUVEC treated with SB203580 alone 
were considered as a control.  
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4.3. RESULTS 
4.3.1. Effects of iron preparations on the apoptosis of HUVEC 
The effect of IV iron preparations treatment on HUVEC was evaluated by the 
TUNEL assay and apoptotic cells identified by a dark brown stain is confined 
to the nucleus. The results are expressed as percentages of apoptotic cells, 
as shown in Figure 4.4. TUNEL assay revealed that few cells treated with IV 
iron sucrose at 2 (6.2%) and 6hr (8.4%) respectively. Similarly treatment with 
IV FCM at 2 (5.9%) or 6hr (7.14%) respectively had undergone apoptosis 
and was not statistically significant compared with non-treated cells (5.2%) 
are shown in Figure 4.5. In contrast, exposure of cells to 50 µg/ml IV iron 
sucrose for 24hr showed a statistically significant increase in apoptotic cells 
compared with non-treated cells. The apoptosis of HUVEC treated with IV 
iron sucrose for 24hr increased to 38.5% when compared with non-treated 
cells (p<0.001) (Figure 4.4). Apoptotic cells showed dark brown nuclear 
staining indicative of DNA fragmentation associated with apoptosis. The 
results of the induction of apoptosis by IV iron preparations treatment of 
HUVEC are shown in Figure 4.4F. In contrast to iron sucrose, 24hr treatment 
with 50 µg/ml IV FCM did not cause any statistically significant increase in 
apoptosis compared to control HUVEC 9.2% (Figure 4.4G). TUNEL assay is 
somewhat subjective method and examination of HUVEC apoptosis was not 
performed by blinded observers. Therefore, a more quantitative method was 
also used. Annexin V-FITC/PI by flow cytometry as described in section 
(4.2.2.1.3) in order to confirm our results by TUNEL assay, which gave 
similar results. 
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Figure 4.4: The effect of IV iron preparations on apoptosis in HUVEC 
evaluated by TUNEL Assay. TUNEL staining performed after HUVECs were 
pre-incubated with 50 µg/ml IV iron preparations for 2, 6 and 24hr. Black 
arrow indicates apoptotic cells (400X). (A): untreated HUVEC, (B): HUVEC 
treated with IV iron sucrose 2hr, (C): HUVEC treated with IV FCM 2hr, (D): 
HUVEC treated with IV iron sucrose 6hr, (E): HUVEC treated with IV FCM 
6hr, (F): HUVEC treated with IV iron sucrose 24hr and (G): HUVEC treated 
with IV FCM 24hr. 
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Figure 4.5: The effect of IV iron preparation on percentage of HUVEC 
apoptosis quantified by TUNEL assay. Apoptotic cells that show irregular 
nuclear staining were counted in four different random image fields, each 
containing approximately 100 cells from each culture. Degrees of apoptotic 
cell death are expressed as percentages compared to total cell number 
within each field. Values are expressed as (mean ± SD) from three different 
donors (n=3). ***p<0.001 for IV iron sucrose at 24hr compared with non-
treated cells or cells treated with IV FCM at 24hr. 
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4.3.2. Effects of iron preparations on the apoptosis in HUVEC using 
Annexin V-FITC/PI staining by flow cytometry 
The percentage of early IV iron-treated HUVEC apoptosis was also 
confirmed using the Annexin V-FITC/PI Apoptosis Detection kit (Abcam). 
Stained cells were analysed by flow cytometry (FACScaliber; Beckman 
Coulter, Inc. UK). Viable cells, were those staining negative for Annexin V 
and PI, early apoptotic cells were positive for Annexin V and negative for PI 
staining while late apoptotic cells were Annexin V and PI staining positive 
(Figure 4.6A). Annexin V-FITC/PI showed that HUVEC treated with IV FCM 
at 24hr were not significantly different to non-treated cells (Figure 4.6B). On 
the other hand, cells treated with IV iron sucrose at 24hr showed significant 
increase in the apoptosis of HUVEC compared with IV FCM-treated HUVEC 
or non-treated cells (p<0.001) (Figure 4.6, A6) The percentage of apoptosis 
was 5.19 ± 0.53% in non-treated cells, 7.12 ± 0.89% in IV FCM, significantly 
increased to 35.18 ± 3% in iron sucrose-treated HUVEC (Figure 4.6B). This 
increase was significantly attenuated by p38 MAPK inhibitor SB203580 
compared with cells treated with IV iron sucrose alone (p<0.05) (Figure 
4.6B). However, the data was still significant compared with non-treated cells 
(p<0.05) (Figure 4.6B), and the percentage of apoptosis was 20.10 ± 0.53% 
in IV iron sucrose and SB203580 treated cells. 
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Figure 4.6: The effect of IV iron preparations on apoptosis of HUVEC using 
Annexin V-FITC/PI by flow cytometry (A-B). HUVEC were treated with 50 
µg/ml IV iron sucrose or IV FCM for 24hr or left untreated as control. In 
addition cells were treated with SB203580 and IV iron sucrose for 24hr to 
examine the effect of p38 MAPK on apoptosis induced by iron sucrose, and 
then incubated at 370C in 5% CO2. Subsequently, HUVEC were harvested 
and labelled with a combination of Annexin V-FITC and PI for 15 min in dark. 
(A: A1-A4): Flow cytometry dot plot figures of apoptotic cells, (A1): Non-
treated cells (control) group, (A2): IV FCM group, (A3): IV iron sucrose 
group, (A4): IV iron sucrose and SB203580. In each dot plot figure, the upper 
left quadrant corresponds to necrotic cells, which are negative for Annexin 
and PI positive (R4); the upper right quadrant contains the later apoptotic 
cells, which are positive Annexin V positive and PI positive cells (R5); the 
lower left quadrant shows viable cells, Annexin V negative and PI negative 
(R6) and the lower left quadrant represents the early apoptotic cells, Annexin 
V positive and PI negative (R7). (B): shows a column bar graph to quantify 
flow cytometry analysis of the percentage of apoptotic cells. All data are 
expressed as (means ± SD) from three different donors (n=3). **p<0.01 for 
IV iron sucrose compared to non-treated cells (control), *p<0.05 for IV iron 
sucrose and SB203580 versus non-treated cells and #p<0.05 for IV iron 
sucrose and SB203580 at 24hr versus IV iron sucrose at 24hr alone. 
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4.3.3. Western Blot analysis 
4.3.3.1. The effects of IV iron preparations on phosphorylation of p38 
MAPK and expression of Bcl-2 and Bax  
4.3.3.1.1. The effects of IV iron preparations on the phosphorylation of 
p38 MAPK 
HUVEC were cultured in complete endothelial growth medium containing 50 
µg/ml of IV iron sucrose or IV FCM for 15 min, 30 min, 60 min, 2, 6 and 24hr. 
Antibodies against phosphorylated p38 MAPK were used to detect p38 
MAPK phosphorylation in the cell lysates. Results from repeated protein 
assays showed the protein concentration in the cell lysates from confluent 6 
well plates as shown below 0.9 mg/ml (Figure 4.6).  
 
Figure 4.7: Graph of Protein assay standard curve shows the absorbencies 
and concentrations of the standards. A serial of dilution of BSA in PBS was 
prepared and absorbance was read at 750 nm. The absorbance of this 
sample was 0.13 and when it is plotted on the graph, protein concentration 
showed to be 0.9 mg/ml. 
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To determine whether the stimulation of HUVEC by IV iron preparations 
sucrose or IV FCM resulted in detectable phosphorylated p38 MAPK 
proteins, Western blotting was conducted.  
Figures 4.8A and 4.9A show a protein band of 43 kDa representing 
phosphorylated p38 MAP kinase for IV iron sucrose or IV FCM at a 
concentration of 50 µg/ml for increasing t times (15 min, 30 min, 60 min, 2, 6 
and 24hr). All figures are representative of 3 different experiments from three 
different donors. The band densities were quantified by the ratios of 
phosphorylated p38 to total p38 MAP kinase expression in the cells using 
Image J and the results are shown as the mean ratio from 3 different 
experiments (mean +/- SD) (Figures 4.8B and 4.9B) 
HUVEC grown in complete endothelial growth media, were considered as a 
negative control and showed a less intense band compared with IV iron 
sucrose or IV FCM-treated HUVEC, These results showed low 
phosphorylation of p38 MAP kinase in non-treated cells (Figures 4.8A and 
4.9A). However, cells grown in endothelial growth media containing 50 µg/ml 
IV iron sucrose or IV FCM at 15 min-6hr showed obvious increased 
phosphorylation of p38 MAP kinase compared with non-treated cells (Figures 
4.8A and 4.9A). HUVEC grown in media containing 50 µg/ml IV iron sucrose 
or IV FCM for 15 and 30 min showed a slight increase in phosphorylation of 
p38 MAP kinase compared with non-treated cells (Figures 4.8A and 4.9A). 
However, this increase was not statistically significant (Figures 4.7B and 
4.9B), while IV iron sucrose at 60 min and 2hr showed a statistically 
significant increase in p38 MAPK activation versus non-treated cells (p<0.01) 
(Figure 4.8B). In addition, p38 MAPK was significantly activated in cells 
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treated with IV FCM for 60 min and 2hr compared with non-treated cells 
(p<0.05) (Figure 4.8B). The p38 MAPK showed to be activated over 6hr, but 
was not significant compared with non-treated cells and slowly declined 
(Figures 4.10B and 4.11B). Chapter 3 clearly showed that, IV iron sucrose or 
IV FCM induced ROS generation in HUVEC. Thus, in order, to investigate 
whether the phosphorylation of p38 MAPK by IV iron sucrose or IV FCM was 
ROS dependent. HUVEC were pre-treated with ROS scavenger, NAC (2 
mM) and then treated with IV iron sucrose or IV FCM for different time 
course as described in section (4.2.2.1.6.7). The results showed that in 
HUVEC treated with NAC and IV iron sucrose or IV FCM at 60 min and 2hr, 
p38 MAPK phosphorylation was significantly reduced compared with HUVEC 
treated with sucrose or IV FCM alone at 60 min and 2hr (p<0.05) (Figure 
4.10B and 4.11B). P-p38 and total p38 MAPK exposure time under UV using 
Chemidoc machine was kept constant between experiments. 
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Figure 4.8: Shows the effect of IV iron sucrose on activation of p38 MAPK in 
HUVECs as determined by p38 phosphorylation. HUVECs were cultured in 6 
well plates until confluence, then cells were cultured in the absence or 
presence of 50 µg/ml IV iron sucrose for 15, 30, 60 min, 2hr, 6hr and 24hr 
and lysed. 30-40 µg protein from each sample was loaded on an SDS-PAGE 
gel and used in the Western blot. (A): representative blots; the phospho-p38 
and total p38 MAPK proteins were detected using specific antibodies and 
were identified by Western blot as a band of approximately 43 kDa. (B): the 
phospho-p38/total p38 ratio were quantified by densitometry and expressed 
as the ratio, compared to the control. All values are expressed as mean (+/- 
SD) from three different experiments (n=3). **p<0.01 compared with non-
treated cells. 
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Figure 4.9: Shows the effect of IV FCM on activation of p38 MAPK in 
HUVECs. HUVECs were cultured in 6 well plates until confluence, then cells 
were treated in the absence or presence of 50 µg/ml IV FCM for 15, 30, 60 
min, 2hr, 6hr and 24hr and lysed. 30-40 µg protein from each sample was 
loaded on an SDS-PAGE gel and used in the Western blot. (A): 
representative blots; the phospho-p38 and total p38 MAPK proteins were 
detected using specific antibodies and were identified by Western blot as a 
band of approximately 43 kDa. (B): the phospho-p38/total p38 ratio were 
quantified by densitometry and expressed as the ratio, compared to the 
control. All values are expressed as mean (+/- SD) from three different 
experiments (n=3). *p<0.05 compared with non-treated cells. 
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Figure 4.10: Shows the effects of NAC and IV iron sucrose on p38 MAPK 
phosphorylation in HUVECs. HUVECs were cultured in 6 well plates until 
confluence, then cells were incubated in the absence or presence of 2 mM 
NAC and 50 µg/ml IV iron sucrose for 60 min and 2hr, and lysed. 30-40 µg 
protein from each sample was loaded on an SDS-PAGE gel and used in the 
Western blot. (A): representative blots; the phospho-p38 and total p38 MAPK 
proteins were detected using specific antibodies and were identified by 
Western blot as a band of approximately 43 kDa. (B): the phospho-p38/total 
p38 ratio were quantified by densitometry and expressed as the ratio 
compared to the control. All values are expressed as mean (+/- SD) from 
three different experiments (n=3). **p<0.01 versus non-treated cells and 
#p<0.05 for IV iron sucrose and NAC at 60 min and 2hr compared with IV 
iron sucrose alone at 60 min and 2hr.  
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Figure 4.11: Shows the effects of NAC and IV FCM on p38 MAPK 
phosphorylation in HUVECs. HUVECs were cultured in 6 well plates until 
confluence, and then cells were incubated in the absence or presence of 2 
mM NAC and 50 µg/ml of IV FCM for 60 min and 2hr, and lysed. 30-40 µg 
protein from each sample was loaded on an SDS-PAGE gel and used in the 
Western blot. (A): representative blots; the phospho-p38 and total p38 MAPK 
proteins were detected using specific antibodies and were identified by 
Western blot as a band of approximately 43 kDa. (B): the phospho-p38/total 
p38 ratio were quantified by densitometry and expressed as the ratio 
compared to the control. All values are expressed as mean (+/-SD) from 
three different experiments (n=3). *p<0.05 versus non-treated cells and 
#p<0.05 for IV FCM and NAC at 60 min and 2hr compared with IV FCM alone 
at 60 min and 2hr . 
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4.3.3.1.2. The effect of IV iron preparations on expression of Bcl-2 and 
Bax proteins by Western blot   
Bcl-2 protein family members, such as Bcl-2 have been shown to play an 
important role in the regulation of apoptosis by blocking cytochrome c 
release from the mitochondria (Gogvadze et al., 2006). In order, to 
investigate the role of IV iron sucrose or IV FCM on mitochondria membrane 
integrity through apoptosis stress pathway protein expression, Western blots 
were conducted using antibodies against Bcl-2 and Bax. The results showed 
that Bcl-2 protein expression was not changed or decreased after HUVEC 
were treated with 50 µg/ml IV FCM for 2, 6 and 24hr or 50 µg/ml IV iron 
sucrose at 2 and 6hr compared with non-treated cells (Figures 4.12A and 
4.14A). However, Bcl-2 protein expression was significantly down-regulated 
in HUVEC treated with IV iron sucrose at 24hr compared with non-treated 
cells (p<0.05) (Figure 4.12B). In addition, protein expression of Bax was not 
up-regulated in HUVEC treated with IV FCM at 2, 6 and 24hr compared with 
non-treated HUVEC (Figure 4.15B). In contrast, HUVEC treated with IV iron 
sucrose at 24hr showed a significant up regulation in Bax protein expression 
compared with non-treated cells (p<0.05) (Figure 4.13B). Several studies 
showed that SB203580 play a key role in inhibiting or reducing the activity of 
p38 MAPK signalling pathway, and therefore prevent cell death in different 
cell types include ECs such as EA.hy926 and pulmonary microvascular ECs 
(PMVECs) (Grethe et al., 2004; Yang et al., 2012; Liu et al., 2014). Thus, in 
order to examine potential links between the p38 MAPK signalling pathway 
and apoptosis in HUVEC, the effect of SB203580 on the expression of Bcl-2 
and Bax in HUVEC treated with IV iron sucrose was examined. HUVEC were 
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pre-treated with 10 µM SB203580 for 1hr and then treated with IV iron 
sucrose for 24hr, and Western blotting method was performed as described 
in section (4.2.2.1.6.8). HUVEC treated with both IV iron sucrose and 
SB203580 for 24hr showed both a significant increase in Bcl-2 protein 
expression compared with cells treated with IV iron sucrose alone at 24hr 
(p<0.05) (Figure 4.16B), and a significant decrease in Bax expression 
(p<0.05) (Figure 4.17B). These results suggest that exposure to IV iron 
sucrose causes EC apoptosis via activation of p38 MAPK. In contrast, IV 
FCM did not induce apoptosis or alter Bcl-2/Bax expression. Furthermore, 
SB203580 showed to have a protective role against IV iron sucrose-induced 
apoptosis in HUVEC by regulating the expression of apoptosis-related 
proteins Bcl-2 and Bax. Our results for SB203580 inhibitor and IV iron 
compounds can be criticised as control was not treated with 0.1% DMSO 
alone and in this case it can not be used as appropriate control. However, 
previous work in our lab and other published studies showed that this final 
concentration of solvent has no effect on HUVEC or ROS generation 
(Alkhoury, 2009; Li et al., 2010; Omae et al., 2013). 
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Figure 4.12: Western blot analysis of Bcl-2 protein expression in HUVEC 
treated with IV iron sucrose. Cells were treated with 50 µg/ml for 2, 6 and 
24hr, cells were then lysed, and 30 μg protein extracts were subjected to 
Western blot analysis using specific antibodies against Bcl-2. (A): 
representative blots; the Bcl-2 and GAPDH proteins were detected by 
Western blot as a band of approximately 28 kDa and 37 kDa respectively. 
(B): the Bcl-2/GAPDH ratio were quantified by densitometry and expressed 
as the ratio to the control. All values are expressed as mean (+/- SD) from 
three different experiments (n=3). *p<0.05 for IV iron sucrose at 24hr 
compared with non-treated cells (control). 
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Figure 4.13: Western blot analysis of Bax protein expression in HUVEC by 
IV iron sucrose. Cells were treated with 50 µg/ml for 2, 6 and 24hr, cells were 
then lysed, and 30 μg protein extracts were subjected to Western blot 
analysis using specific antibodies against Bax. (A): representative blots; the 
Bax and GAPDH proteins were detected by Western blot as a band of 
approximately 20 kDa and 37 kDa respectively. (B): the Bax/GAPDH ratio 
were quantified by densitometry and expressed as the ratio to the control. 
Result from one experiment of three (n=3) performed is shown. All data are 
expressed as (mean ± SEM). *p<0.05 for IV iron sucrose at 24hr compared 
with non-treated cell (control). 
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Figure 4.14: Western blot analysis of Bcl-2 protein expression in HUVEC by 
IV FCM. Cells were treated with 50 µg/ml for 2, 6 and 24hr, cells were then 
lysed, and 30 μg protein extracts were subjected to Western blot analysis 
using specific antibodies against Bax. (A): representative blots; the Bcl-2 and 
GAPDH proteins were detected by Western blot as a band of approximately 
28 kDa and 37 kDa respectively. (B): the Bax/GAPDH ratio were quantified 
by densitometry and expressed as the ratio to the control. All values are 
expressed as mean (+/- SD) from three different experiments (n=3). 
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Figure 4.15: Western blot analysis of Bax protein expression in HUVEC by 
IV FCM. Cells were treated with 50 µg/ml for 2, 6 and 24hr, cells were then 
lysed, and 30 μg protein extracts were subjected to Western blot analysis 
using specific antibodies against Bax. (A): representative blots; the Bax and 
GAPDH proteins were detected by Western blot as a band of approximately 
20 kDa and 37 kDa respectively. (B): the Bax/GAPDH ratio were quantified 
by densitometry and expressed as the ratio to the control. All values are 
expressed as mean (+/- SD) from three different experiments (n=3). 
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Figure 4.16: The effect of IV iron sucrose and p38 MAPK inhibitor on Bcl-2 
expression in HUVEC. HUVEC were pre-treated with 10 μM SB203580 for 
60 min, and then stimulated with 50 µg/ml IV iron sucrose for 24hr. (A): 
representative blots; the Bcl-2 and GAPDH proteins were detected by 
Western blot as bands of approximately 28 kDa and 37 kDa respectively. 
(B): the Bcl-2/GAPDH ratio were quantified by densitometry and expressed 
as the ratio to the non-treated cells (control). All values are expressed as 
mean (+/- SD) from three different experiments (n=3). *p<0.05 compared 
with non-treated cells and #p<0.05 for IV iron sucrose and SB203580 at 24hr 
compared with IV iron sucrose at 24hr alone. 
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Figure 4.17: The effect of IV iron sucrose and p38 MAPK inhibitor on Bax 
expression in HUVEC. HUVEC were pre-treated with 10 μM SB203580 for 
60 min, and then stimulated with 50 µg/ml IV iron sucrose for 24hr. (A): 
representative blots; the Bax and GAPDH proteins were detected by 
Western blot as bands of approximately 20 kDa and 37 kDa respectively. 
(B): the Bax/GAPDH ratio were quantified by densitometry and expressed as 
the ratio to the control. All values are expressed as mean (+/- SD) from three 
different experiments (n=3). *p<0.05 compared with non-treated cells and 
#p<0.05 for IV iron sucrose and SB203580 at 24hr compared with IV iron 
sucrose at 24hr alone. 
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Table 4.1: Summary table of Western blot data presenting an overall 
reference point for p38 MAPK, Bcl-2 and Bax expression changes induced 
by IV iron compounds. Data shown represent group values are (mean ± 
SEM) of three experiments (n=3). *p <0.05, **p <0.01 and ***p<0.001 versus 
control and (ns) = not significant. 
IV iron compound Proteins of interest and/or treatment 
IV iron sucrose P38 MAPK IV iron sucrose 
and NAC 
P38 MAPK 
Control 0.24± 0.06 Control 0.22±0.04 
15 min 0.35 ± 0.04 ns NAC 0.21±0.03 
30min 0.60± 0.06 ns 60 min 1.03±0.10** 
60 min 1.01± 0.10** 60 min+NAC 0.52±0.06# 
2 hr 1.05±0.14** 2 hr 1.07±0.15** 
6 hr 0.55±0.04 ns 2 hr+NAC 0.60±0.08# 
24 hr                 0.10±0.02 ns 
IV FCM P38 MAPK IV FCM and NAC P38 MAPK 
Control 0.21± 0.02 Control 0.23±0.02 
15 min 0.38± 0.04 ns NAC 0.22±0.03 
30min 0.53±0.05 ns 60 min 0.77±0.08* 
60 min 0.76± 0.09* 60 min+NAC 0.39±0.1# 
2 hr 0.79±0.11* 2 hr 0.80±0.15* 
6 hr 0.37±0.03 ns 2 hr+NAC 0.40±0.06# 
24 hr                0.08± 0.01 ns 
IV iron sucrose Bcl-2 Bax 
Control 0.85±0.04 1.64±0.25 
2 hr 0.84±0.05ns 1.65±0.23ns 
6 hr 0.84±0.03ns 1.66±0.26ns 
24 hr 0.39±0.02* 3.3±0.32* 
IV FCM Bcl-2 Bax 
Control 0.92±0.03 1.77±0.20 
2 hr 0.91±0.04ns 1.78±0.22ns 
6 hr 0.92±0.03ns 1.74±0.25ns 
24 hr 0.90±0.02ns 1.76±0.22ns 
IV iron sucrose and 
SB203580 at 24hr 
Bcl-2 Bax 
Control 0.87±0.06 1.49±0.24 
SB203580 alone 0.89±0.04 1.58±0.26 
IV iron sucrose alone 0.43±0.03* 3.30±0.34* 
IV iron sucrose + 
SB203580 
0.70±0.05# 2.01±0.28# 
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4.4. DISCUSSION 
Apoptotic pathways are an important mechanism resulting in programmed 
cell death by altering mitochondrial membrane potential (Elmore et al., 2007). 
Most importantly, apoptosis of ECs can critically disturb the integrity of the 
endothelial monolayer, which contributes to vascular damage and is an early 
step in atherogenesis (Haimovitz-Friedman et al., 1997). It has certainly been 
shown that, in CKD patients, acceleration of atherosclerosis can be as a 
result of endothelial injury (Ross, 1995; Malyszko, 2010). IV iron preparations 
which are frequently used for the management of anaemia in CKD patients, 
promote apoptosis in cultured endothelial HAECs (Kamanna et al., 2012) but 
the mechanisms responsible are unclear. Therefore, the role of IV iron 
sucrose and IV FCM were examined on our model HUVEC to determine cell 
activation and damage. The present study demonstrates that IV iron sucrose 
causes significant EC apoptosis. This effect was demonstrated using both 
TUNEL assay and with Annexin V-FITC/PI using flow cytometry following 
24hr treatment with IV iron sucrose compared to non-treated cells (Figure 
4.5). TUNEL assay is well known as a standard method for late apoptosis 
detection in both cell culture and within tissue (Darzynkiewicz et al., 2008). 
However, since DNA damage can occur as a feature of both apoptosis and 
necrosis, the accuracy of TUNEL assay results as a measure of apoptosis 
has been questioned in several studies (Grasl-Kraupp et al., 1995; Orita et 
al., 1999). Therefore, to confirm our results reflected EC apoptosis in 
HUVEC, apoptosis was also investigated by Annexin V-FITC/PI. The data 
showed that, apoptosis of HUVEC treated with IV FCM slightly increased 
compared to non-treated cells and this increase was not significant 
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compared with non-treated cells (Figure 4.6B). In contrast, IV iron sucrose 
showed significant increase in apoptosis of HUVEC compared with non-
treated cells (Figure 4.6B). These results confirmed the data obtained from 
TUNEL assay method and showed that IV iron sucrose was the most 
injurious to HUVEC. These findings are in agreement with a study by Carlini 
and colleagues who showed that, treating BAECs with 100 and 1000 µg/ml 
IV iron sucrose for 24hr, significantly increased the apoptosis by 20.4 and 
38.3% respectively (Carlini et al., 2006). Our data demonstrates that our 
HUVEC model is more sensitive to apoptosis than BAEC. These authors 
suggested that the effect of IV iron sucrose on BAEC death was due to 
mitochondrial dysfunction induced by this compound, which was confirmed 
by the decreased expression of Bcl-2.  
Our data of apoptosis by Annexin V-FITC/PI are in line with the findings of 
Martin-Malo et al (2012), who used the same method and showed that 
treating PBMC from CKD patients at stage 5 on HD with 200 µg/ml IV iron 
sucrose or IV FCM for 8hr, resulted in a significant increase in apoptotic 
PBMC compared with non-treated cells (p<0.05). The authors suggested that 
PBMC apoptosis was significantly increased primarily due to the increased 
oxidative stress that is caused by HD, and subsequently worsened by the IV 
iron infusion. The role of HD in initial generation of oxidative stress, 
compounded with additional oxidative stress due to IV iron could explain why 
IV FCM had significantly induced the apoptosis of PBMC. While the use of 
healthy primary HUVEC and low concentration of 50 µg/ml of IV iron sucrose 
or IV FCM in our studies may explain the lack of effects of IV FCM on 
apoptosis and may be more relevant to clinical dose regimes. Interestingly, 
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this also shows that even a clinically relevant, relatively low concentration of 
IV iron sucrose is capable of inducing EC death. Similar findings have been 
described in another study, which was performed on blood samples from ten 
healthy individuals. Each blood sample was divided and IV iron sucrose was 
added to reach final concentrations of 20, 100 and 200 mg/L for 4 and 24hr, 
to investigate the effect of this compound on apoptosis of polymorph nuclear 
Leukocytes (PMN), using Annexin V-FITC/PI method. The authors found that 
apoptosis was significantly induced by IV iron sucrose at only 24hr, and 
suggested that this is most likely due to iron induced oxidative stress in these 
cells (Ichii et al., 2012). To investigate the mechanism of IV iron sucrose-
mediated apoptosis, HUVEC were pre-treated with SB203580, then IV iron 
sucrose and at 24hr, flow cytometry analysis using Annexin V-FITC/PI was 
performed. This data, showed partly but significantly reduced apoptosis of 
HUVEC compared with cell treated with IV iron sucrose alone at 24hr (Figure 
4.6B), confirming that activation of p38 MAPK is involved in HUVEC 
apoptosis induced by IV iron sucrose. 
 Bcl-2 proteins family, including Bcl-2 and Bax, are involved in the regulation 
of apoptosis (Soria et al., 2013). The balance of expression of these proteins 
plays a key role in apoptotic signal activation to the mitochondria and 
maintenance of cell morphology and function. Overexpression of Bcl-2 
blocks the release of cytochrome c from the mitochondria to the cytosol, 
preventing caspase-3 activation and the induction of intrinsic pathway of cell 
apoptosis (Suen et al., 2008). Therefore, to confirm our data that IV FCM did 
not induce apoptosis of HUVEC and to investigate the mechanism involved 
in the HUVEC injury by IV iron sucrose, Bcl-2 and Bax expression following 
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IV iron preparation treatment was measured. The effect of IV iron sucrose on 
mitochondria integrity was associated with down-regulation of Bcl-2 and up-
regulation of Bax protein expression, confirming the role of these two 
proteins in the apoptotic stress pathway. By Western blotting, IV FCM at 2, 6 
and 24hr, or IV iron sucrose at 2 and 6hr did not down-regulate the protein 
expression of the anti-apoptotic Bcl-2 compared to non-treated HUVEC 
(Figures 4.12B and 4.14B). In addition, Bax protein expression also did not 
change in these cells compared with non-treated HUVEC (Figures 4.13B and 
4.15B). In contrast, HUVEC treated with IV iron sucrose for 24hr showed 
significantly decreased Bcl-2 protein expression compared with non-treated 
cells (Figure 4.12B). In addition, expression of pro-apoptotic Bax was 
significantly increased in HUVEC treated with IV iron sucrose at 24hr 
compared with non-treated cells (Figure 4.13B). Since these two proteins are 
essential administrative components for caspase enactment and apoptosis, 
these changes in expression could lead to the altered mitochondrial 
permeability, resulting in the release of cytochrome c from the mitochondria 
to the cytosol, representing an irreversible step in cellular apoptosis. These 
results are in line with Carlini et al., (2006) who found that BAECs treated 
with 100 and 1000 µg/ml IV iron sucrose for 8-16hr, results in significant 
down-regulation of Bcl-2 protein expression compared with control (p<0.01). 
However, in their cells, even with higher concentrations of IV iron sucrose 
treatment, Bax protein expression did not change. The authors suggested 
that, the expression of Bax was not changed as both Bcl-2 and Bax might act 
independently. In contrast, our data showed that both proteins were affected 
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by IV iron sucrose, in a way which would promote apoptosis. However, for 
further discussion of these results see section 6.1.1.  
As our study showed p38 MAPK activation to be involved in apoptosis of 
HUVEC in response to iron sucrose, p38 MAPK inhibition was used to 
determine whether the IV iron sucrose induced changes in Bcl-2 and Bax 
could be blocked. Several studies showed that p38 MAPK have a role in 
early induction of the apoptosis by mediating the phosphorylation of Bcl-2 
and the translocation of Bax to the mitochondria (De Chiara et al., 2006; 
Kang et al., 2008; Park et al., 2013). Our study showed p38 MAPK was 
phosphorylated by 50 µg/ml IV iron sucrose or IV FCM at both 60 min and 
2hr compared with non-treated cells (Figures 4.7B and 4.8B). This is the first 
time as far as we are aware that phosphorylation of p38 MAPK has been 
shown in response to IV iron preparations clinically utilised in CKD. The data 
suggests more robust phosphorylation of p38 by IV iron sucrose compared to 
IV FCM, and thus was consistent, but the fact the sample were blotted on 
separate gels means that factors related to antibody incubation, washing 
time, blot exposure or development timing could contribute to differences. 
However, all blots data was produced using identical protocols. Kinase assay 
or downstream p38 MAPK substrate phosphorylation can be quantified to 
confirm these data. 
Gathering evidence proposes ROS may be targeted to modulate 
mitochondrial processes (Ashraf et al., 2014). ROS has been linked to the 
activation of MAPKs such as p38 MAPK pathway, which the latter has been 
shown to play an important role in the induction of apoptosis in some cell 
type (Zhang et al., 2011; Ashraf et al., 2014). Direct exposure of cells to ROS 
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including, exogenous H2O2 to mimic oxidative stress, have been shown in 
previously published work (Usatyuk et al., 2003; Sato et al., 2014) and in our 
lab to cause activation of p38 MAP kinase, see appendix 1. To confirm that 
damage to p38 MAPK phosphorylation contributes to damage to 
mitochondria integrity in IV iron sucrose-treated HUVEC by causing 
imbalance between the apoptotic proteins, Bcl-2 and Bax, inhibition of p38 
MAPK by SB203580 was investigated. Following SB203580 treatment, IV 
iron sucrose did not cause apoptosis as measured by Annexin V. In addition, 
less activation in Bcl-2 and Bax occurred, consistent with cell survival by pre-
treatment of HUVEC with SB203580.  
P38 MAPK is a serine-threonine kinase and was indicated as a potential Bcl-
2 kinase (Torcia et al., 2001). In addition, Bcl-2 phosphorylation is 
synchronous with p38 MAPK activation through direct interaction with Bcl-2 
protein in the mitochondrial compartment. Furthermore, phosphorylation of 
Bcl-2 can occur on serine and threonine residues (including Ser87 and Thr56) 
which are located in a non- structured loop between BH3 and BH4 domains 
(Nencioni et al., 2009), results in a decrease in the anti-apoptotic potential of 
Bcl-2 protein (De Chiara et al., 2006). All these can explain how p38 MAPK 
activation is linked to alteration of Bcl-2 expression and activity. Thus, p38 
MAPK activation seems to be essential for the activation of the intrinsic 
pathway apoptotic signal. Although the mechanism has not been previously 
investigated, our data shows activation of p38 MAPK is affecting the balance 
of expression of Bcl-2 and Bax, which are involved in IV iron induced 
apoptosis, and may potentially lead to release of cytochrome c and 
downstream activation of caspase-3, resulting in apoptosis (Nencioni et al., 
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2009). These results can be in line with a study by Grethe et al (2004) 
showed that inhibition of p38 MAPK by SB203580 attenuated the apoptosis 
in EA.hy926 cell line exposed to 10 μM TNF-α. Another study by Yu et al 
(2006) revealed that, 10 μM SB203580 significantly reduced the apoptosis of 
EC treated with H2O2. Additionally, SB203580 also upregulated Bcl-2 and 
down regulated Bax expression in HUVEC exposed to Lipopolysaccharide 
(Lim et al., 2009). Interestingly, IV FCM phosphorylated p38 MAP kinase but 
did not induce apoptosis of HUVEC either through direct measurement 
(TUNEL assay and Annexin V-FITC/PI staining) or indirectly (alteration of 
Bcl-2 or Bax protein expression). In contrast, IV iron sucrose showed 
significant induction of apoptosis, activation of p38 MAP kinase and down-
regulation of Bcl-2 and up-regulation of Bax protein expression. However, to 
be completely convinced about the role of p38 MAPK in HUVEC apoptosis in 
response to IV iron sucrose, molecular methods would be required to confirm 
these results (see future studies, section 6.1.2).  
Our data in chapter 3 clearly showed that IV iron sucrose or IV FCM 
significantly induced generation of ROS in HUVEC. It has been shown 
previously that p38 MAPK is upstream of ROS production through elevation 
of mitochondrial ROS level under hypoxia (Ashraf et al., 2014). To 
investigate whether ROS is playing a key role in p38 MAPK activation in IV 
iron preparation-treated HUVEC, antioxidant treatment (NAC) was carried 
out. The use of NAC significantly reduced p38 MAPK phosphorylation, which 
implicates that ROS must be at least partly responsible for activating this 
signalling pathway which ultimately plays a role in inducing IV iron sucrose 
mediated apoptosis. Our data are in line with the observation by Usatyuk et 
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al (2003) who found that, treating bovine lung microvascular ECs 
(BLMVECs) with 5 mM NAC and 100 µM H2O2 significantly reduced the 
activation of p38 MAPK, which was mediated by oxidative stress induction. In 
addition, another study by Wang and others (2010) found that, p38 MAPK 
phosphorylation in response to particulate matter (PM), was attenuated by 
treating human pulmonary artery EC with 5 mM NAC compared with non-
treated cells. This can be explained as IV FCM did not activate p38 MAPK to 
the same extent as IV iron sucrose. Further discussions on the upstream 
mechanisms of apoptosis are in chapter 6. All data in this chapter support 
the view that IV iron compounds may impair EC function resulting in 
disintegration of vascular structure, increased vascular permeability, 
proliferation of SMCs and macrophages, and platelet activation and 
aggregation and, thus can be a key element in the progression and increase 
death of CKD patients due to CVD. 
4.5. CONCLUSION 
In conclusion, our study is the first to demonstrate that both IV iron 
preparations (sucrose and FCM) induced p38 MAPK activation and this 
activation was partly due to ROS elevation. IV FCM HUVEC did not induce 
apoptosis, downstream of p38 MAPK, and had no effect on anti-
apoptotic/pro-apoptotic protein family members Bcl-2 and Bax. In contrast, IV 
iron sucrose showed up-regulation of pro-apoptotic Bax and down-regulation 
of anti-apoptotic Bcl-2 proteins to induce mitochondrial membrane 
permeabilization and EC apoptosis as measured by TUNEL assay and 
Annexin V-FITC/PI staining.  
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CHAPTER 5 
THE EFFECT OF IV IRON PREPARATIONS ON HUMAN ENDOTHELIAL 
CELL ACTIVATION AS DEFINED BY INCREASED ADHESION 
MOLECULE EXPRESSION 
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5.1. INTRODUCTION 
As already discussed in chapter 1 section 1.1.5, death among patients with 
CKD due to CVD and accelerated atherosclerosis is 10 to 30 times greater 
than in general populations (Levey and Eknoyan, 1999; Collado et al., 2010). 
Atherosclerosis is a complex and progressive inflammatory disease, affecting 
arterial blood vessels and frequently associated with renal disease (O’Hare 
et al., 2004) with plaques are found in approximately 30% of CKD patients 
(Amann et al., 2004). As part of its important role in leucocyte recruitment 
during inflammation, the endothelium expresses CAMs, including VCAM-1 
and ICAM-1, which promote the adhesion and migration of blood cells such 
as T-lymphocytes and monocytes to attach and migrate into the sub-
endothelial space in the intima (Libby et al., 2002). Under physiological 
conditions, ICAM-1 is constitutively expressed on healthy resting ECs 
surface, while VCAM-1 is expressed only on the surfaces of activated ECs 
and certain leukocytes (such as macrophages). Both adhesion molecules 
can be up-regulated by many cytokines, including TNF-α and IL-1 (Frank and 
Lisanti, 2008). EC damage or activation as some investigators refers to, as 
the key mechanism underlying chronic inflammatory conditions, including 
atherosclerosis, a vascular disease (Sorensen et al., 1994; Gokce et al., 
2002; Libby et al., 2002). The dysfunction of ECs is a well characterized 
phenotype that plays an important role not only in the initiation and the 
development of atherosclerosis, but is also involved in the late stages of 
CVD by the development of thrombosis that leads to vessel occlusion and 
acute cardiovascular events (Hansson, 2005). EC dysfunction is 
characterized by increased vascular permeability and up-regulation of 
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adhesion molecule expression including ICAM-1, VCAM-1 (Libby et al., 
2002). In vitro experiment with serum from CKD patients resulted in damage 
of HAEC in culture compared with control, through the inhibition of eNOS 
which is mediated by serum advanced glycation end product (AGE) from 
these patients. This is indirect evidence that EC are damaged in these 
patients (Schmidt et al., 1999). In addition, EC dysfunction has been 
observed in HD patients as well as in children with advanced renal 
insufficiency (Kari et al., 1997; Passauer et al., 2000), which provides an 
essential relation between CKD and the high risk for CV events that patients 
with CKD exhibit (Félétou and Vanhoutte, 2006; Perticone et al., 2010).  
The expression of both ICAM-1 and VCAM-1, on ECs is thought to be 
important in immune and inflammatory diseases, such as atherosclerosis 
(Price and Loscalzo, 1999). Emerging evidence showed that these 
molecules are present in the progression of atherosclerotic lesions, which 
suggests that they play a key role in the pathogenesis of atherosclerotic CVD 
(Papayianni et al., 2002; Rezzani et al., 2013), which is considered as the 
main cause of death in CKD patients. Levels of soluble adhesion molecules, 
especially sICAM-1 and sVCAM-1 have been consistently shown to be 
increased in CKD patients (Bonomini et al., 1998; Stancanelli et al., 2010). A 
number of in vivo studies found that CKD is associated with oxidative stress 
elevation (Pecoits-Filho et al., 2003; Oberg et al., 2004). In addition, several 
studies have reported that elevated levels of serum soluble adhesion 
molecules were associated with carotid intima media thickness, which is 
considered as a surrogate marker of early-phase coronary atherosclerosis in 
patients with CKD (Stenvinkel et al., 2002; Papayianni et al., 2002). Previous 
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study found that increased carotid intima media thickness was significantly 
associated with annual IV iron doses in patients with ESRD, who 
administered with different doses 50-100 mg of IV iron sucrose weekly for a 
period of one year (Drüeke et al., 2002). The authors also showed that 
increased carotid intima media thickness was significantly associated with 
increased oxidative stress marker, AOPP-induced by IV iron sucrose, 
suggesting that this IV iron preparation play a role in oxidative stress, and 
consequently can cause an increase in the incidence of atherosclerosis 
(Drüeke et al., 2002; Reis et al., 2005). There are different markers can be 
used in vivo to assess EC dysfunction or injury such as, increased plasma 
levels of EC-generated molecules like von Willebrand factor (vWF), elevated 
numbers of circulating EC and endothelial progenitor cells as well as 
vascular activity to an appropriate stimulus (Brevetti et al., 2008). An 
alternative method to assess endothelial activation and dysfunction in vitro 
involves the measurement of adhesion molecules ICAM-1 and VCAM-1 
(Papayianni et al., 2002). One of the main and most common causes of 
anaemia is iron deficiency, which is common in CKD patients (Dillon et al., 
2012). It has been found that, patients who suffer from iron deficiency have 
higher levels of soluble adhesion molecule expression, which by itself can be 
a risk factor of atherosclerosis progression (Yuksel et al., 2010). Yuksel and 
others suggested that the increased adhesion molecule expression in these 
patients can be due to increased risk of atherosclerosis as a result of 
elevated lipid peroxidation. Moreover, IV iron administration can provoke 
ROS production in vivo (Drüeke et al., 2002), results we have been able to 
replicate in our model in chapter 3. ROS under normal conditions, serve as 
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important physiological intracellular messengers (Hensley et al., 2000). 
However, overproduction of ROS such as H2O2 and superoxide anion have 
been found to induce endothelial activation and dysfunction, through the 
activation of redox-sensitive transcription factors, including NF-κB which is a 
key regulator of cytokines, chemokines, and cellular adhesion molecules 
(DiDonato et al., 1997; Lum and Roebuck 2001; Chen et al., 2004). 
Furthermore, IV iron sucrose, showed adverse CV outcomes, leading to 
increased mortality in CKD patients and this was associated with increased 
expression of adhesion molecules ICAM-1 and VCAM-1 in vitro through 
activation of NF-κB (Kuo et al., 2014). In addition, in vitro studies showed 
that, a number of IV iron preparations including, IV iron sucrose, iron dextran, 
ferric gluconate, IV FCM and ferric chloride hexahydrate induced the 
expression of ICAM-1 and VCAM-1 in different cell types, HAEC and  PBMC 
(Kuo et al., 2012; Martin-Malo et al., 2012; Kuo et al., 2014). However, none 
of these studies looked at the effect of IV FCM on adhesion molecule 
expression in ECs. Hence, in this chapter, we hypothesized that IV iron 
preparations might promote EC damage through endothelial adhesion 
molecule expression and consequently accelerate atherosclerotic lesion 
progression in patients with CKD.  
Therefore, the aim was to investigate the effect of clinically relevant 
concentrations of IV iron sucrose or IV FCM used in previous chapters on the 
activation of primary HUVEC by the assessment of EC, ICAM-1 and VCAM-1 
gene and protein expression using real time PCR (RT-PCR), quantitative 
PCR (qRT-PCR) and Western blot methods. Previous work has shown 
beneficial effects of antioxidants in CKD (Agarwal et al., 2004; Swarnalatha 
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et al., 2010). Therefore, in addition we aimed to investigate whether 
treatment with NAC reduces the expression of adhesion molecules in IV iron 
preparations treated HUVEC. 
5.2. MATERIALS AND METHODS  
5.2.1. Materials 
Agarose (15510-027) was purchased from Invitrogen (Paisley, UK). 
Nuclease-free water (129115) was purchased from Qaigen (Crawley, West 
Sussex, UK). For total RNA isolation: GenElute™ Mammalian Total RNA 
Miniprep Kit (RTN10-1KT), DNAse I Amplification Grade (AMPD1-1KT), 
ethidium bromide (E7637) and recombinant human tumour necrosis factor-
alpha (TNF-α, T-0157) were purchased from Sigma-Aldrich (Pool Dorest, 
UK). For complementary deoxyribonucleic acid (cDNA) synthesis: ImProm-
II™ Reverse Transcription System (A3800) and Tris-acetate-EDTA buffer 
(TAE) buffer (V4271) were purchased from Promega (Soughtampton, UK). 
DreamTaq Green PCR Master Mix (2X) (K1081) was purchased from 
Thermo Scientific (Loughborough, UK). For mRNA isolation: GenElute 
mRNA Miniprep kit (MRN10-1KT) was purchased from Sigma-Aldrich (Pool 
Dorest, UK). 
For RT-PCR reaction, PCR reagents were purchased from Promega 
(Southampton Science, UK) and used according to the manufacturer’s 
protocol. PCR primers were purchased from Sigma-Aldrich (Pool Dorest, 
UK). For qRT-PCR, Fast SYBR® Green Master Mix (4385612), MicroAmp® 
Optical 8-Cap Strips (4323032) and MicroAmp® Fast Optical 96-Well 
Reaction Plate (4346906) were all purchased from Life Technologies 
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(Paisley, UK). Real-Time PCR primers include Hs-ICAM1-1 (QT00074900), 
Hs-VCAM1-1 (QT00018347) and Hs-ACTB (QT00095431), all were 
purchased from Qiagen (Manchester, UK). Amplification of individual genes 
was performed on StepOnePlus™ Real-Time PCR Systems. 
For Western blot, rabbit polyclonal CD54/ICAM-1 antibody (4915) and rabbit 
polyclonal VCAM-1 antibody (12367) were purchased from New England 
Biolabs, UK. Anti-GAPDH antibody (ab9485) was obtained from Abcam, 
Cambridge, UK. 
5.2.2. Methods 
5.2.2.1. Assessment of ICAM-1 and VCAM-1 mRNA gene expression in 
IV iron preparation-treated HUVEC 
5.2.2.2. Total RNA extraction from cultured HUVEC 
Total RNA was isolated from differently treated and non-treated HUVECs 
using GenElute mammalian total RNA Miniprep kit (Sigma-Aldrich, UK). Cells 
were grown in 6 well plates at a density of 2x105 cells per well. Upon 
confluence, HUVEC were treated as described before with 50 µg/ml of IV 
iron sucrose or IV FCM or left untreated, which were considered as control. 
Subsequently, cells were washed twice with RNase-free PBS and then cells 
were detached from plates by Trypsin/EDTA (0.05%0.02%). Afterwards, cells 
were collected by scraping into 1 ml RNA lysis buffer. Cells were 
homogenized by passing the lysate at least 5 times through a blunt 20-gauge 
needle (0.9 mm diameter) (NV-2025R, Terumo, Leuven, Belgium) fitted to an 
RNase-free syringe (BD Plastipak). The homogenate was then transferred to 
a GenElute filtration column and centrifuged (Eppendorf 5415 R) at 13000x g 
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for 2 min to remove all cellular debris and to shear the DNA. After 
centrifugation, the filtration column was discarded, and an equal volume of 
70% ethanol (made using 0.05% (v/v) DEPC treated water) was added to the 
filtered lysate and mixed thoroughly by vortexing. Afterwards, the 
combination of lysate/ethanol mixture was then transferred to a clear 
GenElute binding column and centrifuged for 15 seconds at 13000x g to bind 
RNA to the column. The flow through was then discarded, and the binding 
column with the bound total RNA moved back to the collection tube. The 
remaining sample was added to the binding column, and the same 
procedure repeated. The binding column was then transferred to a new 
collection tube. The binding column was washed to remove contaminants; 
500 μl of wash solution 1 was added to the binding column and centrifuged 
for 15 seconds at 13000x g. The column was transferred to a new collection 
tube and a second wash carried out by adding 750 μl wash solution 2 to the 
binding column and centrifuging for 2 min at 13000x g, the flow-through was 
discarded. The column was transferred to a new collection tube to elute the 
RNA from the binding column; 50 μl elution solution was added to the centre 
of the binding column and centrifuged for 1 min at 13000x g. The flow 
through containing the purified total RNA was collected, and checked 
immediately for quality, purity and concentration before RNA extraction for 
each sample, or stored at -80°C until required. 
5.2.2.3. Isolation of mRNA from primary HUVEC  
mRNA was isolated from the total RNA samples using a GenElute mRNA 
Miniprep kit (Sigma-Aldrich, UK) in accordance with the manufacturer’s 
instructions provided. The volume of each total RNA sample was brought up 
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to 250 μl using RNase-free water, then mixed with 250 μl 2X Binding solution 
and 15 μl oligo (dT) beads, and vortexed thoroughly. The samples were 
incubated at 700C for 3 min to denature RNA and were then left at room 
temperature for 10 min. Samples were then centrifuged for 2 min at 13000x g 
to pellet the beads. The supernatants were discarded and the pellets re-
suspended in 500 μl wash solution 1 by vortexing. Each sample suspension 
was then transferred to a spin filter/collection tube and centrifuged for 2 min 
at 13000x g, before the flow through was discarded and the column 
containing the beads: mRNA complex was washed again with a second 500 
μl wash solution 2 followed by centrifugation for 2 min at 13000x g. The 
column was transferred into a fresh collection tube and 50 μl elution solution 
(preheated to 700C) was added to the centre of the filter and incubated for 5 
min at 700C, before centrifuging for 1 min at 13000x g. This elution procedure 
was repeated with an additional 50 μl elution solution. The isolated mRNA 
was then stored at -800C until further use or kept on ice for immediate cDNA 
synthesis. 
5.2.2.4. Measurement of quality and quantity of isolated total RNA by 
spectrophotometer 
The quality and quantity of RNA in each sample was spectrophotometrically 
checked. The spectrophotometer was first calibrated to zero using nuclease-
free water in a quartz cuvette. Then, RNA was diluted in RNase-free water 
(1:20) and then the UV absorbance was detected using a Jenway 6305 
UV/VIS spectrophotometer (Keison product, Essex, UK) at two different 
wavelengths: 280 nm for DNA and 260 nm for RNA.. RNA purity was 
evaluated by calculating the ratio (absorbance at 260 nm/absorbance at 280 
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nm) and RNA quality was considered good if the ratio was between (1.8- 
2.2). RNA concentration was determined by using the equation where Ab 
260 is the absorbance at 260 nm and DF is the dilution factor: 
                        RNA concentration (µg/ml) = Ab 260 x DF x 40 
5.2.2.5. Agarose gel electrophoresis  
A 1.5-2.0% (w/v) gel was formed by melting agarose in 1 x TAE using a 
950W microwave (Proline Micro chef ST44) on power 7 for 180 seconds till 
the agarose was completely dissolved. Subsequently, the solution was left at 
room temperature to cool down to approximately 50-600C and then ethidium 
bromide was added to the solution and mixed (final concentration of 0.6 µM). 
The solution was poured into plastic gel trays containing gel combs to form 
wells, and left for approximately 45 min to set. Subsequently, gel combs 
were removed gently and gel was placed in an electrophoresis tank 
containing enough 1 x TAE buffer to cover the gel. 8 µl of RNA for each 
sample was mixed with 2.5 µl loading dye and carefully loaded into the gel. 
The tank set to run at 100V for approximately 30 min. Subsequently, the 
UVitec gel documentation system (UVItec Limited, Cambridge, UK) was 
used to visualise total RNA and the images were captured using software 
UVitec version 12.06 for windows. 
5.2.2.6. Deoxyribonuclease I (DNase I) treatment 
Amplification grade DNase I (Sigma-Aldrich, UK), was used to eliminate any 
contaminating genomic DNA from the isolated RNA prior to cDNA synthesis 
by reverse transcription. A 0.5 ml Eppendorf tube (Alpha Laboratories, UK) 
was used to make each reaction mix. This consisted of 8 μl of RNA, 1 μl 
187 
 
manufacturer supplied reaction buffer and 1 μl DNase I amplification grade 
which were incubated for 15 min at room temperature. Subsequently, DNase 
I was inactivated by adding 1 μl EDTA (25mM; Invitrogen Ltd), and then the 
reaction was heated to 650C for 10 min. The resulting DNA-free RNA 
samples were either placed on ice to be used immediately for cDNA 
synthesis or stored at -800C until further use. 
5.2.2.7. Complementary DNA synthesis 
The purified RNA was reverse transcribed to cDNA, which is ideal for PCR 
experiments. ImProm-II™ Reverse Transcription System was used. The 
protocol recommended by the manufacturer was followed. All reagents and 
RNA samples were thawed on ice and then any unused portion returned to -
800C as soon as aliquots were taken. Briefly, 2 µl RNA (1 µg/ml) was mixed 
with 1 µl Oligo (dT) primer (0.05 µg/µl), denatured by incubating at 700C for 
10 min and thereafter placed on ice for 5 min. The reaction mix for first 
strand synthesis, including 2 µl of 10X ImProm-II™ reaction buffer, 4 µl 
MgCl2 (25 mM), 2 µl dNTPs Mix (10 mM), 0.5 µl recombinant RNase in 
Ribonuclease Inhibitor (40 units/μl), 0.5 µl of avian myeloblastosis virus 
(AMV) reverse transcripts (high concentration: 25 units/µl). The first strand 
synthesis reaction was incubated at 420C for 60 min to allow cDNA synthesis 
from mRNA by reverse transcription and then at 900C for 5 min to inactivate 
the reverse transcriptase, then volume was made up to 80 µl by Nuclease-
free water. Produced cDNA was aliquoted and maintained at -200C for long 
term storage. Then, β-actin gene was amplified by RT-PCR to ensure 
synthesis of the first-strand of cDNA, had been successfully and validation of 
PCR condition.  
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5.2.2.8. Primer design 
A web-based genome database (www.ncbi.nlm.nih.gov) was used to analyse 
the genomic sequences and protein of the target genes of interest (β-actin, 
ICAM-1 and VCAM-1) to facilitate the design primers for PCR. For each 
gene, pair of primers (forward and reverse) were checked for the purity and 
specificity to the target gene intended via common used software, 
primer3plus (www.bioinformatics.nl). Primers were then ordered from Sigma-
Aldrich (Pool Dorset, UK), and were re-suspended to a final concentration of 
(100 ng/µl) in nuclease free water. 
Table 5.1: The sequences and product size of ICAM-1, VCAM-1 and β-actin 
primers. The primer sequences, their optimised RT-PCR conditions and their 
expected amplicon size are showed below, where F is the forward primer 
and R is the reverse primer.  
 
Gene of interest 
 
Sequence of  primers 
 
Expected product 
size (bps) 
 
β-actin 
 
F:      5'AAATCTGGCACCACACCTTC3' 
R:      5'CTCCTTAATGTCACGCACGA3' 
 
 
392 
 
 
ICAM-1 
 
F:      5'GCAAGAACCTTACCCTACGC3' 
R:      5'TGATCTCTCCTCACCAGCAC3' 
 
154 
 
VCAM-1 
 
F:      5'TTTCTGGAGGATGCAGACAG3' 
R:      5'TACAGCCTGCCTTACTGTGG3' 
 
106 
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5.2.2.9. RT-PCR for detection of ICAM-1 and VCAM-1 mRNA expression 
in HUVEC 
All reagents were thawed on ice and then, RT-PCR was performed using 1 µl 
to 5 µl cDNA, 17 µl of nuclease free water, 2.5 µl of 10 X ImProm-II™ 
reaction buffers, 1.5 µl MgCl2 (25 mM). In order to get the best amplification 
during PCR, each target primer set required optimization of primer 
concentrations and annealing temperatures. The PCR thermocycling 
program was: initial denaturation at 940C for 30 seconds, followed by 30 
cycles of: PCR amplification at 940C, optimum annealing temperature at 58-
630C for 20 seconds, extension at 720C for 1 min, followed by a final 10 min 
extension step at 720C. After the thermocycling finished the tubes were 
cooled at 40C. The PCR products were placed on ice to be analysed 
immediately by agarose gel electrophoresis or could be stored at -200C for 
later analysis. 
5.2.2.10. Quantitative real time PCR (qRT-PCR) for detection of ICAM-1 
and VCAM-1 mRNA expression in HUVEC 
QRT-PCR was carried out to quantify mRNA expression of ICAM-1 and 
VCAM-1 in control or IV iron-treated HUVEC. PCR reaction was placed in 
MicroAmp® Fast Optical 96-Well Reaction Plate (Applied Biosystem, UK) and 
performed using StepOnePlus™ Real-Time PCR Systems (Applied 
Biosystem, UK). All reagents were thawed on ice and then, any unused 
portion returned to the freezer at -200C as soon as aliquots were taken. PCR 
reaction mix was prepared in 0.5 ml Eppendorf tubes (Alpha Laboratories) on 
ice by mixing all of the following reagents: 5 µl Fast SYBR® Green Master 
Mix, 2 µl (10 µM) oligo primers, 2 µl cDNA and then the volume was made up 
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to 15 µl by adding 6 µl RNase-free water. Samples were prepared in 
duplicate and the plate was centrifuged briefly to ensure a good mix of 
reagents. The thermocycler parameters were 500C for 2 min and 950C for 20 
seconds, followed by 50 cycles of 950C for 15 seconds and 600C for 30 
seconds. The data obtained from each reaction was analysed by StepOne™ 
Software v2.2.2. Relative quantification representing the change in gene 
expression from real-time quantitative polymerase chain reaction between 
experimental groups was calculated by comparative CT method. The data 
was analysed by calculating the relative quantification (RQ) using the 
equation: RQ = 2-∆CT X100, where ∆CT = CT of target gene− CT of 
endogenous gene (housekeeping gene). Evaluation of 2-∆CT indicate the fold 
change in gene expression, normalized to the internal control (β-actin) which 
enable the comparison between differently treated cells. All results then were 
logged to the base 10 (Log10x) and a ratio paired t-test was applied to detect 
the significant level of the difference between differently treated cells. 
5.2.2.11. Detection of ICAM-1 and VCAM-1 protein expression in HUVEC 
by Western blot 
The protocol was followed as described in previous section (4.2.1.6). Briefly, 
for ICAM-1 protein analysis, following SDS PAGE separation and Western 
blotting , the PVDF membrane was blocked with blocking buffer as described 
in section (4.2.1.6), and incubated with rabbit polyclonal CD54/ICAM-1 
antibody (1:2000, New England Biolabs, UK). For VCAM-1 protein analysis, 
the membrane was incubated with rabbit polyclonal VCAM-1 antibody 
(1:2000, New England Biolabs, UK). Membranes were then incubated with 
horseradish peroxidise HRP- conjugated donkey anti rabbit IgG (1:5000). 
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GAPDH (1:5000, Abcam, UK) was used as internal control. The diluent used 
to dilute all antibodies was TBS-T including 2% (w/v) BSA. All Western 
blotting experiments were performed on at least 3 independent samples from 
different donors and densitometric analysis of ECL exposure was performed 
using Image J software. The results were expressed in relative densitometry 
compared with GAPDH. 
5.3. RESULTS 
5.3.1. The effect of IV iron preparations on ICAM-1 and VCAM-1 mRNA 
expression in HUVEC 
5.3.1.1. Efficiency of isolated RNA 
Total RNA was isolated from HUVECs as described in section 5.2.2.2. and 
the efficiency of the purification method was assessed by running the 
isolated RNA on 1.5% agarose gel. The image in Figure 5.1 shows RNA 
isolated from seven different samples including non-treated cells, IV iron 
sucrose or IV FCM-treated cells at 2, 6 and 24 hr. Two main bands for each 
sample could be identified representing the two ribosomal RNA (rRNA) 
components 18S and 28S. 28S rRNA band was approximately twice as 
intense as the 18S rRNA band. This indicates that isolated RNA was of good 
quality as intact RNA has these two bands with a 2:1 ratio (28S:18S). 
Degraded RNA will not exhibit 2:1 ratio and will appear as a very low 
molecular weight smear (Skrypina et al., 2003).  
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Figure 5.1: Representative image showing the quality of isolated RNA. Total 
RNA was separated on 1.5-2.0% (w/v) agarose gel in 1 x TAE and allowed to 
run at 100V for approximately 45 min. Two bands represented two rRNA 
compounds 18S and 28S, were obvious in the total RNA samples, exhibiting 
a 2:1 ratio which confirmed good quality of RNA. Lane 1: Non-treated cells 
(control), lanes 2, 4 and 6: HUVEC treated with 50 μg/ml IV iron sucrose at 
2, 6 and 24hr respectively, lanes 3, 5 and 7: HUVEC treated with 50 μg/ml 
IV FCM at 2, 6 and 24hr respectively. The image represents results of 3 
different donors (n=3). 
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5.3.1.2. RT-PCR for ICAM-1 and VCAM-1 mRNA gene expression in 
HUVEC  
ICAM-1 and VCAM-1 mRNA expression was assessed using RT-PCR in 
non-treated and differently treated HUVEC from three different patients, and 
TNF-α treated cells (where ICAM and VCAM gene expression up-regulation 
is well established in our lab and others) were used as positive control. β-
actin primer was used as housekeeping gene for variations in PCR product 
levels due to any differences in RNA isolation efficiency and PCR reaction 
efficiency. In addition, variations in the numbers of cells between differently 
treated wells due to the effect of IV iron preparations sucrose or IV FCM on 
cell proliferation were adjusted by normalizing the results of each sample 
against its own level of β-actin mRNA as β-actin is expressed constitutively 
and not affected by IV iron preparations. Having loaded equal amounts of 
RNA in the PCR reaction, it can be concluded that β-actin mRNA is 
expressed constitutively and is not affected by IV iron preparations treatment 
(Figures 5.2B and 5.3B). All cDNA samples from differently treated cells 
produced PCR products which corresponded to the expected amplicon size 
(154bp: ICAM-1, 106bp: VCAM-1 and 392bp: β-actin), and Figure 5.2 shows 
bands of ICAM-1 and β-actin and Figure 5.3 shows bands of VCAM-1 and β-
actin mRNA respectively from three different donors. The RT-PCR analysis 
showed that ICAM-1 mRNA gene expression was detected in non-treated 
HUVEC, which confirm that ICAM-1 is constitutively expressed on the 
healthy and resting HUVEC surface (Frank and Lisanti, 2008). On the other 
hand, ICAM-1 mRNA gene expression was increased in cells treated by 50 
μg/ml IV iron sucrose or IV FCM in a time-dependent manner (2, 6 and 24hr) 
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(Figure 5.2A). In contrast, Figure 5.3A showed that VCAM-1 mRNA gene 
expression was not detected in non-treated HUVEC. However, in cells 
treated with 50 μg/ml IV iron sucrose or IV FCM, VCAM-1 mRNA was 
detected and elevated in a time dependent manner (2, 6 and 24hr) 
dependent on type of IV iron preparation used. This indicates that VCAM-1 is 
not expressed on resting healthy HUVEC surface, but expressed only on 
activated HUVEC. Figures 5.2A and 5.3A showed significant detection of 
ICAM-1 and VCAM-1 mRNA expression respectively after stimulation with 
the proinflammatory mediator TNF-α (120U/ml; 6hr) as a positive control. RT-
PCR technique only showed the qualitative of ICAM-1 or VCAM-1 mRNA 
gene expression in HUVEC. Therefore, qRT-PCR technique was applied to 
measure and to quantify the differences in ICAM-1 or VCAM-1 mRNA gene 
expression in non-treated and IV iron sucrose or IV FCM-treated cells. 
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Figure 5.2: The effects of IV iron preparations on ICAM-1 mRNA expression 
by RT-PCR. 20 µl of the resultant PCR product from each sample were 
loaded on 1.5% (w/v) agarose gel electrophoresis in 1 x TAE and set to run 
at 100V for approximately 45 min. TAE- agarose gel photographs showing 
ethidium bromide stained RT-PCR products of ICAM-1 and β-actin mRNA in 
HUVEC. (A): ICAM-1 mRNA gene expression in HUVEC was investigated by 
RT-PCR using specific ICAM-1 primer. (B): β-actin mRNA gene expression 
in HUVEC was investigated by RT-PCR using specific β-actin primer. The 
expected amplicon size is 154bp (A) and 392bp (B) for ICAM-1 and β-actin 
respectively. Lane 1: 10 μl molecular weight markers (DNA ladder 100-
1500bp), lane 2: Non-treated cells (control), lanes 3, 5 and 7: HUVEC 
treated with IV iron sucrose at 2, 6 and 24hr respectively, lanes 4, 6 and 8: 
HUVEC treated with IV FCM at 2, 6 and 24hr respectively, lane 9: TNF-α 
(120U/ml; 6hr) (positive control). 
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Figure 5.3: The effects of IV iron preparations on VCAM-1 mRNA 
expression by RT-PCR. 20 µl of the resultant PCR product from each sample 
were loaded on 1.5% (w/v) agarose gel electrophoresis in 1 x TAE and set to 
run at 100V for approximately 45 min. TAE- agarose gel photographs 
showing ethidium bromide stained RT-PCR products of VCAM-1 and β-actin 
mRNA in HUVEC. (A): VCAM-1 mRNA gene expression in HUVEC was 
investigated by RT-PCR using specific VCAM-1 primer. (B): β-actin mRNA 
gene expression in HUVEC was investigated by RT-PCR using specific β-
actin primer. The expected amplicon size is 106bp (A) and 392bp (B) for 
VCAM-1 andβ-actin respectively.. Lane 1: 10μl molecular weight markers 
(DNA ladder 100-1500bp), lane 2: Non-treated cells (control), lanes 3, 5 and 
7: HUVEC treated with IV iron sucrose at 2, 6 and 24hr respectively, lanes 4, 
6 and 8: HUVEC treated with IV FCM at 2, 6 and 24hr respectively, lane 9: 
TNF-α (120U/ml; 6hr) (positive control). 
197 
 
5.3.1.3. Detection of ICAM-1 and VCAM-1 mRNA gene expression in 
HUVEC by qRT-PCR  
In order to quantify the levels of mRNA expression of ICAM-1 and VCAM-1 in 
IV iron sucrose or IV FCM-treated HUVEC, qRT-PCR was carried out. All 
results were adjusted to the internal housekeeping gene β-actin. Figure 5.4 
shows the numbers of PCR amplifying cycles required for each gene to 
reach a fixed threshold (CT value). In addition, Figure 5.5 represents graph of 
melt curve versus temperature in qRT-PCR for ICAM-1, VCAM-1 and β-actin 
mRNA gene expression, which used as an indicator that only one product is 
amplified and to show that there are no nonspecific amplification products, 
such as primer dimers. The results showed that IV iron sucrose or IV FCM 
induced significant increases in the level of ICAM-1 and VCAM-1 mRNA 
gene expression in HUVEC. IV iron sucrose or IV FCM induced a slight 
increase in the level of ICAM-1 mRNA at 2hr. This increase was not 
significant compared with non-treated cells even when a ratio paired t-test 
was applied (Figure 5.6). In contrast, HUVECs treated with IV iron sucrose or 
IV FCM for 6 and 24hr increased the expression of ICAM-1 mRNA gene 
expression compared with non-treated cells. This increase was statistically 
significant for IV iron sucrose-treated cells at 6 and 24hr (p<0.01 and 
p<0.001 respectively), and p<0.01 for IV FCM-treated cells at both 6 and 
24hr (Figure 5.6). Furthermore, there was a significant increase in ICAM-1 
mRNA gene expression in cells treated with IV iron sucrose compared with 
IV FCM-treated cells at 24hr p<0.05 (Figure 5.6). In addition, qRT-PCR 
showed that, level of VCAM-1 mRNA gene expression for IV iron sucrose or 
IV FCM-treated cells at 2hr was also slightly increased. However, this 
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increase was not statistically significant compared with non-treated cells 
(Figure 5.7). On the other hand, HUVEC treated with IV iron sucrose or IV 
FCM at 6 and 24hr showed clear increases in VCAM-1 mRNA expression 
compared with non-treated cells. Ratio paired t-test was applied and 
indicated that the increase in VCAM-1 mRNA was significant for both 
compounds at 6 and 24hr compared with non-treated cells (p<0.01) and 
(p<0.001) respectively (Figure 5.7).  
 
 
Figure 5.4: Graph shows the amplification curves and the number of qRT-
PCR amplification cycles required for each gene to reach fixed threshold 
fluorescence. The genes which were amplified are: β-actin (blue), ICAM-1 
(red) and VCAM-1 (orange). 
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Figure 5.5: Representative graph of melt curve versus temperature in qRT-
PCR. The genes which were amplified are: β-actin (blue), ICAM-1 (red) and 
VCAM-1 (orange). 
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Figure 5.6: The effect of IV iron sucrose or IV FCM on the ICAM-1 mRNA 
expression in HUVECs by qRT-PCR. ICAM-1 mRNA was amplified in 
differently treated cells using qRT-PCR. HUVECs were grown in complete 
endothelial growth medium either non-treated or treated with 50 µg/ml IV iron 
sucrose or IV FCM for the times indicated. Non-treated values were defined 
as 100% and other values were adjusted accordingly. Data are expressed as 
mean (+/-SEM) from 3 different donors (n=3). **p<0.01 and ***p<0.001 
compared with non-treated cells. *p<0.05 for IV iron sucrose at 24hr versus 
IV FCM- treated cells at 24hr. 
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Figure 5.7: The effect of IV iron sucrose or IV FCM on the VCAM-1 mRNA 
expression in HUVECs by qRT-PCR. VCAM-1 mRNA was amplified in 
differently treated cells using qRT-PCR. HUVECs were grown in complete 
endothelial growth medium either non-treated or treated with 50 µg/ml IV iron 
sucrose or IV FCM for the times indicated. Non-treated values were defined 
as 100% and other values were adjusted accordingly. Data are expressed as 
mean (+/-SEM) from 3 different donors (n=3). **p<0.01 and ***p<0.001 
compared with non-treated cells.  
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5.3.1.4. Detection of ICAM-1 and VCAM-1 protein expression using 
Western blot  
5.3.1.4.1. The effects of IV iron preparations on ICAM-1 and VCAM-1 
protein expression  
In order to determine whether treatment of HUVEC by IV iron sucrose or IV 
FCM resulted in increased endothelial ICAM-1 and VCAM-1 protein 
expression, Western blotting was conducted. 
Figure 5.8 A shows a protein band of 90 kDa representing ICAM-1 after 
HUVEC treatment with IV iron sucrose and IV FCM at concentration of 50 
µg/ml across a 24 hour time course (2, 6 and 24hr). HUVEC grown in 
complete endothelial growth media which was considered as a negative 
control showed a less intense band compared with the IV iron treated cells 
confirming that HUVEC express ICAM-1 under basal conditions (Figure 
5.8A). HUVECs grown in media containing 50 µg/ml IV iron sucrose or IV 
FCM at 2hr showed some increase in ICAM-1 protein expression compared 
to control (Figure 5.8B). However, this increase was not statistically 
significant. In contrast, IV iron sucrose or IV FCM at 50 µg/ml for 6hr and 
24hr showed a significant increase in ICAM-1 expression compared with 
non-treated HUVEC, IV iron sucrose or IV FCM at 6hr compared with non-
treated (p<0.05), IV FCM at 24hr compared with non-treated cells (p<0.01) 
and IV iron sucrose at 24hr compared with non-treated cells p<0.001 (Figure 
5.8B). Furthermore, there was a significant increase in ICAM-1 protein 
expression in cells treated with IV iron sucrose compared with IV FCM-
treated cells at 24hr p<0.05 (Figure 5.8) 
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Figure 5.9A shows a representative blot with a protein band of 95 kDa 
corresponding to VCAM-1. VCAM-1 was not detected in non-treated HUVEC 
as shown in (Figure 5.9A). In contrast, the protein expression of VCAM-1 
was detected in HUVEC treated with iron sucrose at 2hr or IV FCM at 2hr 
and 6hr (Figure 5.9A), however this increase was not significant compared 
with non-treated cells (Figure 5.9B). On the other hand, cells treated with iron 
sucrose at 6hr or IV FCM at 24hr showed clearly a significant increase 
versus non-treated cells (p<0.05 and p<0.01) respectively (Figure 5.9B). In 
addition, HUVEC treated with iron sucrose at 24hr showed significant 
increase in VCAM-1 protein expression compared with non-treated cells 
(p<0.001) (Figure 5.9B). In addition, there was a significant increase in 
VCAM-1 protein expression in cells treated with IV iron sucrose at 6 and 24hr 
compared with IV FCM-treated cells at 6 and 24hr p<0.05 respectively 
(Figure 5.9). 
Pre-treatment of HUVEC with 2 mM NAC was used to study the effects of a 
ROS scavenger/anti-oxidant on IV iron sucrose or IV FCM-induced ICAM-1 
and VCAM-1 protein expression, to determine if this response was oxidative 
stress dependent. HUVECs were treated with either IV iron sucrose or IV 
FCM alone or in the presence of an experimentally relevant concentration of 
NAC (2mM). Figures 5.10 A and B showed that 2 mM NAC alone had no 
effect on ICAM1-1 protein expression. However, cells treated with IV iron 
sucrose or IV FCM and NAC together at 24hr showed significant reduction in 
the expression of ICAM-1 protein compared with cells treated with IV iron 
sucrose or IV FCM alone at 24hr (p<0.01) (Figure 5.10 A and B). Figure 5.10 
A and B showed a significant reduction in ICAM-1 protein expression in cells 
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co-treated with 2 mM NAC and 50 µg/ml IV iron sucrose at 24hr compared 
with IV iron sucrose-treated HUVEC alone p<0.05. Similar to ICAM-1, 2 mM 
NAC alone had no effect on VCAM1-1 protein expression on cells treated 
only with NAC (Figure 5.11 A and B). In contrast, VCAM-1 protein expression 
in HUVEC cells treated with IV iron sucrose or IV FCM and NAC together at 
24hr was significantly decreased compared with IV iron sucrose or IV FCM-
HUVEC treated cells at 24hr p<0.01 (Figure 5.11 A and B). In addition, 
VCAM-1 protein expression was significantly reduced in HUVEC co-treated 
with 2 mM NAC and 50 µg/ml IV iron sucrose at 24hr compared with IV iron 
sucrose-treated HUVEC alone p<0.05 (Figure 5.11 A and B).  
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Figure 5.8: The effect of IV iron preparations on ICAM-1 expression in 
HUVECs by Western blot. HUVECs were incubated with or without 50 µg/ml 
IV iron sucrose or IV FCM for 2, 6 and 24hr. TNF-α (120U/ml, 6hr) was used 
as a positive control. (A): shows a representative blot indicating a protein 
band of 90 kDa representing ICAM-1. (B): data (mean ± SEM) are shown as 
a bar graph of densitometry data from 3 different donors (n=3). *p<0.05, 
**p<0.01 and ***p<0.01 compared with non-treated HUVECs. *p<0.05 for IV 
iron sucrose at 24hr versus IV FCM- treated cells at 24hr. 
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Figure 5.9: The effect of IV iron preparations on VCAM-1 expression in 
HUVECs by Western blot. HUVECs were incubated with or without 50 µg/ml 
IV iron sucrose or IV FCM for 2, 6 and 24hr. TNF-α (120U/ml, 6hr) was used 
as a positive control. (A): shows a representative blot indicating a protein 
band of 95 kDa representing VCAM-1. (B): data (mean ± SEM) are shown as 
a bar graph of densitometry data from 3 different donors (n=3). *p<0.05, 
**p<0.01 and ***p<0.01 compared with non-treated HUVECs. *p<0.05 for IV 
iron sucrose at 24hr versus IV FCM- treated cells at 24hr. 
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Figure 5.10: The effect of NAC co-incubation on ICAM-1 protein expression 
in iron-stimulated HUVECs by Western blotting. HUVECs were incubated 
with or without 50 µg/ml IV iron sucrose or IV FCM and 2 mM NAC for 24hr. 
TNF-α (120U/ml, 6hr) was used as a positive control. (A): show protein band 
of 90 kDa representing ICAM-1 and (S) represents iron sucrose. (B): data 
(mean ± SEM) are shown as a bar graph of densitometry data from 3 
different donors (n=3). *p<0.05, **p<0.01 and ***p<0.01 compared with non-
treated cells. ##p<0.01 for IV iron sucrose or IV FCM and NAC together at 
24hr compared with IV iron sucrose or IV FCM alone at 24hr. 
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Figure 5.11: The effect of NAC co-incubation on VCAM-1 protein expression 
in iron-stimulated HUVECs by Western blotting. HUVECs were incubated 
with or without 50 µg/ml IV iron sucrose or IV FCM and 2 mM NAC for 24hr. 
TNF-α (120U/ml, 6hr) was used as a positive control. (A): show protein band 
of 95 kDa representing VCAM-1 and (S) represents iron sucrose. (B): data 
(mean ± SEM) are shown as a bar graph of densitometry data from 3 
different donors (n=3). *p<0.05, **p<0.01 and ***p<0.01 compared with non-
treated cells. ##p<0.01 for IV iron sucrose or IV FCM and NAC together at 
24hr compared with IV iron sucrose or IV FCM alone at 24hr.   
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5.4. DISCUSSION 
Atherosclerosis is an inflammatory vascular disease, which presents 
frequently in patients with CKD (Amann et al., 2004). EC activation has been 
proposed to be one of the initiating events of atherosclerosis and it is 
characterized by the induction of several intracellular signalling pathways 
leading to up-regulation of several proteins including CAMs, which will be 
expressed and mobilized to the activated EC surface (Lusis, 2000; Galkina 
and Ley, 2009). During EC activation, ICAM-1 and VCAM-1 are up-
regulated, and play an important role in early stages of atherosclerosis by 
enabling the circulating mononuclear cells (MNCs) to bind to ECs and 
migrate into the sub-endothelial space (Badimon et al., 2012).  
In this study, to investigate whether IV iron preparations induce EC 
activation, we have looked into the effect of the two commercially and 
routinely used forms of IV iron preparations from earlier chapters (IV iron 
sucrose or IV FCM) on ICAM-1 and VCAM-1 expression in HUVEC. Firstly, 
an established RT-PCR technique was used in this study and we observed 
that the level of gene expression of both ICAM-1 and VCAM-1 mRNA were 
up-regulated in HUVEC treated by IV iron sucrose or IV FCM at 6 and 24hr 
compared to non-treated cells (Figures 5.2A and 5.3A). To quantify the data 
obtained by RT-PCR in gene expression, qRT-PCR was performed. QRT-
PCR data clearly showed that HUVEC treated with IV iron sucrose or IV 
FCM at 2hr increased ICAM-1 and VCAM-1 mRNA gene expression levels, 
however this increase was not statistically significant compared with non-
treated cells. In contrast, cells treated with IV iron sucrose or IV FCM at 6 
and 24hr, showed significant increase in ICAM-1 and VCAM-1 mRNA gene 
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expression levels compared with non-treated cells (Figures 5.6 and 5.7). 
Although gene expression level of ICAM-1 and VCAM-1 was up-regulated, it 
is important to determine if surface expression of protein is altered. 
Therefore, Western blotting was performed using specific anti-ICAM-1 and 
anti-VCAM-1 antibodies. ICAM-1 was detectable in non-treated cells in a 
similar way to published results because it is well known that HUVEC 
express low level of ICAM-1 under basal conditions (Salas et al., 2002). In 
contrast, no VCAM-1 was detected in our study, in agreement with others 
that VCAM-1 is not expressed on resting healthy HUVEC surface but 
expressed only on activated HUVEC (Frank and Lisanti, 2008). HUVEC 
treated with IV iron sucrose or IV FCM at 6 and 24hr showed significant 
increase in protein levels of ICAM-1 compared with non-treated cells (Figure 
5.8B). In addition, only cells treated with IV iron sucrose at 6 and 24hr or IV 
FCM at 24hr showed significant increase in protein levels of VCAM-1 
compared with non-treated cells (Figure 5.9B). Our data are line with a 
number of studies which investigated the role of IV iron preparations on 
adhesion molecule expression in other vascular cell types. A recent study by 
Kuo et al (2014) showed that, HAECs treated with IV iron sucrose at 80 and 
160 µg/ml for 5hr, significantly up-regulated ICAM-1 and VCAM-1 protein 
expression in these cells via the enhancement of NF-kB binding activity. 
Furthermore, in vivo study by Kuo et al (2014) who, treated 20 CKD patients 
at stage 5 (ESRD) with 1000 mg IV iron sucrose showed that, plasma levels 
of soluble sICAM-1 and sVCAM-1 were significantly up-regulated compared 
with those who were treated with IV iron compound. In addition, Martin-Malo 
et al (2012) treated primary PBMCs isolated from CKD patients with four IV 
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iron preparations, ferric gluconate, iron sucrose, iron dextran and IV FCM at 
a concentration of 200 µg/ml for 2, 8 and 24hr. Their data showed that all 
compounds caused significant increases in ICAM-1 protein expression. 
Interestingly, the authors claimed that, there were no significant differences 
between the four iron preparations in the level of ICAM induced (p<0.05).  
Kuo et al (2012), treated HAEC in vitro with 80 and 160 µg/ml IV ferric 
chloride hexahydrate for 4hr and measured adhesion molecule expression 
using Western blot methods. They found that protein level of VCAM-1 was 
significantly up-regulated by IV ferric chloride hexahydrate at 80 and 160 
µg/ml for 4hr, while ICAM-1 protein expression was significantly increased 
only at 160µg/ml for 4hr. In addition, these authors also showed this was the 
case in vivo, when they treated a group of HD patients with IV ferric chloride 
hexahydrate at concentration of 400 and 800 mg over 6 months. They found 
that, plasma level of soluble sICAM-1 and sVCAM-1 were significantly 
elevated at 800 mg compared with patients who did not receive IV iron 
treatment, demonstrating sustained endothelial cell activation. Although our 
study is consistent with the findings of Kuo and colleagues study, we did not 
measure up-regulation at 4hr but levels were significantly up-regulated at 6hr 
and increased further at 24hr. In addition, the authors showed that ICAM-1 
protein expression was not significantly up-regulated by 80 µg/ml IV ferric 
chloride hexahydrate at 4hr and they did not look at a longer time exposure, 
so they might have looked too early to see up-regulation of expression of 
ICAM-1 (Hadad et al., 2011). Although, our study used a lower concentration 
of IV iron sucrose or IV FCM (50 µg/ml), our success in demonstration up-
regulation of ICAM-1 and VCAM-1 protein is likely to be due to the time point 
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chosen in our study. Collectively both our and published observations could 
be considered as markers of EC activation/dysfunction, which indicate that IV 
iron preparations could accelerate early atherogenesis through endothelial 
activation and up-regulation of adhesion molecule expression. In contrast to 
the data by Kuo’s group, one in vivo study involving 40 HD patients showed 
that treating those patients with 50 and 100 mg/kg IV iron sucrose had no 
significant effect on level of serum sICAM-1 (Garcia-Fernandez et al., 2010). 
Another recent in vivo study by Prats et al (2013) showed that there was no 
significant increase in ICAM-1 and VCAM-1 expression compared with 
baseline after treating 47 CKD patients at stages 3-5 with IV FCM (15 
mg/kg). The authors stated that the lack of IV FCM effect on expression level 
of ICAM-1 and VCAM-1, could be due to IV FCM characteristics itself where 
there is less possibility, when administrated even at high doses did not 
release large amounts of ionic iron in the serum. In addition, Prats and others 
also noted that patients who were on lipid lowering treatment have a lower 
level of VCAM-1, suggesting that these drugs might block the effect of IV 
FCM on adhesion molecule (Prats et al., 2013). However, Prats and others 
study cannot be directly compared to our and other in vitro data as they 
measured the expression of ICAM-1 and VCAM-1 levels at 1hr, 3 weeks and 
then 3 months after administration of IV FCM. Thus, this period of time 
measurements are taken can be crucial as they could have missed the 
increased level of adhesion molecule between 1hr of IV FCM administration 
and three weeks. Previous clinical and experimental studies showed the 
protective effect of NAC on reducing ICAM-1 and VCAM-1 adhesion 
molecule expression in ECs treated with IV iron preparations, iron sucrose, 
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iron dextran, FCM and ferric chloride hexahydrate (Schmidt et al., 1997; 
Weig and et al., 2001; Kuo et al., 2012). Our results showed that, NAC 
significantly reduced protein expression of adhesion molecule ICAM-1 and 
VCAM-1 in HUVEC treated with IV iron sucrose or IV FCM over 24hr p<0.01, 
as shown in Figure 5.10 A and B. Our data implies that antioxidants such as, 
NAC may potentially protect against iron-mediated endothelial dysfunction. 
The mechanisms responsible for NAC’s effects are more fully discussed in 
Chapter 6. The NAC and iron preparation co-incubation data may indicate 
that, IV iron sucrose or IV FCM induced ROS generation, which in turn might 
promote endothelial adhesion molecule expression through the activation of 
NF-kB and subsequently promote early atherogenesis in CKD patients.  
Our results of co-treatment of HUVEC with NAC and IV iron preparation are 
consistent with the two studies by Kuo and colleagues, where expression of 
ICAM-1 and VCAM-1 was significantly attenuated by the co-treatment of 
ferric chloride hexahydrate-treated  HAEC with 10 mM NAC (Kuo et al., 2012; 
Kuo et al., 2014). This group needed 10 mM NAC to produce significant 
effects of IV iron preparation induced on ICAM-1 and VCAM-1 protein 
expression. However, we did not use such high concentrations as previous 
shear stress studies in our laboratory showed that, treating HUVEC with 10 
mM NAC significantly blocked all interactions between DL-homocysteine-
treated HUVEC and neutrophils and reduced interactions to below non-
treated control level, which indicates that NAC at such high concentration 
might have affected the cellular response to stimuli (Alkhoury, 2009).  
We carefully chose clinically relevant IV iron concentrations for our studies 
(Kamanna et al., 2012), yet intriguingly, all of the other published studies 
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have used higher concentrations of IV iron preparations than those used in 
our study. However, despite the lower concentrations that were used in our 
study, there was still up-regulation of adhesion molecules, which was 
significantly attenuated by pre-treatment with NAC. This suggests that 
treatments with IV iron sucrose or IV FCM gives rise to oxygen radicals. This 
can lead to EC dysfunction through up-regulation of EC adhesion molecule, 
ICAM-1 and VCAM-1 which play vital role in the prevalence of 
atherosclerosis, a major CVD in CKD patients and, thus potentially increase 
the mortality in these groups. 
 
5.5. CONCLUSION 
In conclusion, the results of our in vitro experiments provide compelling 
evidence that IV iron sucrose or IV FCM significantly induce EC activation 
through both increased mRNA expression and protein up-regulation of 
ICAM-1 and VCAM-1 adhesion molecules in cultured HUVEC. In addition, 
our study, showed for the first time, that IV FCM increases mRNA expression 
and up-regulates ICAM-1 and VCAM-1 protein expression in EC (HUVEC). 
These findings will result in EC dysfunction and increase the mortality of 
CKD patients as a result of CVD progression. It was interesting to note that 
adhesion molecule upregulation by IV FCM was not as high as that by IV iron 
sucrose. The fact that, treatment with NAC significantly attenuated the effect 
of IV iron administration on adhesion molecule protein expression 
emphasises the role of ROS in the endothelial cell damage sustained. 
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6.1. GENERAL DISCUSSION AND FUTURE STUDIES 
6.1.1. General discussion  
In vitro studies have used ECs from a variety of sources to study the 
mechanisms of EC dysfunction that lie behind atherosclerotic plaque 
formation (Zhang et al., 2001a; Lee et al., 2002; Dalal et al., 2003; Ferretti et 
al., 2004). In our study HUVECs were chosen for several reasons, initially as 
these cells represent one easily accessible in vitro model principally because 
of the umbilical cord availability. These cells have played a major role as a 
model system for the study of EC function and have been used successfully 
in several studies (Outinen et al., 1999; Xu et al., 2000; Dong et al., 2005; Xu 
et al., 2011). Although atherosclerotic lesions occur in large arteries and 
veins are not typically vulnerable to the development of atherosclerosis 
(VanderLaan et al., 2004), venous endothelium plays a key role in 
inflammation as veins provides an important site of leukocyte recruitment to 
venule walls (Savoia et al., 2011). This results in the up-regulation of 
adhesion molecule expression (including ICAM-1, VCAM-1). Patients with 
CKD present with systemic inflammation as measured by elevated levels of 
inflammation markers including CRP, TNF-α, and interleukin -6 (IL-6), which 
have been shown to correlate with CV outcome (Dungey et al., 2013, 
Machowska et al., 2015).Therefore, inflammation associated with EC 
dysfunction is considered as CVD risk factors for patients with CKD. Thus, all 
types of ECs are likely to be activated, leading to leukocyte recruitment into 
kidney tissue which will further promote chronic inflammation, and making 
the use of HUVEC in our study relevant in determining the mechanisms of 
EC activation/damage important in CKD.   
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Both in vivo and in vitro studies have been conducted to determine the effect 
of IV iron preparations on oxidative stress and the role of these compounds 
on EC dysfunction and subsequent CVD progression and this will be 
discussed in the context of our data (Rooyakers et al., 2002; Kell, 2009; 
Vaziri, 2012; Kamanna et al., 2012). Most published studies investigated the 
role of IV iron sucrose, because it has been the most commonly used in the 
clinic (McMahon, 2010; Cançado and Muñoz, 2011; Kayode et al., 2012). 
Therefore, it was one obvious choice for our studies as a benchmark of a 
routinely used therapeutic. In contrast, little is known about the role of IV 
FCM on EC dysfunction, because it is considered as a newer clinical agent. 
Most recent scientific investigations have focused mainly on in vivo (patient) 
study, with most of these studies concluding this drug is safe (Barish et al., 
2012; Bregman and Goodnough, 2014; Macdougall et al., 2014), with data 
indicating similar effects on EC function measured by serum biomarkers to 
iron sucrose. However, the research that has been conducted and the 
relatively short time the agent has been approved in Europe and USA means 
there is insufficient in vitro experimental evidence on the effects of this 
compound on EC function. Long term administration to CKD patients may 
lead to acceleration of CVD through EC damage in the kidney. Therefore, 
our in vitro study aimed to directly compare effects of these two commercially 
available compounds on EC function, particularly to compare their effects on 
ROS generation and apoptosis in HUVECs as well as studying the potential 
mechanisms responsible. From early dose response studies using HUVEC 
and endothelial cell line (EA.hy926), we chose a concentration of 50 µg/ml 
for both IV iron sucrose and IV FCM, because higher concentration had 
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adverse effects on EC morphology and apoptosis induced by IV iron 
sucrose. However, these concentrations are relevant to the clinically 
measured range of plasma iron concentrations that are achieved in CKD 
patients after injected with IV iron sucrose or IV FCM as described in section 
2.2.2.7. (Van Wyck et al., 2004; Kuo et al., 2012; Kamanna et al., 2012; 
Praschberger et al., 2013). From the experiments carried out in this thesis, 
our data showed that IV iron sucrose, results in morphological changes in 
HUVEC within 24hr and cells displayed typical features of apoptosis as these 
cells shrunk and became star-shaped with sharp outlines compared with 
non-treated cells from the same donor. In contrast, HUVEC treated with IV 
FCM showed normal morphology with typical cobblestone appearance 
compared with non-treated cells. In addition, trypan blue and MTT data 
following 24hr of treatment showed, IV iron sucrose significantly induced a 
marked decrease in HUVEC proliferation and inhibition of the survival of the 
HUVEC when compared with non-treated cells while, IV FCM did not 
produce EC damage measured by MTT assay at this time point. However, 
long term treatment with IV iron sucrose or IV FCM, MTT data for 96hr 
showed that, IV iron sucrose was the more toxic agent inducing further 
significant reductions in the proliferation of HUVEC by 80% compared with 
non-treated cells. Interestingly, IV FCM did not kill EC but caused significant 
delay in HUVEC proliferation rate at 72hr and 96hr compared with non-
treated cells. Our results show for the first time that, IV FCM in vitro can 
affect the proliferation rate of EC on long term treatment with repeat dose 
administration using MTT assay. In order to identify potential therapeutic 
agents for safe use in CKD patients, it was important to examine exact 
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mechanism of this IV iron induced EC damage, TUNEL assay and Annexin 
V-FITC/PI, data demonstrates that IV iron sucrose at 24hr causes significant 
HUVEC apoptosis compared with non-treated cells. In line with the earlier 
data IV FCM did not induce HUVEC apoptosis which suggests it may have a 
safer profile. Our data are in line with the findings of Carlini et al., 2006; 
Martin-Malo et al., 2012, who showed that, 100-1000 µg/ml IV iron sucrose 
significantly increases apoptosis rate in BAEC and PBMC using TUNEL and 
Annexin V-FITC/PI. In addition, Fell et al., (2014) found a significant 
reduction in monocyte viability treated with 500 µg/ml IV iron sucrose for 3hr 
versus non-treated cells, which was not the case in cells treated with IV 
FCM, as there was no significant decrease in the cell viability compared with 
non-treated cells. Zager et al (2002) also showed that IV iron sucrose inhibits 
HAEC proliferation when these cells were treated with 60 and 1000 µg/ml for 
72hr using MTT assay. These groups suggested that impaired mitochondria 
function was the cause for inhibition of HAEC proliferation by this compound. 
In addition, another study was done by Carlini et al (2006), who agreed with 
the finding of Zager et al, treating BAECs with 500 and 1000 µg/ml IV iron 
sucrose, showing this compound significantly decreased BAEC proliferation 
compared with non-treated cells. 
It has been shown that IV iron sucrose can cause renal injury due to direct 
drug toxicity induced by the drug; this injury per se can cause the production 
of oxidative stress and EC damage (Agarwal, 2004). Our data agree with the 
findings of several in vitro studies. Kamanna et al (2012) showed that, 
treatment of HAEC with 100 µg/ml IV iron sucrose had an adverse effect on 
cell morphology and cells exhibited typical features of apoptosis including 
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condensed and fragmented nuclei when compared to non-treated cells. They 
also showed that IV iron sucrose at 24hr significantly decreased cellular 
viability using MTT assay compared with non-treated cells. These authors 
suggested that, alteration of ECs morphology could be due to the increased 
oxidative stress after IV iron being administered. Furthermore, Masuda et al 
(2014) showed that 200 mg/l IV iron sucrose resulted in significant decrease 
in viability of isolated pancreatic islet cells using tetramethylrhodamine ethyl 
ester (TMRE) methods, which occurred as a result of increased oxidative 
stress. Several studies, both on CKD patients and experimental animals 
have demonstrated the capability of IV iron preparations to cause oxidative 
stress (Agarwal, 2004; Agarwal, 2006; Anirban et al., 2008). In addition, in 
vitro studies have also shown that IV iron preparation such as IV iron 
sucrose, iron dextran, IV FCM and ferric gluconate and ferric chloride 
hexahydrate treatment, induced ROS generation in HAEC, PBMC and 
pancreatic islet cells (Kuo et al 2008; Gupta et al., 2010; Kuo et al., 2012; 
Martin-Malo et al., 2012; Fell et al., 2014; Masuda et al.,  2014).Our results 
obtained using both NBT and DCFH-DA showed that, treatment with IV iron 
sucrose or IV FCM induced significant increases in superoxide anion 
production and total ROS generation in HUVEC when compared with non-
treated HUVEC, leading to oxidative stress. Our data are in line with the 
above mentioned studies, which suggest the increase in ROS can be due to 
a number of reasons including the molecular weight and stability of the IV 
iron compounds, which then release more free iron Fe2+  that could enter the 
cells via divalent metal transporter (DMT1) (Sturm et al., 2005) or it could be 
due to IV iron altering the intracellular labile iron pool, leading to increased 
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oxidative stress by affecting the antioxidant enzymes system for instance, 
glutathione reductase and catalase (Gupta et al., 2010). After showing the 
ROS generation and apoptotic effects of IV iron sucrose on HUVEC, the 
mechanism was next studied. ROS are known to mediate the activation of 
multiple signalling pathways, including p38 MAPK signalling pathway (Sato 
et al., 2014), and are a known stimulus of p38 MAPK in EC (Usatyuk et al., 
2003). Many studies have shown that apoptosis can be mediated by p38 
MAPK in EC, including BPAEC or EA.hy926 cell line induced by TNF-α (Yue 
et al., 1999; Grethe et al., 2004). Therefore, we confirmed by Western blot 
data that IV iron sucrose or IV FCM each significantly activated p38 MAPK in 
HUVEC in time dependent manner (peaking at 1 and 2hr). However, 
phosphorylation of p38 MAPK in HUVEC treated by IV FCM was less 
significant and not to the same extent as IV iron sucrose-treated HUVEC. 
Strong evidence provided in the literature suggests a key role for p38 MAPK 
pathway in induction of the apoptosis by mediating the phosphorylation of 
Bcl-2 and the translocation of Bax to the mitochondria (De Chiara et al., 
2006; Kang et al., 2008; Park et al., 2013), It was important to link the 
activation of p38 by IV iron sucrose to apoptosis we detected, as IV FCM and 
iron sucrose both induced p38 but did not both induce apoptosis. To do this 
we examined Bcl-2 and Bax proteins involved in the regulation of the 
apoptotic stress pathway (Soria et al., 2013). Treatment of HUVEC with IV 
iron sucrose significantly down-regulated Bcl-2 and upregulated Bax protein 
expression compared with non-treated cells, confirming the role of these the 
two proteins in the apoptotic stress pathway. In contrast, IV FCM had no 
effect on Bcl-2 and Bax expression. These results are in line with Carlini et 
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al., (2006) who found that, BAECs treated with 100 and 1000 µg/ml IV iron 
sucrose, demonstrated significant down-regulation of Bcl-2 protein 
expression. However, no change in Bax protein expression was observed. 
The authors suggested that, the expression of Bax was not changed as both 
Bcl-2 and Bax are acting independently. In contrast, our data showed that 
both proteins were affected by IV iron sucrose, in a way which would 
promote apoptosis confirming that up-regulation of Bax is essential for cell 
death, either through binding of Bax to Bcl-2 and therefore possibly 
inactivating it or by creating cytotoxic channels for ions or other molecules in 
the intracellular membranes where it resides (Zha and Reed, 1997). In 
addition, cell type that has been used in our study might be more sensitive to 
IV iron sucrose to those used by these authors.To confirm that p38 MAPK 
phosphorylation contribute to mitochondria integrity in IV iron sucrose-treated 
HUVEC through the imbalance between the apoptotic proteins, Bcl-2 and 
Bax, HUVEC were treated with the p38 MAPK inhibitor, SB203580. On pre-
treatment with SB203580 HUVEC showed partially but significantly reduced 
expression of Bax and increased expression of Bcl-2 protein compared with 
cell treated with IV iron sucrose alone and the percentage of apoptotic cells 
was significantly reduced to 19%. These data indicate that the activation of 
p38 MAPK is a critical link affecting the balance of expression of Bcl-2 and 
Bax, and their involvement in IV iron sucrose induced apoptosis. However, 
treatment with IV iron sucrose and SB203580 was not comparable to non-
treated cells, which indicates that apoptosis in response to IV iron sucrose 
treatment in HUVEC is likely to involve either different signalling pathways 
involved in HUVEC apoptosis or could be through directs effect of the drug 
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toxicity on HUVECs. This is worthy of further investigation, (see future 
studies, section 6.2.1). These results are in line with Grethe et al (2004); Yu 
et al (2006) who showed that inhibition of p38 MAPK by SB203580 
attenuated the apoptosis in EA.hy926 cell line exposed to TNF-α or H2O2. 
Additionally, SB203580 has been shown to upregulate Bcl-2 and down 
regulate Bax expression in HUVEC exposed to Lipopolysaccharide (Lim et 
al., 2009).   
 
Figure 6.1: Schematic diagram of proposed mechanism of IV iron sucrose 
lead to EC apoptosis. IV iron sucrose increases ROS generation in HUVEC 
which can mediate the activation of p38 MAPK, leading to down-regulation of 
Bcl-2 and up-regulation of Bax, and subsequently cell apoptosis. ROS 
generation can be prevented by treatment with antioxidant, NAC 
demonstrating that ROS cause direct activation of p38 MAPK. 
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While apoptosis is a critical feature important in CVD, EC activation is the 
key mechanism underlying chronic inflammatory conditions including 
atherosclerosis, which in turn lead to CVD (Sorensen et al., 1994; Gokce et 
al., 2002; Libby et al., 2002), which is the main cause of death in CKD 
patients (Levey and Eknoyan, 1999). EC activation is characterized by 
increased vascular permeability and up-regulation of adhesion molecule 
expression, including ICAM-1, VCAM-1 (Libby et al., 2002). Hence, we 
examined the role of IV iron preparations in EC activation that might play a 
critical role in atherosclerosis and subsequently CVD progression in CKD 
patients. Results obtained by both RT-PCR and qRT-PCR showed that, IV 
iron sucrose or IV FCM induced significant up-regulation of both ICAM-1 and 
VCAM-1 mRNA compared with non-treated cells. Downstream protein 
expression was also significantly up-regulated in response to the 2 iron 
preparations as shown in Figure 6.2. Interestingly our data shows that there 
is more significant upregulation of adhesion molecule protein expression 
following treatment with IV iron sucrose, compared to IV FCM. Our data are 
in line with number of studies that showed that 1000 mg IV iron sucrose or 
200 µg/ml IV iron sucrose, iron dextran, ferric gluconate and IV FCM all 
significantly activated the expression of soluble and surface, ICAM-1 and 
VCAM-1 protein expression in CKD patients (Martin-Malo et al., 2012; Kuo et 
al., 2014). 160 µg/ml IV ferric chloride hexahydrate also significantly elevated 
the surface expression of VCAM-1 protein and soluble ICAM-1 and VCAM-1 
in serum (Kuo et al., 2012), of patients with CKD (Frank and Lisanti, 2008). 
All the above findings could be considered as demonstrating that CKD 
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patients treated with IV iron preparations demonstrate expression of markers 
of EC activation/dysfunction.  
 
Figure 6.2: Schematic diagram of proposed mechanisms of IV iron 
preparations result in ROS generation in HUVEC, up-regulation of ICAM-1 
and VACM-1, EC activation/dysfunction and therefore atherosclerosis, which 
can be attenuated by treatment with antioxidant, NAC. 
In our studies co-treatment with antioxidant, 2 mM (NAC) significantly 
attenuated the production of both superoxide anion and ROS generation 
induced by IV iron sucrose or IV FCM. These results are matched with others 
(Agarwal et al., 2004; Swarnalatha et al., 2010), who found that ROS 
induction in response to 100 mg of IV iron sucrose and 600 mg NAC 
treatment resulted in significant reduction of plasma MDA compared to CKD 
patients without NAC treatment. We hypothesized that EC damage, 
apoptosis and p38 MAPK activation induced by IV iron preparation are ROS 
dependent, and might be improved by antioxidant treatments of NAC. The 
activation of p38 MAPK in response to IV iron preparation treatment in 
226 
 
HUVEC was ROS dependent and our experiments convincingly showed 
NAC, reduced the phosphorylation of p38 MAPK in HUVEC treated with IV 
iron sucrose or IV FCM compared with non-treated cells. This confirmed that 
p38 MAPK activation was ROS dependent, suggesting that p38 MAPK 
activation can lead to EC apoptosis. These findings are in line with other 
studies that showed 5 mM NAC and 100 µM H2O2 significantly reduced 
activation of p38 MAPK in BLMVECs compared with H2O2-treated cells 
(Usatyuk et al., 2003; Wang and others, 2010). In addition, our data also 
showed that NAC significantly attenuated the protein expression of ICAM-1 
and VCAM-1 in HUVEC treated with IV iron sucrose or IV FCM compared 
with IV iron sucrose or IV FCM alone, indicating that the up-regulation of 
gene and increased protein expression of ICAM-1 and VCAM-1 which may 
facilitate leukocyte adhesion to the vascular endothelium, leading to EC 
dysfunction and atherosclerosis is ROS dependent. These results are 
consistent with the two studies by Kuo and colleagues who showed that NAC 
significantly reduced the expression of proteins ICAM-1 and VCAM-1 in 
lymphocytes (Kuo et al., 2012; Kuo et al., 2014). Therefore, the reduction of 
proliferation rate and EC damage by IV iron preparation would be expected 
as consequences of increased level of ROS particularly superoxide anion 
production. Collectively our results suggest that, ROS were responsible for 
activating the p38 MAPK pathway and downstream pathways inducing 
apoptosis in HUVEC via the up-regulation of Bax and down-regulation of Bcl-
2 in response to IV iron sucrose as well as EC activation or dysfunction. 
Our results show for the first time that IV iron sucrose or IV FCM activated 
p38 MAPK expression in HUVEC can be as a result of ROS induction. 
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However, IV FCM did not induce HUVEC apoptosis; suggesting the role of 
additional pathways in the induction of apoptosis alongside p38 MAPK. 
Pharmacokinetic differences exist between IV iron sucrose and IV FCM such 
as rapid iron absorption, distribution, metabolism and excretion. In addition, 
differences in their molecular weight, reactivity and thermodynamic stability, 
which differ in their carbohydrate ligands leading to passive absorption, 
saturation of the transport protein (transferrin) and generation of weakly 
bound NTBI, which can prompt oxidative stress and cellular damage 
(Geisser and Burckhardt, 2011). We suggest that IV iron sucrose can be 
toxic and can cause apoptosis in HUVEC via all these differences which are 
mentioned and discussed in more details in section 1.6.3.1. Although, our 
data shows additional information on mechanisms by which IV iron sucrose 
or IV FCM may damage ECs, these effects may not be observed in vivo. 
Future studies are needed to determine the exact mechanism underlying IV 
iron sucrose-induced EC apoptosis (see future studies, section 6.1.2). 
Overall, our data in this thesis concludes that low and pharmacologically 
relevant concentration of both IV iron preparations affect EC function. 
Importantly IV iron sucrose exerts a greater inhibitory effect on cell 
proliferation, intracellular ROS generation and superoxide anion production 
than IV FCM in EC. Additionally, IV iron sucrose produced greater effects on 
apoptosis and cellular activation by the up-regulation of key EC adhesion 
molecules, which regulate monocyte recruitment and play a pivotal key role 
in early atherosclerosis compared with IV FCM. The mechanisms involved in 
EC activation may be partly due to the increased oxidative stress by both 
compounds. Furthermore, Cell toxicity of IV iron sucrose occurs through 
228 
 
induction of HUVEC apoptosis and the mechanisms involved in this process 
may be related to up-regulation and down-regulation of Bax and Bcl-2 protein 
expression respectively, which shown to be at least partly mediated by the 
activation of p38 MAPK. This study also highlighted the possibility of 
antioxidant NAC and p38 MAPK inhibition as protective agents against 
HUVEC oxidative stress and damage. All these in vitro findings suggest a 
potential novel causative role for therapeutic IV iron preparations particularly 
IV iron sucrose in EC dysfunction and provide convincing evidence for IV iron 
preparations in the pathogenesis of atherosclerosis and CV complications in 
CKD patients, which might result in significant morbidity and mortality in 
these individuals. What is promising is that this study has shown that IV FCM 
can be more promising in anaemia treatment for CKD patients than IV iron 
sucrose as it shown to have a higher efficacy and less toxicity on HUVEC to 
IV iron sucrose for similar compound concentration and exposure to cells. 
Thus, IV FCM may have positive clinical consequences such as less 
oxidative stress and less cell damage/dysfunction. However, further work 
needs to be done to confirm these promising preliminary findings and 
clinically it will be important to look at the mean survival time or to compare 
the percentage of CKD patients treated with IV iron sucrose or IV FCM who 
die due to CVD. Effects of long terms treatment with either compound on EC 
dysfunction in CKD patients using physiological techniques such as flow 
mediated dilatation or measurement of soluble cell adhesion molecules 
would be beneficial in assessing the comparative effects of these drugs on 
CV function. 
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6.1.2. Future studies 
Based on findings and discussion in this thesis, additional techniques could 
be used to further investigate the role and mechanisms of IV iron 
preparation-induced EC dysfunction/activation and apoptosis, which will 
eventually result in CVD progression in patients with CKD. 
1. Investigate whether human serum from late stage CKD or HD 
patients, who are on short and long term treatment of IV iron 
preparation (IV iron sucrose or IV FCM), impair EC function in healthy 
cultured HUVEC. This is to mimic conditions present in CKD patients 
as this serum may contain high level of metabolites able to induce 
oxidative stress, either because of IV iron preparations treatment or by 
uremic toxins which known for its role in inhibition antioxidant 
enzymes in CKD (Kumbasar et al., 2012). Briefly, whole blood 
samples can be collected from age and disease stage matched CKD 
patients who are on short (1-3 months from first dose) or long 
treatment (6-12 months) with IV iron preparations (IV iron sucrose or 
IV FCM). Serum samples then can be isolated from whole blood by 
centrifugation and HUVEC from healthy donors can be incubated with 
this serum for different time course (2, 6 and 24hr). Subsequently, cell 
viability, proliferation, production of intracellular ROS, superoxide 
anion production, cell activation (up regulation of cell adhesion 
molecules) and apoptosis can be measured in vitro using the same 
methods in this study and whether treatment with NAC can attenuate 
the effect of IV iron preparations. 
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2. Since IV iron sucrose or IV FCM up-regulated EC adhesion 
molecules, in vitro flow experiments could also be performed to 
simulate laminar blood flow through a human blood vessel. 
Classification of EC: leukocyte interactions (tethering, rolling, fixed 
and transmigration) will be investigated using Vacuum Flow Chamber 
Assay  (Shishir Shetty et al., 2014) to observe the effect of:  
a) The recruitment of leukocytes from healthy individuals on HUVEC 
which have been pre-treated for different time course (2, 6 and 
24hr) with serum from late stages CKD or on dialysis patients who 
are on either short (1-3 months) or long term (6-12 months) of IV 
iron sucrose or IV FCM.  
b)  The recruitment of leukocytes isolated from blood of CKD patients 
who are on either short (1-3 months from first dose) or long term 
(6-12 months) of IV iron sucrose or IV FCM on healthy HUVEC.  
c)  The recruitment of leukocytes isolated from blood of CKD patients 
who are on either short (1-3 months) or long term (6-12 months) of 
IV iron sucrose or IV FCM on activated HUVEC (which have been 
pre-treated for time course in a) with serum from the same patient. 
d) Determine roles of antioxidant treatment on leukocyte recruitment 
in CKD model under flow conditions, and this will be as follow: 
leukocytes isolated from blood from late stages CKD or on dialysis 
patients and NAC to determine the effect of ROS from blood cells 
on EC activation. HUVEC (which have been pre-treated for time 
course in a) with CKD patient serum and NAC to determine 
protective effect of antioxidant on EC function.  
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3. Directly quantify the strength of the p38 MAPK signal following IV iron 
sucrose or IV FCM treatment by carrying out p38 MAPK kinase assay. 
Confirmation of importance of the role of p38 MAPK pathway 
activation in apoptosis of HUVEC following IV iron sucrose treatment 
by using molecular methods such as using small interfering RNA 
(siRNA) (Bramsen and Kjems, 2011) to knock down p38 MAP kinase 
and measure apoptosis compared to cells where p38 MAPK signal is 
intact. 
4.  JNK pathway is also known to play a role in apoptosis in some cell 
types (Dhanasekaran et al., 2008). The role of the JNK pathway in 
HUVEC apoptosis and alterations in intrinsic pathway proteins, Bax 
and Bcl-2, will be demonstrated through selective inhibitors such as 
SP600125 using techniques previously described in this thesis 
(section 4.2.2.1.3 and 4.2.2.1.3), include Western blotting and flow 
cytometry with Annexin V-FITC/PI. Confirmation of importance of the 
role of JNK pathway activation in apoptosis of HUVEC following IV 
iron preparation treatment could also be confirmed using the siRNA 
technology to knock down JNK pathway and measure apoptosis as 
previously described for p38 MAPK in 3.  
5. From the findings of this study, the significant increase in ROS 
generation observed in response to IV iron sucrose or IV FCM will be 
likely to reduce NO bioavailability (Kolluru et al., 2012; Hsieh et al., 
2014), which plays a major role in EC dysfunction and is a contributor 
to atherosclerosis in CKD patients. Therefore, evaluation of 
intracellular NO production in HUVEC could be investigated to look at 
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the role of ROS induced by IV iron compounds in NO production by 
treating HUVEC with serum of CKD patients for different time course 
(2, 6 and 24hr) as described above using NO-specific fluorescent dye 
4-Amino-5-Methylamino-2',7'-Difluorofluorescein Diacetate (DAF2-DA) 
(Li et al., 2010) by flow cytometry. The data obtained from this 
experiment might show a reduction in NO production which is known 
to enhance expression of adhesion molecules such as VCAM-1 and 
ICAM-1. This can provide more detailed information about the role of 
elevated ROS by IV iron preparations in EC activation/dysfunction 
which will eventually lead to CVD in patients with CKD. 
6. The importance of revealing the mechanism responsible for activation 
of HUVEC and subsequent apoptosis may lead to usage of novel new 
small molecules which target these pathways as future therapeutics to 
protect against accelerated vascular disease within CKD patients. In 
addition to NAC and SB203580, there are other molecules or drugs 
which can be used to improve EC function for example NO donors 
include SP/W 5186 and 3672 as they have shown to inhibit EC 
activation via inhibition of endothelial leukocyte adhesion molecule 
expressions, ICAM-1 and VCAM-1 in Human saphenous vein 
endothelial cells (HSVECs) (Pescador et al., 2013). In addition, 
angiotensin-converting enzyme inhibitors and angiotensin receptor 
blockers can be other possible drugs as they shown to improve EC 
function, and thus slow CKD progression in CKD patients (Wu-Wong, 
2008). 
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APPENDIX 2 
 
Preliminary experiments to demonstrate that exposure ROS causes 
phosphorylation of p38 MAPK in EA.hy926 endothelial cell line. 
 
 
Figure: Shows the effects of H2O2 on p38 MAPK phosphorylation in 
EA.hy926 endothelial cell line. EA.hy926 were cultured in 6 well plates until 
confluence, then cells were treated with 500 µM of H2O2 for different time 
course 5, 15, 30, 60, 90 min, 2hr and 4hr, and lysed. 30 µg proteins from 
each sample was loaded on an SDS-PAGE gel and used in the Western blot. 
(A): representative blots; the phospho-p38 and total p38 MAPK proteins 
were detected using specific antibodies and were identified by Western blot 
as a band of approximately 43 kDa.(B): the phospho-p38/total p38 ratio were 
quantified by densitometry and expressed as the ratio compared to the 
control. All values are expressed as mean (+/-SD) from three different 
experiments (n=3). ***P<0.001 versus control. 
